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ABSTRACT 
Unipolar depression is a common mental disorder and is the leading cause of mental 
disability worldwide. Medication adherence is a complex process, particularly in 
people with unipolar depression. The signs and symptoms of depression can also 
contribute to non-adherence and it is a risk factor for non-adherence in other chronic 
conditions such as diabetes and HIV. The overall aim of the research presented in this 
thesis was to explore and examine issues pertaining to medication adherence in 
people with unipolar depression. To address the overall aim, the methods used in this 
research included a systematic review of published literature, semi-structured 
interviews with consumers, and a content validation study involving health care 
professionals. The ABC taxonomy which conceptualises adherence into three 
components—initiation, implementation, and discontinuation—was used as the 
framework for this research.  
The major outcome for this research was the development and content validation of 
a depression-specific medication adherence framework, based on the literature, 
qualitative findings, and experience of the research team. It was designed as a guide 
for health care professionals to better understand the adherence process from the 
consumer perspective and to inform tailored interventions to facilitate adherence. 
The framework acknowledges the different nature of potential factors influencing 
medication adherence at the specific phases of medication taking. Key considerations 
included individual perceptions, personal experience/s, and the influence of people 
around them. The findings also highlighted the need for valid measures to evaluate 
adherence across the three phases of adherence. A standout measure with strong 
reliability and validity was not apparent. Hence, a range of different subjective and 
objective measures is recommended to assess medication adherence across the 
different phases of medication taking. The overall findings of this thesis can be 
applied in everyday practice to enhance medication adherence in people with 
unipolar depression. 
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THESIS OVERVIEW 
This thesis is divided into five parts (A–E). An overview of the relationship between 
each of the parts is presented in Figure 1.  
Part A of the thesis (Chapters One and Two) provides the background and overview 
of the concepts discussed in this thesis, including detailed methods of the research 
described in this thesis. Chapter One contains the overall framework of the thesis. It 
also provides a brief overview of the burden, scope, and consequences of medication 
non-adherence in unipolar depression, definition of adherence, adherence measures, 
factors influencing medication adherence in unipolar depression, and a medication 
adherence framework. Chapter Two describes the methods used in this thesis. 
Part B of the thesis (Chapter Three) presents a systematic review of the measures of 
medication adherence in consumers taking antidepressant medicines for unipolar 
depression. This part identifies and evaluates the range of measures that have been 
used to assess medication adherence in the past two decades. These measures were 
investigated and categorized under the Ascertaining Barriers to Compliance (ABC) 
taxonomy or the ABC project2, which focuses on three components of adherence: 
initiation, implementation, and discontinuation. This chapter also describes the 
evaluation of the psychometric properties of these measurements in order to 
facilitate selection of an appropriate measure(s) for the specific phases of adherence. 
Part C of the thesis comprises two chapters (Chapters Four and Five) and investigates 
both facilitators of and barriers to medication adherence at specified phases from 
initiation to discontinuation, focusing on the consumer perspective. A qualitative 
approach was applied in order to elicit the consumers’ experiences as well as their 
perceptions of antidepressant-taking behaviour. Themes were divided into four main 
categories: 1) consumer, 2) health care professionals, 3) health care system, 4) family 
and social-related factors. Part C elucidates potential factors which may influence 
medication-taking behaviour in individuals. The findings were used as the basis for 
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the next phase, that is, to create a medication adherence framework in consumers 
living with unipolar depression.  
Part D of the thesis (Chapter Six) presents and content validates a new medication 
adherence framework for consumers with unipolar depression. It encompasses the 
entire process of adherence, including potential factors that influence medication-
taking behaviour in unipolar depression from the initiation to the discontinuation 
phase. This framework will allow health care professionals to better understand 
antidepressant medication adherence in people living with unipolar depression. 
Hence, health care professionals can select specific strategies to address medication 
adherence at specific phases of medication adherence, to aid their patients in 
reaching their treatment goal. As previously mentioned, the proposed framework 
was created based on the findings from previous qualitative study (Chapters Four and 
Five), systematic review of the literature (Chapter Three), and the collective 
experience of the research team. A content validation using an expert panel was 
applied in order to evaluate face and content validity of the framework components. 
Part E of the thesis (Chapters Seven and Eight) provides a general discussion of the 
overall findings of the studies described in this thesis. Chapter Seven discusses the 
main findings of the entire thesis, including study implications, strengths, and 
limitations. Lastly, Chapter Eight reports the conclusions for this research and 
provides a guide for future studies. 
xiii
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PART A - INTRODUCTION 
1
CHAPTER ONE: Background 
1.1 Introduction 
Poor adherence to medicines for the treatment of chronic conditions is a worldwide 
problem of striking magnitude, particularly as the burden of chronic conditions 
increases.3 Non-adherence to prescribed medicines is recognised as a major barrier 
to successful treatment outcomes in people living with chronic conditions. Major 
consequences of non-adherence to long-term therapies are poorer health outcomes 
and increased health care costs.3, 4 The enhancement of adherence to long-term 
therapies is one of the main strategies adopted by the World Health Organisation 
(WHO) towards the management of chronic conditions (particularly focusing on 
diabetes, depression, and HIV/AIDS) and health promotion worldwide.5  
Unipolar depression or major depression is a well-established risk factor for non-
adherence to medicines.6, 7 Both current and remitted depression disorders have 
been proven as risk factors for medication non-adherence.7 Consequently, poor 
adherence to antidepressant medicines among people with unipolar depression is 
relatively high.6-10  
Depression is a common mental disorder that affects many people around the world 
and is a leading cause of work absence, poor health in general, and suicidal ideation.11 
It is a chronic condition which may require long-term treatment, and most treatment 
guidelines recommend a minimum course of antidepressant treatment for 6–9 
months after the alleviation of depressive symptoms.12-16 However, studies have 
shown the average length of antidepressant medicine to be less than 6 months with 
approximately 50–60% of patients ceasing their antidepressant medicine dosage 
within the first four months.17-19 In certain cases, for example, people who have had 
three or more prior major depressive episodes or who have chronic major depressive 
disorder may require longer treatment periods or, occasionally, maintenance therapy 
to reduce the risk of recurrent depressive episodes.12, 16 Non-adherence frequently 
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results in an increase in the dosage of medicines, which contributes to higher medical 
costs as well as increased risk of adverse drug events, misdiagnoses, unnecessary 
treatment, increased severity of disease, and death.20, 21 The consequences of non-
adherence are significant not only for individuals, but also in terms of the impact on 
the health system, such as overall health care costs.21 Therefore, adhering to 
antidepressant therapy is a key solution to tackle and prevent these problems; it is 
also an important strategy to achieve desired therapeutic effects and potentially 
improve overall outcomes for patients with unipolar depression.22 
Non-adherence to antidepressant medicines in people living with unipolar 
depression is complex and multifactorial. The symptoms of depression, such as 
lowered mood, excessive sadness, feelings of guilt or low self-worth, and pessimism, 
negatively impact adherence to antidepressant treatment. In addition, negative 
consequences in relation to antidepressant medicine consumption are frequently 
reported and can significantly decrease medication adherence. Adherence is a 
dynamic process and is influenced by numerous factors. Furthermore, medication 
adherence generally decreases as the duration of therapy lengthens.23 Therefore, 
comprehensive strategies to address non-adherence to antidepressant medicines are 
important, particularly from the consumer perspective on taking medicines. Accurate 
evaluation of medication adherence is also critical. This requires precise measure(s) 
to assess medication adherence in order to assess medication-taking behaviour. The 
series of research studies described in this thesis focuses on the above-mentioned 
issues in accordance with the ABC taxonomy in which medication adherence is 
divided into three components: initiation, implementation, and discontinuation of 
medicines.2  
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1.2 Unipolar depression 
Unipolar depression is a common mental illness that affects people around the world 
with unique symptoms which directly impact the mood or feelings of the affected 
persons; it is characterised by abnormal and persistent low mood, such as sadness, 
loss of interest or pleasure, feelings of guilt or low self-worth, pessimism, disturbed 
sleep or appetite, feelings of tiredness, and poor concentration and attention.3, 24 
Depending on the severity, depression may be categorised as mild, moderate, or 
severe.12-16, 25 It can be long-lasting, ranging from months to years, and recurrent, 
substantially impairing an individual’s ability to function at work or school or cope 
with daily life.11, 24 In severe cases, depression can lead to suicide.11, 24 The risk of 
becoming depressed is increased by poverty, unemployment, life events such as the 
death of a loved one or break up of a relationship, physical illness, and problems 
caused by alcohol and drug use.11 
1.2.1 Epidemiology and burden of illness 
Depression is a high prevalent chronic condition worldwide. In 2017, 322 million 
people globally were living with depression, which is approximately 4.4% of the world 
population.11 Globally, the number of people with depression has increased by 18.4% 
over the period 2005–2015. It is twice as common among females (5.1%), compared 
to males (3.6%).11 Depression is the single largest contributor to global disability, with 
7.5% of years lived with disability (YLDs), and is ranked as the major contributor to 
death by suicide.11 The consequences of depression are significant in terms of 
personal, clinical, social, and economic burden.4 A 2016 systematic review indicated 
that people who were non-adherent to antidepressant medicines were more likely 
to experience increased risk of relapse and/or recurrence, emergency department 
visits, and hospitalisation rates, increased severity of depression, a decrease in 
response and remission rates, and an increase in healthcare utilisation and charges.4 
In Australia, mental disorders, including depression, are the third largest disease 
group, after cancer and cardiovascular diseases. Mental health contributed an 
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estimated 12.1% of the total burden of disease in 2011, resulting in significant 
disability and morbidity.26 The National Survey of Mental Health and Wellbeing 
reported that almost half the Australian population aged 16–85 years (45%, which 
equates to 8.5 million people based on population data in 2015) experience at least 
one mental health condition, including unipolar depression, at least once in their 
lifetime.27 The mean age of diagnosis of unipolar depression is 27 years, but 40% have 
first episode by the age of 20 years.25 Over 80% of those affected by depression 
experience at least two episodes in their lifetime.25 
1.2.2 Antidepressant treatment in unipolar depression 
Antidepressant medicines are often considered the best treatment option for 
unipolar depression, particularly in moderate to severe depression, and are 
recommended as an initial treatment choice for patients with mild to moderate 
depression.12, 13, 24, 28 The goal of achieving adherence with antidepressants is to treat 
depressive episodes with full functional recovery, prevent relapse, and decrease risk 
of suicide.25, 29 Some clinical practice guidelines recommend the following three 
phases of antidepressant treatment: acute, continuous, and maintenance.12, 13, 16, 30-
32  
For the acute phase, the aim of treatment is to induce remission of the major 
depressive episode and achieve full recovery to the patient’s baseline level of 
functioning.12, 13 In this phase, a range of treatment options are available, such as 
pharmacotherapy, depression-focused psychotherapy, a combination of medicines 
and psychotherapy, or other somatic therapies such as electroconvulsive therapy2, 
transcranial magnetic stimulation (TMS), or light therapy.12, 25 The selection of 
treatment is influenced by clinical features (e.g. severity of symptoms, presence of 
co-occurring disorders, or psychosocial stressors) as well as other factors (e.g. patient 
preference and prior treatment experiences).12, 25 The first-line antidepressants 
recommended for the acute phase of the treatment in Australia are selective 
serotonin reuptake inhibitors (SSRIs) such as citalopram, escitalopram, fluvoxamine, 
and fluoxetine), noradrenergic and specific serotonergic antidepressants (NaSSAs) 
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such as mirtazapine, mianserin, noradrenaline -dopamine reuptake inhibitors (NDRIs) 
such as bupropion, noradrenaline reuptake inhibitors (NARIs) such as reboxetine, and 
melatonin agonist (agomelatine). The second-line treatments include tricyclic 
antidepressants (TCA) such as amitriptyline, clomipramine or serotonin 
norepinephrine reuptake inhibitors (SNRIs) such as desvenlafaxine and venlafaxine 
are suggested.25  
The other treatment guidelines such as the American Psychiatric Association 
guideline (APA guidelines 2010)12 and the American College of Physicians guidelines 
(ACP clinical practice guidelines 2008)16 recommend SSRIs, SNRIs, and selective 
serotonin and noradrenaline reuptake inhibitors (SSNRIs) as the first-line medicines 
owing to their similar efficacy with lower toxicity in overdose when compared to 
tricyclic antidepressants and monoamine oxidase inhibitors. However, other factors 
such as adverse effect profiles, cost, safety profile, history of prior medication 
treatment, and patient preference are important in the initial selection of 
antidepressant medicines, which health care professionals must consider.12, 16 
During the acute phase, at least 4–8 weeks of treatment is needed in order to 
evaluate adequate response to antidepressant therapy.12, 13 In cases of minimal or no 
improvement in symptoms, an additional 4–8 weeks of treatment is recommended 
for investigation and changes to the treatment plan.12, 13  
In the continuous phase, the aim is to reduce the risk of relapse, with people who 
have been treated successfully during the acute phase recommended to continue 
treatment for 6–9 months.12, 13, 16, 30-32 In this phase, systematic assessment of 
symptoms, adverse drug reactions (ADRs), adherence, and functional status is 
essential.12 In addition, it is crucial to monitor both remission and signs of possible 
relapse.12, 16 
Lastly, for the maintenance phase, in certain cases, people with two or more previous 
episodes of depression, longer treatment (one or more years or even for lifetime) 
may be required in order to reduce the risk of early relapse.16, 32, 33 One study 
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reported a relapse risk of 25% in the first year after remission, 42% after 2 years, 60% 
after 5 years and 50–85% after 15 years.33 Hence, regular consumption of 
antidepressant medicines is crucial for both successful treatment and prevention of 
recurrent episodes. Maintenance therapy is recommended in people with additional 
risk factors for recurrence, such as the presence of residual symptoms, ongoing 
psychosocial stressors, early age at onset, and family history of mood disorder.12 A 
full therapeutic dose of antidepressant medicine which produces symptoms 
remission in the acute and continuation phases should be continued throughout the 
maintenance phase.12  
Although generally well tolerated, all antidepressant medicines have been known to 
have negative consequences, including intolerable adverse events which are well-
known leading causes of non-adherence.34-39 A recent systematic review and network 
meta-analysis (2018), which included 522 trials comprising 116,477 participants, 
reported that all antidepressants were more effective than placebo.40 Agomelatine, 
amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine 
were more effective than other antidepressants; whereas fluoxetine, fluvoxamine, 
reboxetine, and trazodone were the least efficacious antidepressants.40 For 
acceptability (treatment discontinuations due to any cause), agomelatine and 
fluoxetine were associated with fewer dropouts than placebo, while clomipramine 
was worse than placebo.40  
 
1.3 Medication adherence in the treatment of unipolar depression 
1.3.1 Overview of adherence terminology and definitions  
Over the past four decades, a variety of terms have been used interchangeably to 
describe medication-taking behaviour among patients, such as ‘compliance’, 
‘adherence’, ‘persistence’, and ‘concordance’.2, 41, 42 Although it is noteworthy that 
these terms have occasionally been used with slightly or significantly different 
meanings, particularly when considering the nature of professional relationships 
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between patients and health care professionals,42 this has contributed to much 
confusion and misunderstanding in the literature.  
In general, compliance refers to the notion of the patient being passively obedient to 
the physician’s instruction, while adherence has a greater sense of cooperation 
between the prescriber and patient.2, 41-45 Concordance focuses more on the 
therapeutic alliance between the physician and patient in negotiating a process, with 
equal respect, and is occasionally incorrectly used as a synonym for compliance and 
or adherence.42, 43, 45 Persistence reflects the duration of time from initiation to 
discontinuation of therapy.41 
‘Medication adherence’ is the most widely used term that refers to medication-taking 
behaviour. It is often a key to successful treatment, particularly in chronic conditions. 
The most cited definition of adherence, proposed by the WHO, defines it as ‘the 
extent to which a person’s behaviour—taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider’.3 
Many patterns of non-adherence have been documented. The WHO classifies non-
adherence to medicine into two main types: ‘primary non-adherence’ and ‘secondary 
non-adherence’.3 Primary non-adherence refers to patients who fail to fill the 
prescription. Secondary non-adherence refers to patients not taking their medicines 
as intended after they have had their prescriptions dispensed; this behaviour can 
range from not following the frequency or dose instructions of the prescription (e.g. 
skipping doses, taking medications at incorrect times or in incorrect doses, taking 
more than prescribed), forgetfulness, errors of purpose, or use of inadvertent 
combinations.3, 8, 46-49  
Secondary non-adherence can be categorised into many other types, such as non-
persistence or non-conformance, and intentional and unintentional non-adherence. 
Non-persistence or non-conformance occurs when a person decides to stop taking a 
medication after starting it, without being advised by a health care professional to do 
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so.8, 46 Intentional non-adherence can be considered as a process in which the person 
actively decides not to use the treatment or follow treatment recommendations.42 It 
is usually related to a personal decision-making process, in which people with 
depression weigh the pros and cons of their treatment plan.42 Intentional non-
adherence arises from the beliefs, attitudes, and expectations that influence peoples’ 
motivation to begin and persist with the treatment regimen.42, 45 On the other hand, 
unintentional non-adherence refers to unplanned behaviour which is less associated 
with beliefs and level of cognition when compared with intentional non-adherence.42 
Unintentional non-adherence can occur due to capacity and resource limitations 
which prevent people from implementing their decision to follow treatment 
recommendations (e.g. problems of accessing prescriptions, cost, competing 
demands, etc.) and occasionally involves individual constraints (e.g. problems 
remembering doses etc.).48 
In 2012, a European consortium of researchers in the field of medication adherence 
conducted the ABC project which proposed a new taxonomy on medication 
adherence in order to identify the different conceptual approaches to adherence 
research.2 They reported ‘adherence to medication’ as ‘the process by which patients 
take their medications as prescribed, composed of initiation, implementation and 
discontinuation. Initiation occurs when the patient takes the first dose of a prescribed 
medication. Implementation is the extent to which a patient’s actual dosing 
corresponds to the prescribed dosing regimen, from initiation until the last dose. 
Discontinuation marks the end of therapy, when the next dose to be taken is omitted 
and no more doses are taken therafter’.2 Figure 2 illustrates the definition of the 
adherence process endorsed by the ABC project.2 
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 Figure 2: The process of adherence to medication and definition of medication 
adherence endorsed by the ABC project (2012),2 adapted from the original article.   
 
The ABC framework is the first taxonomy that endorses the conceptual foundation of 
medication adherence based on behavioural and pharmacological science which 
supports quantifiable parameters.2 The framework is suitable for our research, as it 
provides a transparent taxonomy which makes a clear distinction between processes 
that describe actions through established routines. Therefore, it was adopted as the 
main conceptual framework for studies conducted in this thesis. Specifically, this 
framework provides a clear delineation for a more detailed and nuanced 
understanding of consumers’ medication-taking process. This framework may enable 
a better and more detailed understanding of medication-taking in consumers with 
depression from the consumer’s perspective, a necessary consideration when 
strategies to improve medication adherence are being implemented. 
1.3.2 Scope of non-adherence to antidepressants in unipolar 
depression 
Low adherence and persistence to antidepressant medicines in people with unipolar 
depression are commonly reported. At the initiation of treatment, only a limited 
number of studies pertaining to antidepressant adherence was found. One study in 
the United States reported that 5% of participants (40 of 765 patients) have filled but 
never initiated antidepressant medicine.38 Another study reported that one-third of 
patients did not fill their antidepressant prescription for six months following the 
receipt of their first prescription (approximately 1,620 of 4,860 patients), with the 
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rates being higher among those prescribed tricyclic antidepressants compared with 
newer generation antidepressant medicines.50 A US database study has also shown 
that adherence to antidepressant medicines has decreased over time (41% at 3 
months, 31% at 6 months, 24% at 9 months, and 21% at 12 months respectively).22 
For the maintenance phase of recurrent depression, adherence rates have been 
reported to be between 39.7% to 52.7%, when assessed with the Morisky, Green, 
and Levine Self-reported Medication-taking Scale (MGLS).51 
Early discontinuation rates occur during the first month of therapy, with 
approximately 25% of people with unipolar depression ceasing their antidepressant 
medicine without informing their physician.17, 52 A recent study stated that 28% of 
patients (6,952 of 24,817 patients) discontinued their antidepressant medicine after 
receiving their first prescription.53 Overall, approximately 50–60% of patients 
discontinued their antidepressant medicine within the first 10–24 weeks of 
treatment, while the average length of treatment is commonly reported as less than 
six months.17-19, 54, 55 Non-adherence to antidepressant medicine was varied among 
different types of antidepressant medicines (according to their pharmacological 
properties), severity of depressive symptoms, duration of episode, as well as the 
inconsistency of adherence/non-adherence rate obtained from using different 
measures of medication adherence.35, 56-66 
Depression is a well-known risk factor to non-adherence.6, 7 People with depression 
reported three times greater non-adherence (odds ratio) than non-depressed 
patients, and 1.76 times higher than those with asthma, coronary heart disease, 
diabetes, hyperlipidaemia, or hypertension.6, 67 Being depressed impacts adherence 
to chronic treatment regimens irrespective of disease and, therefore, depression can 
have an added impact on non-adherence to antidepressant medicines. Furthermore, 
worsening adherence can worsen depression, which in turn can worsen adherence, 
and then the cycle repeats itself.  
The consequences of non-adherence to long-term therapy include poorer health 
outcomes and increased healthcare utilisation and charges.3, 4 Medication non-
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adherence in depression has led to unnecessary switches in antidepressant medicine, 
unnecessary instructions to increase doses, initiation of unwarranted adjuvant 
treatments, increased risk of relapse and/or recurrence, and misclassification of 
treatment resistance.68 In addition, it is associated with an increase in emergency 
department visits and hospitalisation.4 
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1.4 Measures of medication adherence in unipolar depression  
In order to evaluate medication adherence in people with unipolar depression, the 
percentage of prescribed doses of the medicine actually taken by the person over a 
specified period (adherence rate) is usually reported.10 In general, good adherence 
has been defined as an adherence rate greater than or equal to 80%.69, 70 It may be 
estimated by the objective measure of pill counts: [No. of pills absent in time X/ No. 
of pills prescribed for time X ] x 100].70 
The methods available to assess medication adherence can be categorised into 1) 
direct or indirect measures44, 71 and 2) objective or subjective measures.72, 73 Direct 
measures include measurement of the medicine or its metabolite concentration in 
body fluids, such as blood or urine and the presence of biological markers which 
indicate a patient’s medication taking behaviour.73 Although direct approaches are 
one of the most accurate measures of medication adherence, they are less useful in 
practice due to their cost, their intrusive nature, and because they may be technically 
demanding, time consuming, and impractical.17 Most of the currently available tools 
to evaluate medication adherence in clinical settings are indirect measures of 
adherence (e.g. pill counts, patient self-report, clinical response, Medication Event 
Monitoring System (MEMS), and medical record or prescription refill records).71 
Indirect measures like specifically standardized adherence questionnaires are 
generally considered more practical due to their ease of administration, affordability, 
and relatively unobtrusive approach.74, 75 Furthermore, a number of patient self-
reported measures include specific advantages such as the ability to provide 
information on attitudes and beliefs regarding medications (Beliefs about Medicines 
Questionnaire or BMQ by Horne76) and the ability to distinguish between intentional 
and unintentional non-adherence (the MGLS77).74, 75 As beliefs regarding particular 
health conditions and its treatment are closely linked to medication-taking 
behaviour,76 the identification of the intention to take medicines can differentiate 
causes of non-adherence and, therefore, inform the use of different interventions.74 
For this reason, apart from the validity and reliability of the tools, the selection of an 
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appropriate type of adherence measure is another important consideration. At the 
same time, ‘questioning’ the patient can be susceptible to misrepresentation, 
depending on the willingness to disclose information, which can influence response 
accuracy as well as validity.44, 75 Further, it can also overestimate a patient’s 
medication adherence as well as the overestimation from patient self-report.44  
Objective measures of medication adherence may provide a higher level of reliability 
when compared to subjective measures. Objective measurements include drug 
metabolite and biological markers, MEMS, pill counts, prescription refill, and data 
from claims databases, although each type of measure has both pros and cons. MEMS 
is often accepted as an accurate measurement; however, the system is expensive and 
impractical for everyday use. It requires device installation, connection, and data 
processing. In addition, it is generally only used for selected dosage forms and not for 
others such as patches, drops, creams, etc. Pill counts do not provide important 
information on dose timing and patterns of missed dosages or drug holidays.3, 44 
Further, pill counts are time-consuming, labour-intensive, and less accurate when 
compared with other measures.58 Pill counts may not reflect adherence if a patient 
suspects that they are being monitored, as they may simply throw the pills away to 
lower the pill count. However, pill counts are useful, particularly if an “unannounced” 
home visit is made. Prescription refill and claims data provide accurate measures of 
dispensing in a closed pharmacy system (e.g. a health maintenance organization or 
countries with universal drug coverage and linked dispensing systems) and are useful 
for long-term investigations.44 They can be used to check when prescriptions are 
initially filled, refilled over time, and prematurely discontinued. Inaccuracies clearly 
occur when databases are incomplete. Prescription refill and claims data do not 
directly reflect whether or not a medicine has been used, rather, they indicate 
whether or not a medicine has been dispensed.44 
Despite the various methods used to evaluate medication adherence, there is no 
universally accepted gold standard measure.3 Ideally, a ‘gold standard’ measure 
would be 1) direct, 2) objective, and 3) unobtrusive.3 Currently, MEMS, is recognised 
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as a more sensitive measure; however, it cannot be ‘proven’ that the patient has 
taken the medicine with the correct dose or at the correct time.44 Consequently, 
multiple measures are typically recommended to evaluate medication adherence in 
practice.  
To sum up, measurement of medication adherence provides useful information 
regarding the estimation of a patient’s actual medication-taking behaviour and is 
beneficial to health care professionals when monitoring treatment outcomes and 
developing and modifying treatment plans. In order to assess accurate adherence 
rate, health professionals should select measurement(s) with good reliability and 
validity to ensure the precision and accuracy of obtained results. In addition, 
adherence measures may be better suited to measure a particular phase or phases 
of adherence (e.g. initiation, discontinuation).71  
 
1.5 Factors influencing medication adherence in unipolar depression  
Numerous factors, both positive and negative, influence medication adherence in 
people with unipolar depression. The WHO (2003) classified these factors into five 
dimensions: social and economic factors, health care team and system-related 
factors, condition-related factors, therapy-related factors, and patient-related 
factors.3 Since the ability of people to follow their treatment plan is frequently 
compromised by multiple factors, tailored-interventions with multidimensional 
aspects should be implemented in order to address non-adherence problems to 
enhance adherence to medicines.3 
While the complexity associated with taking medicines on a routine basis by people 
with depression represents a good starting point, other factors should also be 
considered. These include the influence of health care professionals, carers, and 
society in general as well as the consequences of antidepressant use (e.g. potential 
adverse effects and the effectiveness of the selected treatment). Furthermore, it is 
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noteworthy that some factors may have a positive influence on adherence in certain 
individuals but a negative influence on others and vice versa.  
1.5.1 Facilitators of medication adherence in unipolar depression 
Common factors associated with good adherence include a positive attitude towards 
antidepressant medicine, previous experiences, and vicarious experiences of 
depression or treatment, and welcoming positive effects of antidepressant medicines 
(i.e. effectiveness of antidepressant medicines).20, 35, 55, 62, 78, 79 Other factors which 
are associated with increased adherence in unipolar depression are sufficient 
information and knowledge of depression and antidepressant medicines provided by 
health care professionals, accessible health care professionals, and family support 
with positive attitude towards antidepressant treatment.38, 61, 62, 80 36, 37, 60, 81 These 
factors are depicted in Table 1.  
1.5.2 Barriers to medication adherence in unipolar depression 
Many studies have reported that feeling better and unbearable ADRs are the two 
most common barriers to ongoing adherence, thereby contributing to early 
discontinuation of antidepressant use.17, 39 35-39, 55, 64, 78, 81, 82 Sexual dysfunction, sleep 
disturbances, and weight gain were perceived to be of most concern.82 In addition, 
forgetfulness, a common unintentional reason for non-adherence, was also found to 
lead to omission of doses.29, 39, 83 Self-stigma, a well-known barrier to medication 
adherence, is a significant factor with negative correlation to good adherence.65, 84-86 
From the long-term viewpoint, inadequate adherence to treatment may be related 
to beliefs and perceptions regarding antidepressant medicines rather than its 
undesirable effects.23  
Unsatisfactory interactions between health care professionals and people with 
unipolar depression, including a lack of health care professional attention to the 
consumer’s concerns, may also decrease adherence to antidepressant medicines.66,
78, 80 Difficult access to physicians or to having medicines dispensed, over-prescribing 
on the part of the physician, dissatisfaction with treatment, low income, low 
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socioeconomic status, and severity of depression were also found to be associated 
with poorer adherence or persistence.23, 35, 39 
In terms of early discontinuation of antidepressant treatment, one significant reason 
perceived by people with unipolar depression was the lack of perceived need for 
antidepressant medicines once they felt better.39, 82 The absence of a support 
network, particularly family support, was perceived to be a potential factor to non-
adherence as well as poor lifestyle factors and unstable living conditions.61, 82 A 
summary of factors influencing non-adherence are presented in Table 1. 
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Table 1 Facilitators of and barriers to antidepressant adherence in unipolar depression 
Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
1. Factors relating to health care professionals and health care system 
1) Health care 
professionals 
(HCPs) influence on 
medication 
adherence  
• HCPs role as a facilitator87  
 
• Multiple prescribers36 
2) Relationships 
between HCPs and 
patients 
• Good relationship17, 35, 62, 
78, 80, 81 
• Rapport established80  
• Positive HCP-patient 
interaction66 
• Lack of attention to the 
patient80 
• Apparent dismissive 
reaction80 
• Superficial or glib 
responses from doctors to 
patients80   
• Unsatisfactory interaction 
with HCPs78 
• Disconnected 
relationship78 
• Patient fear of HCPs36 
• Negative HCP-patient 
interaction66 
3) Support from 
HCPs/ helpfulness 
of HCPs visits  
• Rating general 
practitioners (GPs) visits 
as moderately to 
extremely helpful60 
• Good support from 
HCPs37, 80 
 
4) Interactive 
communication 
and open dialogue 
between HCPs and 
patients  
• Communication60, 78, 88 
• Two-way communication/ 
being listened too80 
• Shared decision-making80 
• Early discussion62 
• Problems communicating 
with HCPs36 
• Poor provider-patient 
communication44 
• Patient-physician 
discordance44 
5) Adequate 
information about 
depressive 
treatment from 
HCPs 
• Adequate information38, 62, 
80 
• Patients are expected to 
be informed about 
medicines before 
treatment initiation78 
• Required more 
information from their 
doctors before taking the 
first dose80 
• Inadequate knowledge 
about antidepressant 
medicine and its use44 
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Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
• Sufficient information 
form HCPs37, 81 
• Knowledge about the 
causes of depression and 
mechanism of 
antidepressant 
medicines37 (and other 
relevant issues51) 
 
6) Adequate time to 
see the doctor/ 
length of GPs visit 
• GP visits longer than 20 
mins60 
• Sufficient time during the 
consultation17, 78, 80 
• No obligation to rush62 
• Insufficient time to see 
the doctor/ in a rush60 
2. Factors relating to the health care system 
1) Accessibility to 
HCPs/ Access to 
practice 
• Accessible36, 60 
 
• Difficult access44, 61, 82 
2) The continuity of 
care in public 
system/ health 
system 
• Continuity of care60 
 
• Lack of continuity of care60 
3) Management issue • Frequent clinic visits36 
 
• Long waiting time at the 
clinic36 
• Frequent medication 
refills36 
• No supply of 
medications36 
3. Factors relating to patients and carers 
1) Patient self-
motivation 
• ‘will power’62 
• Wish for complete 
recovery36 
• Fear of relapse36 
• The ownership of the 
decision37 
 
2) Acknowledgement 
of their depression 
condition 
• Accepted their health 
conditions78/diagnosis62 
 
• Non-acceptance of the 
diagnosis78  
3) Previous 
experience of 
antidepressant 
treatment 
• Previous experience of 
antidepressant 
treatment35, 39, 78 
• Unfavourable experiences 
towards antidepressant 
treatment*  
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Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
• Personal or family 
experience of 
antidepressant medicine, 
frequently negative62 
4) Family support • Family’s positive attitude 
toward medication61 
• Family support 
(family/spouse)36 
• Cultural beliefs36 
• Family’s negative attitude 
toward medication61 
• Cultural beliefs36 
• Lack of family support61, 82 
5) Peer support • Support from friends36 
• Trusted friends62 
• Social support36, 81, 89 
• Similar experience 
sharing/ support from 
people with depression79 
 
6) Patient regular 
activities 
• Habit such as taking with a 
meal36 
 
7) Stigma about 
depression/ 
antidepressant 
medicines 
 • Stigma related to 
perceived drug 
dependency80  
• Strong self-stigma 
attached80  
• ‘Felt’ Stigma79; refers 
principally to the fear of 
discrimination on the 
basis of perceived 
unacceptability or 
inferiority, as opposed to 
actual instances of 
discrimination. 
• Self-stigma35, 65, 85 
• Stigma associated with 
both having depression 
and taking antidepressant 
medications82 
8) Stigma in society  • Societal stigma36, 39 
• This type of stigma was 
connected to the view 
that psychotropic 
medications would affect 
cognitive functions. It was 
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Dimensions Facilitators of antidepressant 
adherence 
Barriers to antidepressant 
adherence 
based on actual 
discriminatory remarks by 
others and can therefore 
be interpreted as 
‘enacted’ stigma.79 
• Public opinion about
depression and its
treatment reveals
reluctance to consult
practitioners about
depressive symptoms, and
evidence that counselling
is favoured over
antidepressant
treatment.62
9) The ability to self-
manage on
medication taking
• Self-help practices60
10) Concern about the
effect of stopping
antidepressant 
therapy 
• Experiencing symptoms
worsening when they
weren’t regularly taking
antidepressant39
• Fear of withdrawal
symptoms87
• Fear of relapse87
• Uncertainty about what
would be like without
antidepressants87
11) Clinical
improvement/ 
feeling better 
• Welcoming effects of
antidepressant78
• Recovery62, 79 and positive
treatment outcome35
• Early treatment
response81
• Feeling better55
• Lack of therapeutic
response38
• Lack of efficacy36, 37, 39, 55, 66
• Feeling better17
12) Patients who have
trust in their HCPs
• Trust in HCPs36, 78, 80 , Trust
in GPs60
• They believe that ‘doctor
knows best’80
13) Knowledge about
depression and 
• Knowledge78, 80 • Lack of knowledge about
the use of antidepressant,
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Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
antidepressant 
medicine 
the effect of 
antidepressant36, 82 
14) Forgetfulness  • Forgetfulness29, 36, 39, 83 
• Including: having a busy 
schedule, being away 
from home, simply 
forgetting to take their 
antidepressant36 
15) Perceive drug 
dependency and 
addiction 
 • Fear of drug dependency 
and/or addiction80 
• Fear of drug 
dependence36, 55 
(erroneous belief, 
misconceptions about 
depression and/or 
antidepressant)36 
16) Patient perceptions 
and beliefs about 
depression 
• Positive perceptions and 
beliefs about depression78, 
80 
• Negative perceptions and 
beliefs about depression78, 
80 
 
17) Patient concerns 
about sense of self 
while using 
antidepressant 
medicines 
 • Sense of self,80 not feeling 
like oneself39 
• Worries about the feeling 
‘fluffy’ or ‘out of control’ 
when using 
antidepressant80 
• Sense of self control55 
• Self-reliance39 
18) Patient beliefs 
about the need for 
antidepressant   
• Beliefs about the need for 
antidepressant66, 78, 80 
• Awareness about the 
need to take 
antidepressant36 
• Uncertainty about the 
benefits of and the need 
for antidepressant87 
 
19) Attitudes towards 
antidepressant 
• Positive attitudes towards 
antidepressant37 
• Beliefs about efficacy of 
antidepressant78 
• Belief/ perception16, 36, 62, 
63, 90 
• Faith81 
• Negative attitudes such as 
a dislike for the pill36, 37 
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Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
• Beliefs and attitudes 
towards depression and 
antidepressant35 
• Attitudes toward 
antidepressant35, 78, 81 
20) Reminders • Such as using pillboxes, 
reminder form family 
members, keeping 
medications in visible 
places36 
 
4. Demographic and socioeconomic factors 
1) Level of education • Higher level of education 
predicted the correct 
intake of antidepressant81 
• Education level61 
 
2) Cost of 
antidepressant 
medicines 
 • Cost of antidepressant36, 44 
 
3) Benefits as main 
source of income 
• Benefits as main source of 
income60 
 
4) Family income  • Low family income35 
5. Disease and medicine factors 
1) The severity of 
depressive 
symptoms 
• Severity of depression60, 62-
66 
 
• Severity of depression60, 62-
66 
2) Inherent of 
depressive 
symptoms  
• Diagnosis of depression69  
• Clinical features of 
depression35 
• Clinical features of 
depression6, 7, 9, 35, 82 
 
3) Chronic conditions 
that require long-
term treatment  
 • Chronic condition of 
depression which requires 
long-term treatment60, 78 
4) Recurrent episode  • Recurrent depressive 
episode60, 61 
5) Comorbidity  • Comorbidity35, 36, 60, 65, 80, 90-
92 
• Including alcohol 
dependence7, 36 and 
substance abuse90 
6) Length of 
depressive illness 
 • Length of previous 
illness62 
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Dimensions Facilitators of antidepressant 
adherence  
Barriers to antidepressant 
adherence 
• Longer onset of 
depression81 
7) Category of 
antidepressant 
used 
• Category of 
antidepressant used60 
• Category of 
antidepressant used60 
8) Other medicines 
used 
• Polypharmacy69  • Pill burden36 
 
9) ADRs  • Experiencing ADRs17, 35-39, 
55, 64, 78, 81, 82 
• Concern about the 
potential ADRs39, 78, 80 
• Fear of ADRs44 
10) Medication 
duration of 
treatment  
 • Medication duration of 
treatment36, 61 
• Long term drug regimens44 
11) Medication onset • Pharmacological factors35 • Pharmacological factors35 
12) Complex regimen  • Complex regimen44 
13) The absence of 
pathology 
 • Absence of personality 
pathology65 
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1.6 Medication adherence frameworks 
In the past two decades, many strategies have been implemented to improve 
medication adherence in people living with unipolar depression, such as behavioural 
interventions, educational interventions, and multifaceted interventions.93 In order 
to develop effective approaches, there is a need for clear understanding of the entire 
process of adherence/non-adherence to antidepressant medicine. A conceptual 
framework is a tool that has been extensively used to explain the phenomena that 
are linked to multidisciplinary bodies of knowledge, and has been adopted to better 
understand and enhance adherence to medicine in many conditions such as diabetes 
and heart failure.94, 95 A few frameworks have been developed for unipolar 
depression, but none of them has been specific to medication adherence.96-103 
1.6.1 Conceptual frameworks and theoretical models  
The current usage of the terms ‘conceptual framework’ is not precise and occasionally 
has been used erroneously.104 A conceptual framework is a logical structure of a 
theory or model in a discipline.105, 106 Jabareen (2009) has defined a conceptual 
framework as ‘a network or a plane of interlinked concepts that together provide a 
comprehensive understanding of a phenomenon or phenomena’.104 The concepts that 
constitute a conceptual framework support one another, articulate their respective 
phenomena, and establish a framework-specific philosophy.104 Conceptual 
frameworks usually denote a structure, overview, outline, system, or plan comprising 
various descriptive categories.107 The relationships among these categories are 
presumed to account for the phenomenon.107 Generally, the framework describes 
the phenomena by fitting them into a set of categories.107 Consequently, conceptual 
frameworks have been extensively implemented in various disciplines to elucidate 
relationships between concepts of interest (such as in business and marketing, 
politics, tourism management) as well as in health sciences, including medication 
adherence in specific conditions.94, 95, 108-114 For unipolar depression, conceptual 
frameworks have been applied to improve the quality of treatment.96, 98, 99, 101-103, 115 
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However, no framework has been specifically created to address the non-adherence 
problem in people with depression. 
A model typically involves a deliberate simplification of a phenomenon or a specific 
aspect of a phenomenon.107 It is closely related to theory and can be described as 
theory with a more narrowly defined scope of explanation.107 Many theoretical 
models are commonly implemented to explain health behaviours, including 
adherence to medicines. For example, the Health Belief Model (HBM), theory of 
planned behaviour, transtheoretical model of behaviour change etc.47, 109, 116-118 
However, none of the existing conceptual frameworks or behavioural models are 
specifically focused on depression. The strengths and limitations of these models 
when they were employed to enhance medication adherence is presented in Table 
2. 
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Table 2 Strengths and limitations of the theoretical behavioural models that have 
been commonly applied to improve medication adherence in chronic diseases.118-122 
Model Strengths Limitations 
Health Belief 
Model (HBM) 
It is able to explain why people 
fail to undertake preventive 
health behaviour, investigating 
based on the assumption that 
patients weigh the benefits 
versus the barriers to treatment 
when deciding whether or not 
to adhere to medications. Six 
components were 
conceptualized: perceived 
barriers, perceived benefits, 
perceived susceptibility, 
perceived severity, cues to 
action, and self-efficacy.118, 119 
This model is limited to health-
risk behaviours and as such 
cannot help the researchers 
understand the environmental, 
social and personal factors that 
influence specific health 
conditions.118 Also, it has low 
predictive capacity of the 
variables.120 Lack of clear rules 
of combination and relationship 
between the individual variables 
is indicated.120 
Theory of planned 
behaviour 
The efficacy in explaining 
substantial amounts of variance 
in both intentions and 
behaviour in health domains 
from a relatively parsimonious 
set of predictors.122 
The manipulations based on the 
theory lead to substantial 
changes in behaviour and the 
gap between intentions and 
behaviour.122 
Self-regulatory 
model 
It accounts for both emotional 
and cognitive influences in 
explaining patient’s 
behaviour.119 
Little supporting data and 
difficult to use in studies 
because of multivariate 
nature.119, 121
The 
transtheoretical 
It presents behaviour change as 
a series of stages, therefore, it is 
It ignores social context of 
change, i.e., socioeconomic 
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Model Strengths Limitations 
model of 
behaviour change  
important to tailor approach to 
behaviour change by first 
identifying an individual’s 
stage.119, 123
status differentiation between 
the stages can be arbitrary, 
because there are no set criteria 
to determine an individual’s 
stage of change.119  
The cognitive 
model 
Adherence is directly related to 
an individual’s attitudes, beliefs, 
and expectations regarding 
treatment. This model focuses 
on the conscious, intentional 
decision-making.119, 121   
It does not adequately address 
the automatic, habitual 
behaviours.119, 121
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1.6.2 Conceptual framework and theoretical model used in medication 
adherence  
Current frameworks pertaining to medication adherence have been designed to 
address non-adherence problems in non-specific conditions. Some of them have 
been adopted to explain non-adherence to antidepressant medicines in unipolar 
depression such as the Capability, Opportunity, and Motivation (COM-B) model of 
behaviour and the necessity-concerns framework (NCF).110, 116, 124, 125  
The COM-B is a comprehensive framework that focuses on behaviour change; 
therefore, it is applicable in medication-taking behaviour. The framework comprises 
three main components—capability, opportunity, and motivation—which impact the 
performance of the behaviour and, hence, can provide explanations for why a 
recommended behaviour has not been implemented.116, 126 In light of medication 
non-adherence, the COM-B framework helps to describe a wide range of factors 
which have been identified to explain non-adherence to medication as well as 
identify appropriate change techniques to improve adherence.116 However, because 
of the complexity of the non-adherence process, the COM-B framework does not 
clearly explain or classify all factors pertaining to non-adherence in certain 
circumstances such as depression and substance abuse.116 This indicates the need for 
a more specific framework for people with depression.  
The approach to medication adherence has shifted over recent years, from a focus 
on the role of the doctor to patients’ beliefs, motivation, and planning abilities.116, 127 
Consequently, there is a need for a nuanced medication adherence framework for 
use in practice: in other words, a medication adherence framework that can be 
adopted to everyday practice which adopts a patient-centred approach.116, 128 One 
such approach is the NCF. The NCF has been used extensively and has proved to 
provide a conceptual framework for understanding patients’ perspectives on 
prescribed medicines.110, 124, 125, 129 The NCF highlights patients’ beliefs regarding 
medicines which influence medication adherence.110, 125, 129 It indicates that patients 
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weigh up their perceived personal need for treatment against their concerns 
regarding negative consequences. Essentially, patients are more likely to adhere to 
their treatment when perceived need exceeds perceived harm. In other words, 
people who were less sceptical (high necessity and low concerns) were more likely to 
adhere to antidepressant medicines.110, 125  
Although the NCF has been widely used, its focus is on the belief aspect. As previously 
mentioned, medication adherence is a multidimensional behaviour which requires a 
multifaceted approach, hence the adoption of a single concept may not be adequate 
to address other aspects of medication non-adherence for the entire process of 
adherence. 
Although existing frameworks have been created to address medication non-
adherence, they do not necessarily directly map to conditions such as depression. 
Nor do they directly consider the dynamic nature of medication-taking, which can 
change over time.116, 130-136 Even though some frameworks have identified a range of 
explanatory factors pertaining to medication-taking behaviour, they do not explicitly 
identify relevant details in the adherence process, which is crucial for health care 
professionals when creating tailored interventions as the most effective strategy to 
enhance medication adherence in chronic diseases, including unipolar depression.93  
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1.7 Aims and objectives  
In order to achieve a successful treatment outcome in unipolar depression, it is 
crucial to ensure that consumers are constantly and correctly taking their 
antidepressant medicines. Because adherence is a multidimensional process in which 
various factors may influence an individual’s medication taking behaviour, it is 
important to provide a framework for health care professionals to better understand 
medication-taking behaviour in consumers with depression. 
The overall aim of the research described in this thesis was to explore and examine 
issues pertaining to medication adherence in people living with unipolar depression.  
To address these research aims, three key steps of investigation were conducted 
(Figure 1: The overview of the thesis). The specific objectives of each step are 
reported below: 
Part B: The psychometric property of medication adherence measures in unipolar 
depression.  
1) To systematically identify and evaluate the range of medication adherence 
measures used to assess medication adherence in a specific phase (i.e. 
initiation, implementation, and discontinuation), in consumers taking 
antidepressant medicines for unipolar depression.  
2) To evaluate the psychometric property of adherence measures used in 
unipolar depression. 
Part C: Factors influencing medication adherence to antidepressant medicine in 
unipolar depression. 
1) To explore the strategies or positive influencing factors which promote 
medication adherence in three phases of adherence (i.e. initiation, 
implementation, and discontinuation) in unipolar depression from the 
consumer perspective. 
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2) To explore the barriers or negative influencing factors which reduce 
medication adherence at three phases of adherence (i.e. initiation, 
implementation, and discontinuation) in unipolar depression from the 
consumer perspective. 
Part D: Development and validation of the medication adherence framework in 
consumers with unipolar depression.  
1) To develop and propose the conceptual framework that illustrates potential 
factors influencing medication-taking behaviour in consumers with unipolar 
depression. 
2) To evaluate face and content validity of the proposed framework.  
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CHAPTER TWO: Methods  
 
This chapter provides detailed information pertaining to the rationale of the methods 
used in conducting the research presented in this thesis. The overall aim of the 
research described in this thesis was to explore and examine issues pertaining to 
medication adherence in people living with unipolar depression, using the ABC 
taxonomy as a framework. The specific objectives are reported in Chapter One, 
section 1.7. This thesis comprises four main parts (Parts A–D). 
Part A of this thesis presents the thesis overview, including the background and scope 
of the problems of the research as well as the aims and objectives of the research 
included in this thesis.  
Part B of this thesis involves a systematic review of the literature. This part employs 
a standard approach for conducting systematic reviews, the Preferred Reporting 
Items for Systematic Reviews, and Meta-Analyses (the PRISMA statement).137 
Specifically, the aim was to systematically identify and evaluate the range of 
medication adherence measures used at specific phases of adherence in accordance 
with the ABC taxonomy (initiation, implementation, and discontinuation) and then 
evaluate the psychometric properties of these measures of adherence.  
Part C of this thesis explores the factors influencing medication adherence at each 
phase of adherence in accordance with the ABC taxonomy, elicited from people living 
with unipolar depression. For this stage, a qualitative approach informed by 
phenomenology was adopted. This approach was considered appropriate as it can be 
used to obtain a profound understanding of a particular issue or phenomenon (i.e. 
factors influencing medication adherence at specific phase of adherence) based on 
the lived experiences of consumer perspectives.138-142 Both facilitators of and barriers 
to medication adherence were identified for each phase of medication-taking. This 
approach allows an in-depth exploration of ‘what influences medication adherence’, 
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‘how adherence is facilitated’ or ‘why medication adherence or non-adherence 
occur’, rather than just measuring the phenomenon.138 Due to the complexity of the 
behaviour (phenomenon of interest), a qualitative approach was deemed 
appropriate, as it allows for a detailed understanding of concepts and generates 
hypotheses on the phenomenon of interest. Thereafter, the obtained information 
could be further generated for the next step of framework development (Part D).143 
Part C is informed by the consolidated criteria for reporting qualitative research 
(COREQ) in order to ensure the comprehensiveness of the procedure.144  
Part D of this thesis comprised the development and validation of the medication 
adherence framework for people with unipolar depression. This framework was 
informed by the findings of qualitative study (Part C), review literature, and the 
experience of the research team. The aim of this part was to develop and content 
validate this adherence framework. A content validation method using an expert 
panel was employed for the validation process of the framework. This approach is 
common for framework evaluation.  
The chapters in this thesis have been presented in the form of research manuscripts 
and in accordance with journal word counts. Although, each manuscript includes a 
section on methods, due to word limits, a detailed explanation of the rationale 
behind the methods used was not included. Therefore, in order to address this, this 
chapter further describes the methods used. It also includes supportive principles 
employed in the research included in this thesis. It should be noted that the 
information written in journal formats are not presented in this chapter in order to 
avoid repetition. 
This chapter contains three main sections on methods employed: 1) psychometric 
properties of adherence measures, 2) qualitative methods, and 3) the development 
and validation of the conceptual framework. 
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2.1 Psychometric properties of adherence measures  
The precise and accurate measurement of medication adherence is critical to any 
study of medication adherence. No previous research has documented the 
psychometric properties of the measures of medication adherence used by 
consumers who were prescribed antidepressant medicines for the management of 
depression. Part B (Chapter Three) of this thesis focused on an appraisal of the 
psychometric properties of adherence measures used to evaluate medication 
adherence to antidepressant medicines for the management of depression in 
accordance with the ABC framework. The PRISMA statement was adopted to 
systematically search and analyse the obtained information in the systematic review. 
This section expands critical areas of the method employed for the systematic review 
to underpin the underlying rationale. This section contains three main aspects. The 
first part contains detailed information on the systematic review process. The second 
part focuses on the issues relevant to the psychometric properties of the 
measurements. The third part provides key information pertaining to the adoption of 
the ABC framework in the analysis process.  
2.1.1 The systematic review process  
A systematic review was conducted as it provides both reliable and defensible 
findings due to the rigorous procedure, when compared to other types of reviews.137, 
145-148 Although systematic reviews of the measurement of medication adherence and 
its psychometric properties have been conducted in certain conditions such as HIV 
and adult transplant patients,149, 150 no previous study has been conducted among 
people with unipolar depression. Our focus for this study was to robustly evaluate 
the psychometric properties of tools used to evaluate medication adherence in 
people with unipolar depression. Consequently, we needed to make precise 
assessments and to comprehensively understand the psychometric properties of 
adherence measures. Strict inclusion and exclusion criteria for included papers were 
applied. This helped to maximise the internal validity of our findings, potentially 
trading off with external validity. In addition, in order to strengthen the internal 
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validity of the study, we excluded people over 60 years of age. Although we 
acknowledge that there is no clear cut-off for memory (which can influence 
adherence) and aging, we chose a conservative cut-off value for this study.151 
Similarly, children and pregnant women were also excluded as the consumption of 
medicines in children is usually administered by carers and depression during 
pregnancy is very specific condition. That is, the inclusion of potential confounding 
comorbidities might impair the internal validity of our findings.  
During the search procedure, the timeframe for searching was set for the last two 
decades (1994–2015), because this period captures a time in the literature where the 
term ‘compliance’ shifted to ‘adherence’. Conceptually, this change reflects a shift 
from the notion of ‘obedience’ to the notion of ‘cooperation’.2 The period also 
allowed for adequate time to obtain a comprehensive answer to our research 
questions. Importantly, this period also included the development of several well-
known and used self-report measures of adherence (e.g. MGLS and BMQ).76, 77  
2.1.2 Psychometric properties of the measurements 
Despite the range of surrogate measures which have been developed to assess 
medication adherence in unipolar depression, there is no a recognised standard 
measure which provides an accurate and precise measurement of adherence. In 
general, the selection of an ‘appropriate’ measurement should consider the specific 
propose of the measure, population and settings, and the accuracy of the tool. 
Because the accuracy of the measure is key to obtain credible findings, there is a need 
to evaluate psychometric properties of the measure. When evaluating psychometric 
properties, the key concepts are reliability and validity, as provided in the definitions 
used in the manuscript (Table 1). 
With regard to the evaluation and data analysis process, a number of measurement 
properties were reported, such as reliability and validity of the measure, correlation 
between measures, agreement between measures, correlation between clinical 
outcome (depressive symptomatology scores) and adherence scores, and 
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concordance between measures. Many studies did not clearly specify the type of 
psychometric tests performed; therefore, the researchers categorised measures 
based on the definitions presented in Table 1 (page xx). For example, we categorised 
validity tests into different types such as ‘concurrent validity’, which occurs when 
medication adherence is assessed simultaneously using two different measures. In 
the absence of a universally accepted gold standard measure for adherence, we used 
the MEMS, as it is widely accepted as one of the most accurate tools. 
The reliability of medication adherence measures was predominantly reported when 
consumer self-report measures were used both for the researcher developed self-
report scales and standardised self-report scales. Therefore, the main type of 
reliability test provided was that for internal consistency reliability, reported as 
Cronbach’s alpha. The interpretation of Cronbach’s alpha values were made in 
accordance with ranges reported in the literature.152, 153 For example, in general, the 
minimum acceptable level of Cronbach’s alpha varies between 0.60–0.80, while the 
value 0.70 is more commonly accepted.152, 153 In addition, considering another study, 
the range of the Cronbach’s alpha value of the Antidepressant Adherence Scale (ASS) 
was reported from 0.60-0.86 in a different time frame during the first 12 weeks of 
treatment.83 Consequently, we concluded that the AAS represents acceptable 
reliability. For the MGLS, a range of values for Cronbach alpha between 0.62-0.70 
have been reported in the text and we have described this appropriately as 
demonstrating ‘adequate reliability’, as that value was within the range of the 
minimum accepted value.152  
The evaluation of agreement between measures was also commonly reported as a 
form of assessment. To a certain extent, this may indicate consistency between 
measures. However, this does not fit the standard classification of reliability 
testing.154-158 Therefore, we separately categorised these evaluations as ‘agreement 
between measures’ (Table 2 in the manuscript, page xx).  
In terms of researcher-developed self-report scales, these were seldom used in 
multiple studies reported during the period 1994–2004, before a standardised 
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measure such as the MGLS became widely used. Prior to 2004, the majority of 
researchers who developed their own tools validated their self-report measures 
against existing objective measures, mainly pharmacy dispensing records.57, 159  
2.1.3 The adoption of the ABC framework in the analysis process  
There is no universally accepted conceptual framework for medication adherence 
that includes all major components of medication-taking behaviour. Despite the fact 
that several medication adherence frameworks have previously been established,94, 
95, 98, 99, 101, 103, 116, 160 none have provided full coverage of the major components of 
medication-taking behaviour. The ABC framework was employed in this study 
because it provides a transparent taxonomy which makes a clear distinction between 
different phases of medication-taking behaviour from the initiation of the medicine 
right through to the discontinuation of the medicine.2 Therefore, this framework was 
considered well-suited for the main purpose of our systematic review and 
subsequent studies.  
Because the ABC framework was proposed in 2012, there were relatively few 
included studies which have already employed this framework in their studies. Most 
studies focused on the implementation phase of medication adherence. For the 
studies which recruited newly diagnosed patients or patients who received their first 
prescription for an antidepressant medicine, we classified participants as being in the 
initiation phase. However, it appeared that measurements and their psychometric 
properties were applied across the initiation and implementation phases without 
specifically examining initiation of therapy and, therefore, measuring initiation of 
therapy. That is, adherence was assessed at some point between initiation and 
implementation and/or between implementation and discontinuation. Therefore, no 
measure was used exclusively to evaluate the initiation phase of medication 
adherence. Similarly, for the assessment of adherence at the discontinuation phase, 
adherence between the two phases of implementation and discontinuation was 
evaluated.   
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2.2 Qualitative study 
Adherence is a sophisticated process and is simultaneously influenced by multiple 
factors. The ability of people with unipolar depression to follow their treatment plan 
may be influenced by different factors—those related to health care professionals, 
health care system, family and society, the characteristics of depression, depression 
therapies, and consumer-related factors. In order to effectively tackle non-adherence 
problems in people with unipolar depression, it is crucial for health care professionals 
to better understand their patients and potential factors influencing medication 
adherence. This part of the thesis (Part C) aimed to explore both facilitators of and 
barriers to medication adherence in people with unipolar depression. Therefore, 
detailed information and in-depth understanding of medication-taking behaviour 
and relevant aspects (such as personal beliefs and perceptions of depression and 
antidepressant medicines) were required from the consumer’s perspective. In this 
case, a qualitative study was considered to be the most appropriate method, as it can 
be used to comprehensively explore experiences of interest in a particular group of 
people by evaluating abstractions, concepts, hypotheses, and theories from the 
obtained data.143, 161 In our study, adherence to antidepressant medicine was 
influenced by many factors including personal beliefs, concerns, attitudes, and 
experiences toward the use of antidepressant medicines and unipolar condition. 
These are intangible and, thus, a quantitative approach was unlikely to be suitable 
for this study. Moreover, as medication adherence is a complex human behaviour, 
qualitative methods can provide a rich understanding of the behaviour, which is 
unlikely from a purely quantitative study.143  
A number of qualitative inquiry frameworks may be applied in health services 
research, for example, grounded theory, phenomenology, ethnography, and 
narrative inquiry frameworks. These frameworks contain their own characteristics; 
therefore, the selection of a specific framework should be done in accordance with 
the aim of the study. In this study, we employed a phenomenological approach in the 
methods as it allowed for an exploration of lived experience with the phenomenon 
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of interest (i.e. factors influencing medication adherence to antidepressant medicine 
at specific phases).142 A phenomenological approach was considered suitable for the 
aim of our study, to explore and better understand individual experiences pertaining 
to the consumption of antidepressant medicines in consumers living with unipolar 
depression, with a particular focus on both positive and negative influencing factors. 
In contrast, grounded theory is applied when researchers aim to develop the theory 
based purely on fieldwork data. Similarly, an ethnography framework is used when 
the focus is on understanding how culture explains the participant’s perspectives and 
behaviour, while a narrative framework is used when researchers are interested in 
the interpretation of life story to understand and illuminate the life and culture that 
create it.142 
Individual face-to-face interviews were selected as this medium aids the collection of 
detailed information on the participants’ perspectives and experiences pertaining to 
medication-taking behaviours.138, 162 In addition, semi-structured face-to-face 
interviews allow researchers to modify the line of questioning. They also provide a 
medium to discuss sensitive personal issues with skilled experienced interviewers.141, 
162 In this case, a skilled interviewer is able to discuss private matters such as personal 
beliefs and perceptions pertaining to the consumption of antidepressant medicines 
and their actual behaviour on medication-taking. Face-to-face interviews allow 
participants to speak freely; moreover, it allows the researcher to probe further into 
the responses that participants provide through both verbal and nonverbal ques (e.g. 
facial expressions, gestures, and body language), including emotions and behaviours 
during the interview. These aid the interviewer to seek further information as well 
clarity.163 As it is a one-on-one method, it is also easier to gauge from the participant’s 
non-verbal responses whether they are comfortable or uncomfortable with the 
questioning. It must be noted that focus groups were not considered suitable for this 
research because of the sensitive and very personal nature of participant 
experiences. In addition, we were concerned about the privacy of the participants 
and the stigma attached with mental illness.  
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Purposive sampling was selected to identify and select information-rich cases in 
accordance with the objectives of this study.164, 165 In our study, a wide range of 
participants (in terms of their age, background, length of diagnosis, duration of using 
antidepressant medicines, and variety of antidepressant medicines) were expected 
in order to obtain a full range of different views. Further, a snowball sampling 
technique was not considered suitable for this research due to the inherently 
personal nature of experiences of depressive illnesses.166 Theoretical sampling is 
recommended when the searcher applies a grounded theoretical approach owing to 
its principle of building interpretative theories from the emerging data and selecting 
a new sample to examine and elaborate on the theory.164 Hence, theoretical sampling 
was not considered suitable for the purpose of our study as we did not aim to 
generate a theory.164, 166 Notwithstanding the selected approach of purposive 
sampling, the recruitment of participants presented a challenge for this research and, 
hence, a broad recruitment approach was adopted which initially included 
recruitment through community pharmacies and a range of online platforms. 
However, due to the relatively slow rate of recruitment, a third approach using a 
market research company was added to facilitate participant recruitment until there 
was data saturation.  
With regard to the analysis approach, inductive analysis, deductive analysis, content 
analysis, and thematic analysis are frequently used in qualitative studies in health 
services research.142 In particular, content analysis and thematic analysis are 
commonly used.161 These approaches have some elements in common and 
occasionally the terms are used interchangeably.161 However, one distinction 
between them is that content analysis generally uses a descriptive approach in coding 
of the data and can include quantitative counts of the codes. In contrast, thematic 
analysis provides a purely qualitative, detailed, and nuanced account of data.161 
Thematic analysis was employed in this study as we attempted to generate and 
categorise potential factors influencing medication adherence in particular phases of 
adherence. This process requires narrative interpretation, and thematic analysis 
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assisted us to consistently extract the obtained themes and classify them in 
accordance with the ABC framework. 
The qualitative methods employed in this research have some limitations. One 
particular limitation was the inability to include people (diagnosed) with unipolar 
depression who did not believe in the diagnosis or the use of antidepressant 
medicines. This group of participants may align with those categorised as displaying 
primary non-adherence. Primary non-adherence refers to patients who fail to fill the 
prescription.3 Hence, this study focused on people who acknowledged their own 
experience of depression as a disease and were willing to use antidepressant 
medicines as a choice of treatment. 
On the other hand, a strength of the employed sampling methods was the very broad 
range of participant experiences with the use of antidepressant medicines and their 
experiences within the broader healthcare system. This included the diversity of 
antidepressants used and the wide range of duration of antidepressant consumption 
(a range from the first diagnosis to recurrent depression with approximately 20 years 
of treatment). Therefore, the findings were assumed to encompass the main issues 
influencing medication adherence in the target sample.    
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2.3 Development and validation of the conceptual framework  
A conceptual framework may serve as a helpful tool to illustrate and understand 
different aspects of participant behaviour and the impact of broader factors such as 
the influence of health care professionals, health care system, carers and views of the 
general public. Such an approach may provide a useful guide for health care 
professionals when dealing with complicated behavioural issues such as medication 
adherence.  
Building on the findings of Part C (Chapters Four and Five) and Part D (Chapter Six) of 
this thesis, the main purpose was to develop and propose a framework to aid 
medication adherence in people with unipolar depression. The ABC taxonomy was 
adopted for the framework in order to obtain a detailed understanding of the 
adherence process. 
This section comprises two main parts: 1) the rationale for developing the framework 
and 2) the validation of the proposed framework. This conceptual framework 
elucidates the entire process of medication adherence and its components, including 
potential factors that influence medication-taking behaviour at each phase of 
adherence, from the initial diagnosis to the discontinuation of antidepressant 
medicines. Therefore, this framework provides a clear and comprehensive disease-
specific framework that captures factors which may influence medication adherence 
at specific phases of medication-taking behaviour.  
2.3.1 Rationale for developing the conceptual framework  
Although a number of conceptual frameworks have previously been proposed to 
answer a range of research questions in unipolar depression, they have not been 
related to medication adherence but instead have generally had a focus on the 
etiology and treatment of depression.96, 98, 99, 101-103, 115 Currently, there is no 
framework which aims to comprehensively understand medication-taking behaviour 
in people with unipolar depression. Therefore, this proposed framework was 
developed with the aim of providing an overall view of the adherence process and 
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potential factors influencing medication-taking behaviour for individuals with 
unipolar depression.  
Initially, a preliminary framework and its components were created by the 
researchers, based on multiple resources that included a review of the published 
literature and the findings of the qualitative studies (Part C, Chapters Four and Five). 
These concepts were combined with the clinical and research experiences of the 
researchers. Accordingly, item generation of factors influencing medication 
adherence at each phase of medication-taking were generated. As the proposed 
framework adopted the key concepts of the ABC taxonomy to explain the adherence 
process, potential factors were categorised into five dimensions (factors relating to 
health care professionals; factors relating to consumers; factors relating to health 
care system; factors relating to family, society, and economy; and factors relating to 
depression) and then mapped to each phase of medication adherence (i.e. initiation, 
implementation, and discontinuation).2 The initial generation of factors influencing 
medication adherence at each adherence phase are presented in Appendix Four 
(Table A—Initial items generated from previous qualitative research study and review 
literature). 
As evident, the implementation of the proposed framework is limited to people who 
could not/did not want to access the health care system. This included people who 
acknowledged depression but did not access or were unable to access the health care 
system, people who acknowledged depression but preferred alternative treatment 
to antidepressant medicines, and people who did not acknowledge their depressive 
disorder at all. 
2.3.2 Validation of the proposed framework 
Two types of validation were conducted: face and content validity. These are 
common tests when creating new tools or frameworks. Whilst face validity is 
subjective, and non-quantifiable, and not always considered important. It is often the 
first step in the validation process. Content validation is a more robust process than 
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face validation for new tools or frameworks. It is conducted assess the development 
process and to determine the representativeness and importance of the tool or 
framework content.167 Content validity is recommended to be assessed prior to the 
implementation of any new tool or framework, especially if it concerns a complex 
behaviour such as medication adherence. Content validation may subsequently be 
followed by more sophisticated quantitative processes such as construct validation 
and criterion validation.167  
Content validation relies on the use of a panel of experts to evaluate the tool 
elements or framework. Content experts are asked to rate items in relation to a 
number of areas including their relevance to and representativeness of the content 
domain.167 We followed a two-stage process of content validation as described by 
Lynn (1986). The first step is the development process followed by second step which 
is the judgment-quantification process.168  
For the development stage, there are three steps: domain identification, item 
generation and instrument formation.168  
In our study, the development process was accomplished via multiple inputs 
including a comprehensive review of the literature, the findings of our qualitative 
studies (Part C: Chapter 4 and 5) combined with the experiences of our research 
team. These multiple sources were used to inform item generation. For the next step, 
instrument formation, the items generated in the previous step were assembled in a 
usable form. Those items were refined and arranged into five main domains (i.e. 
health care professionals, consumer, health care system, depression, and family/ 
society and economy) and then mapped to specific phases of adherence in 
accordance with the ABC taxonomy.   
For the judgment-quantification stage of content validity, there are two steps. The 
first involves an assessment of individual items by a specific number of experts that 
the items are content valid, and second involves an assessment of the entire 
instrument or tool.168 
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At this stage, the content validity index (CVI) was adopted in both steps of the 
judgement stage, item-level (content validity index of the item or I-CVI) and the entire 
instrument level (content validity index of the entire instrument—the averaging 
calculation method or Ave-CVI). The CVI is the most widely accepted index for 
quantifying the content validity.167-170 Also, it is easy to compute, understand, and 
interpret when compare to other methods such as the Content Validity Ratio 
(CVR).167, 169 The CVI is derived from the rating of the content relevance (and 
importance) of the individual items on an instrument generally using a 4-point ordinal 
rating scale, where 1 connotes an irrelevant (unimportant) item and 4 an extremely 
relevant (extremely important) item.168 The actual CVI is the proportion of items that 
received a rating of 3 or 4 by the experts (or 4 or 5 if a 5-point scale is used).167, 168 
There are some important considerations. A four-point scale has a potential 
limitation as it forces the rater to make a decision about relevance (or importance). 
As a four-point ratings are collapsed into two dichotomous categories of ‘content 
valid’ and ‘content invalid’ the chance of agreement among the raters is higher. There 
may also be a risk of losing some critical information.167 Hence, in our study, a five-
point scale was chosen. In addition, we acknowledge the presence of a middle 
category (i.e. neither relevant or irrelevant; and neither important or unimportant). 
To overcome this a open text field was included so that expert panel members could 
provide comments about items including issues of clarity for each item.   
In order to overcome chance agreement, Lynn (1986) recommended a minimum of 
five experts to limit the inflation of chance agreement when using the CVI as the index 
of inter-rater agreement.167, 169, 171 An appropriate number of the panel should be 
between five and ten experts to yield credible results.167 With respect to the cut-point 
for the CVI score, we used the standard of 80% agreement or CVI 0.8 for both I-CVI 
and Ave-CVI, the recommended value when the panel comprises 6-10 experts.167, 168, 
171     
The developed framework was examined for content and face validity via the 
internet-based survey using an expert panel. The validation process was conducted 
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virtually, in a confidential manner, enabling all participants to freely provide their 
views without the process being overtaken by dominant individuals, which can occur 
during face-to-face interactions. In contrast, it must be noted that the dynamics of a 
group discussion can be lost when the internet-based survey is performed 
individually without immediate group feedback. Nevertheless an internet-based 
survey using an expert panel method was employed for the validation process of 
reassuring whether the framework subcomponents (influencing factors) were 
relevant to and import for a specific phase of adherence.  
In accordance with the purpose of the framework, experienced health care 
professionals were selected as panellists for the validation process. The rationale for 
engaging health care professionals was because they are the target people who may 
directly apply the framework in practice. In this respect, considerable thought was 
given to who both the number of panellists and their collective scope of expertise. 
That is, both number of panellists and their individual and collective qualifications 
was an important consideration.172 In our study, a broad range of the expert panel 
members were recruited (GPs, pharmacists, and researchers).168, 169, 172 Hence the 
expert panel in our study had an adequate number and range of expertise needed 
for the content validity process.  
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CHAPTER THREE – A systematic review of measures of 
medication adherence in consumers with unipolar depression 
Chapter introduction 
As outlined in the introduction, non-adherence to antidepressant medicine is a 
hindrance to successful treatment in unipolar depression. Adherence is a dynamic 
process and is likely to decrease over time. Furthermore, depressive symptoms can also 
worsen adherence to medicines. Therefore, it is crucial that health professionals 
regularly monitor adherence to antidepressant medicines in consumers with depression. 
Unfortunately, the absence of a gold standard to measure adherence as well as the 
inconsistency between ranges of measures have been highlighted by a number of 
research studies in this area. Consequently, the actual adherence rate is not necessarily 
comparable or known. Therefore, in this chapter, precise measure(s) of medication 
adherence with acceptable psychometric properties were systematically evaluated at 
the specific phases categorised under the ABC taxonomy (initiation, implementation, and 
discontinuation). This review may aid the selection of appropriate measures of 
medication adherence for specific phases of adherence.  
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Objective: To identify and evaluate the range of adherence measures used to assess diﬀerent phases of medi-
cation adherence (initiation, implementation, and discontinuation) to antidepressants, including the psycho-
metric properties of the measures.
Methods: This systematic review followed the PRISMA statement. Medline, Embase, International
Pharmaceutical Abstracts, CINAHL and PsychINFO were searched (1994–2015) for articles which reviewed or
reported the psychometric properties of adherence measures in adults with unipolar depression without co-
morbidity. Included articles were reviewed for the reliability and validity of their adherence measures.
Results: 26 studies met the inclusion criteria. Most assessed medication adherence at implementation and/or
discontinuation phases. Self-report measures were the most frequently used, followed by electronic lid devices
and pharmacy records. Standardized self-report measures such as Morisky, Green, and Levine Self-Reported
Medication Taking Scale (MGLS) and Antidepressant Adherence Scale (AAS) demonstrated acceptable reliability
and validity, while medication claims data showed good reliability as a long-term measure.
Conclusions: Although the psychometric properties of various measures have been evaluated across the three
phases of adherence, a standout measure with strong reliability and validity was not apparent. No single measure
demonstrated reliability and validity throughout the adherence process. A range of diﬀerent subjective and
objective adherence measures is recommended to assess medication adherence across the diﬀerent phases.
1. Introduction
Medication adherence is a key to successful treatment in many
chronic conditions including depression. Over the past two decades, a
range of terms have been used to describe the medication taking be-
haviour of patients, including medication compliance, adherence, and
persistence.1 Although these terms have often been used to describe
diﬀerent aspects of medication taking behaviour, in many cases they
have been used without a consistent understanding of what particular
aspect of medication taking behaviour is being measured and described.
The inconsistent use of these terms and the multitude of diﬀerent de-
ﬁnitions of medication adherence have led to diﬃculties in interpreting
studies investigating medication taking behaviour in consumers with
depression. A frequently cited deﬁnition of adherence and one endorsed
by the World Health Organization is “the extent to which a person's
behaviour – taking medication, following a diet, executing lifestyle
changes – follows medical advice”.2 Extending this broad deﬁnition,
Vrijens et al. (2012) conceptualized a framework for describing and
deﬁning adherence to medicines. Speciﬁcally, they argued that
adherence is a continuous process, but can be divided into three key
phases, initiation, implementation, and discontinuation of therapy.1
‘Initiation’ starts when a patient take the ﬁrst dose of their prescribed
medicine. The process continues as the ‘implementation’ until the last
dose has been taken and no further doses are taken afterwards. The
stage is recognized as ‘discontinuation’.1
Medication adherence has become a topic of intense investigation in
the management of many chronic conditions.3 It has been reported that
all current and remitted depression disorders are risk factors for med-
ication non-adherence.4,5 Non-adherence to antidepressant medicines is
a major obstacle to the successful management of unipolar depression, a
high prevalence condition which generally requires a minimum course
of treatment of 6–9 months after recovery.6 Globally, over 300 million
people are estimated to suﬀer from depression, equivalent to 4.4% of
the world's population.7 Non-adherence in unipolar depression can lead
to an unnecessary deterioration in health. It can contribute to un-
necessary switches in antidepressant treatment, unneeded instructions
to increase doses, initiation of unwarranted adjuvant treatments, and
misclassiﬁcation of treatment resistant.8 It has been estimated that the
https://doi.org/10.1016/j.sapharm.2018.02.008
∗ Corresponding author.
E-mail address: psri6621@uni.sydney.edu.au (P. Srimongkon).
Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
1551-7411/ © 2018 Elsevier Inc. All rights reserved.
Please cite this article as: Srimongkon, P., Research in Social and Administrative Pharmacy (2018), 
https://doi.org/10.1016/j.sapharm.2018.02.008
51
odds of patients with depression being non-adherent were 1.76 times
the odds of non-depressed patients with asthma, coronary heart disease,
diabetes, hyperlipidaemia, or hypertension.9 The average length of
antidepressant treatment in patients with depression has been reported
to be less than 6 months, and the discontinuation rate was 50–60%
within 10–16 weeks.10–12 In a European study of dispensing records,
only 22% of individuals were reported as being adherent to their an-
tidepressant medicine. In this study adherence was calculated using
prescription records and deﬁned as an adherence rate above 80%, that
is, taking more than 80% of the daily dose of their medicine at 16
weeks.11 Five percent of patients from one study in the United States
reported that they never initiated therapy with their antidepressant
medicine (40 of 765 patients).13 For the maintenance phase of recurrent
depression, the proportion of non-adherent consumers has been re-
ported to vary from 39.7% to 52.7% when assessed using the four-item
Morisky, Green, and Levine Self-Reported Medication Taking Scale
(MGLS),14 reported as the Medication Adherence Questionnaire.12 Non-
adherence on this scale occurs when patients miss 20% or more of their
antidepressant medicine.15 The two most common reasons for dis-
continuation of antidepressant medicines were feeling better (55%) and
adverse events such as side eﬀects (23%).10 Moreover, greater than
60% of those consumers who discontinued their antidepressant medi-
cine did not inform their general practitioner about their decision.10
A number of medication adherence measures have been used to
evaluate medication taking behaviour in consumers with depression,
however consensus on a gold standard measure or group of measures
which map to the diﬀerent phases of adherence (i.e. initiation, im-
plementation, and discontinuation) has yet to be accepted. Although,
electronic lid devices, such as MEMS (Medication Event Monitoring
System), have been used in trials and reported as a standardized mea-
sure, they only apply if the medicine can be re-packed in a container
with the electronic lid and their high cost makes them impractical for
routine use in clinical practice.16 Direct biological measurements such
as drug metabolites or markers in a body ﬂuid are invasive and have not
been established for routine use with antidepressant medicines.16
Moreover they do not show the regularity of medication taking. In-
dividual indirect measurements such as patient self-reporting, pill
counts, and pharmacy records may be readily used in clinical practice
however there is signiﬁcant variability in the reliability and/or validity
of these measures when used alone.17 In addition, diﬀerent adherence
measures can produce inconsistency in adherence reports, non-com-
parable adherence results, and hence increase the risk of an incorrect
conclusion.18,19
Medication adherence is a dynamic process, which can be inﬂu-
enced by many factors and change over time. Particularly in unipolar
depression, a unique condition, a signiﬁcant impact on the mood can
lower adherence at any time. Hence tailored interventions which con-
sider speciﬁc factors, depending on the phase of adherence, are likely to
facilitate improved adherence in people living with unipolar depres-
sion. Furthermore, selection and use of a medication adherence mea-
sure(s), appropriate for the phase of adherence, will provide a more
accurate assessment of medication adherence, and therefore better in-
form the selection of tailored intervention strategies designed to im-
prove medication adherence. The aim of this systematic review was to
identify and evaluate the range of medication adherence measures used
to assess diﬀerent phases of medication adherence (initiation, im-
plementation, and discontinuation), in consumers taking antidepressant
medicines for unipolar depression. Speciﬁcally, the reliability and/or
validity of these adherence assessments were evaluated.
2. Methods
The Preferred Items for Reporting of Systematic Reviews and Meta-
Analyses20 guideline was followed for conducting this systematic re-
view. Five databases; Medline, Embase, International Pharmaceutical
Abstracts (IPA), CINAHL and PsychINFO were searched for English
language articles published from January 1994–December 2015. Search
terms (MeSH) for three diﬀerent concepts were combined: depression,
antidepressant medicines, and adherence. Concept one included terms
such as depression, major depression, and depressive disorders. Con-
cept two included terms such as antidepressive agents, antidepressant
drugs, and antidepressant agents. Concept three included terms such as
patient compliance, medication adherence, treatment refusal, patient
dropouts, directly observed therapy, and persistence.
2.1. Eligibility criteria
Articles were included if they met the following inclusion criteria:
1. Reviewed or evaluated antidepressant medication adherence in
adult individuals with unipolar depression without co-morbidity
(age ≥18 years old).
2. Reported their own statistical data on the reliability and/or validity
and/or agreement of the adherence measurement/s, or referred to
the primary research which had established the reliability or va-
lidity of the measurements used. In the latter case, original articles
were searched and included in the study.
2.2. Articles were excluded if they
1. Reported adherence measured in depression with comorbidity
2. Included participants who were children, adolescents, pregnant
women or elderly (age≥ 60 years) persons with depression.
3. Did not report an adherence measure in the study.
4. Did not report on the reliability and/or validity and/or agreement of
adherence measures in the study.
5. Were reported as book chapters, conference proceedings, disserta-
tions, commentaries, editorials letters or reviews.
2.3. Selection process
The ﬁrst author (P.S.) conducted a systematic search following the
PRISMA guidelines. Firstly, all retrieved articles were screened based
on titles. If the titles indicated the information relevant to the aim of the
study, the abstracts were then screened and reviewed for more details.
If the abstracts indicated that the studies fulﬁlled the eligibility criteria,
full papers were then searched to extract the essential information. All
duplicates were removed. The bibliographies of included articles and
relevant review articles were also iteratively searched for additional
articles which met the speciﬁc inclusion criteria. Primary data extrac-
tion was conducted by P.S. Then, the second researcher cross-checked
20% of the eligible articles. The inconsistencies were then discussed
and resolved if required.
2.4. Data extraction and evaluation
Data extracted from studies included: country in which the study
was conducted, study setting, study design (e.g. randomized controlled
trial), study time frame, length of subject follow up, medication of in-
terest, medication adherence measure(s), reliability and/or validity
and/or agreement of measure/s, adherence outcome, deﬁnition of ad-
herence and/or non-adherence, number of participants, age group,
gender, diagnosis, severity of depression, new or continuing treatment,
and the phase of medication adherence assessed (i.e. initiation, im-
plementation or discontinuation). Researchers evaluated adherence
phases according to the ABC framework.
The ABC conceptual framework proposed by Vrijens et al. was used
for this systematic review as follows, “adherence process starts with in-
itiation, when patients start the ﬁrst dose of medicines. Following by the
implementation which referred to the extent to which a patient's actual
dosing corresponds to the regimen from the ﬁrst to the last dose.
Discontinuation is considered where no more doses are taken thereafter.”1
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Therefore, we categorized studies as the ‘initiation phase of the ad-
herence process’ when participants with new prescriptions for anti-
depressant medicines were recruited to the study or if the study stated
that participants were commencing therapy with antidepressant medi-
cines for the ﬁrst time. Studies which evaluated antidepressant medi-
cation adherence, following participants who had commenced therapy
were classiﬁed as ‘implementation phase of adherence’. Studied which
assessed medication adherence when patients ceased taking anti-
depressant medicines were classiﬁed as the ‘discontinuation phase of
adherence’. This process was conducted by one researcher, however,
20% of results were rechecked by the second researcher. The incon-
sistencies were then discussed and ﬁnalized.
2.5. Outcome of interest
The psychometric properties of the medication adherence measures
were assessed in accordance with the deﬁnitions in Table 1. In general,
validity refers to the extent to which any instrument measures what it is
intended to measure.21,22 Reliability concerns the extent to which an
experiment, test, or any measuring procedure yields the same results on
repeated trials.21,22 Relevant measures of reliability were: internal
consistency and test-retest reliability. Relevant measures of validity
were: content, criterion-related, construct, convergent and face validity.
In some studies, other types of psychometric properties were evaluated,
including the correlation or agreement between diﬀerent measures of
adherence. As there is no universally accepted gold standard measure
for medication adherence, MEMS was selected as the criterion measure
for the purpose of this review.
The results were presented under the following structure, 1) an
overview of ﬁndings 2) psychometric properties of the measures. The
latter section contained data on the frequency of use of each measure to
assess adherence in unipolar depression, how it was used in unipolar
depression, and the psychometric properties of each measure among
samples of patients with unipolar depression.
3. Results
The search following PRISMA guidelines resulted in 26 records
(Fig. 1). Most of them were conducted in primary care settings or
outpatient settings in the United States of America. More than half (15
of 24) of them used 2 or more adherence measures to assess anti-
depressant medication adherence in consumers with unipolar depres-
sion.23–37 Twelve studies used both subjective and objective adherence
measures to assess antidepressant adherence.23–30,33,35–37 All studies
focused on medication adherence at the implementation phase, and
most of them assessed adherence from implementation to dis-
continuation. The reliability of adherence measures was assessed by
researchers in 5 studies23,32,35,38,39 while the validity of adherence
measures was assessed in 12 studies.24–28,30–33,35,36,39 Some studies
cited previously reported reliability and/or validity testing of ad-
herence measures.12,15,29,30,32,34,37,40–44 Characteristics of the included
studies are reported in Table 1A, in the appendix. A summary of ad-
herence measures identiﬁed from this systematic review is presented in
Table 2. The psychometric properties (e.g. reliability, validity) of
medication adherence measures are reported in Table 3.
3.1. Adherence measures
Diﬀerent types of adherence measures have been used to evaluate
antidepressant adherence in consumers with unipolar depression. Self-
report measures of adherence were the most commonly used type of
measure and covered initiation, implementation, and discontinuation of
therapy. MEMS (Medication Event Monitoring System) was the second
most commonly used measure. Researcher developed measures were
commonly used prior to 2004. After that time, validated self-report
measures (e.g. the four-item Morisky, Green, and Levine Self-Reported
Medication Taking Scale (MGLS),14 and the Beliefs about Medicines
Questionnaire45) became more widely used.12,15,30,32,34,35,37
Although ten studies assessed medication adherence at the initiation
phase, none of the included studies speciﬁcally reported about the in-
itiation phase of antidepressant medication adherence. Most studies
focused on assessing medication adherence during the implementation
to the discontinuation phase of therapy. Therefore, all psychometric
properties of adherence measures reported in this systematic review
were evaluated during implementation and discontinuation phases.
3.2. Reliability and validity of adherence measures
Diﬀerent types of reliability and validity tests were used to evaluate
the psychometric properties of individual measures of medication ad-
herence. The most common assessment of reliability used was
Cronbach's alpha coeﬃcient, a measure of internal consistency.32,35,39
Some studies reported agreement between diﬀerent measures as a form
of reliability assessment.23,24 Various types of validity tests were pre-
sented, including concurrent, construct and face validity. Most assess-
ments of validity involved concurrent validity in which diﬀerent ad-
herence measures were evaluated against the selected criterion measure
(MEMS) at the same time.25,26,31,32,35
Table 1
The deﬁnitions of reliability and validity of adherence measures used in this study.22,59–62
Types of reliability and validity Deﬁnitions
Reliability Internal consistency reliability/
Coeﬃcient alpha
Internal consistency reﬂects the coherence of the components of a scale. It shows the equivalence reliability. Cronbach's
alpha coeﬃcient is the most frequently used statistic to show internal consistency reliability.22 Commonly accepted
minimum values for reliability coeﬃcients are 0.70 for group comparisons and 0.90–0.95 for individual comparisons.59
Test-retest reliability Test-retest reliability is estimated by administering the same test to the same group of respondents at diﬀerent times. The
correlation between the two scores, and often between individual questions, indicates the stability of the instrument.22
Validity Face validity Face validity is a subjective assessment. An instrument is face valid if it appears to measure the construct/s of interest.22
Content validity Content validity refers to the extent to which an empirical measurement reﬂects a speciﬁc domain of content.60
Criterion-related validity Criterion-related validity pertains to evidence of a relationship between the attributes in a measurement tool with its
performance on some other variable. Cohen's kappa above 0.61 was considered as acceptable if at least one relationship was
found.22
- Concurrent validity Concurrent validity is conﬁrmed when scores on a measure are correlated to a related criterion (ideally, a gold standard
criterion) at the same point in time.60
- Predictive validity Predictive validity is conﬁrmed when there is evidence that the scale predicts a gold-standard criterion that is measured at
some time in the future.60
Construct validity Construct validity refers to the degree to which an instrument measures the construct it is intended to measure.61
- Convergent validity Convergent validity occurs when there is correspondence or convergence between constructs that are theoretically
similar.22
- Discriminant validity Discriminant validity occurs when there is diﬀerentiation or discrimination between constructs that are theoretically
diﬀerent.22
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3.3. Objective adherence measures
1) MEMS (Medication Event Monitoring System)
MEMS was the most commonly used objective adherence measure
in this systematic review (7 studies).25,26,31,35–37,40 It has been reported
to be the “gold-standard” for criterion-related validity testing against
other measures such as pill counts, self-report adherence measures and
pharmacy records.25,26,31,35
2) Pharmacy records, prescription reﬁll, and claims data
Pharmacy records and prescription reﬁll were used in 6 stu-
dies23,24,30,31,33,42 and claims data were used in 2 studies.29,33 Phar-
macy records revealed acceptable validity when compared with MEMS.
Brook et al. reported 5% underestimation of medication adherence by
pharmacy records when compared with MEMS.31 Rickles et al. reported
fair consistency between claims data and MEMS.33 Pharmacy records,
prescription reﬁll, and claims data were useful measures for long-term
adherence assessment in consumers with depression.
Fig. 1. Search ﬂow diagram.
P. Srimongkon et al. Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
4 54
Ta
bl
e
2
Su
m
m
ar
y
of
ad
he
re
nc
e
m
ea
su
re
s
us
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
.
N
o
A
ut
ho
rs
,y
ea
r
O
bj
ec
ti
ve
da
ta
Su
bj
ec
ti
ve
da
ta
Se
lf
-r
ep
or
t
Ph
ar
m
ac
y
re
co
rd
s/
pr
es
cr
ip
ti
on
re
ﬁ
ll
C
la
im
s
da
ta
A
pp
oi
nt
m
en
t
ke
pt
Pl
as
m
a/
Se
ru
m
le
ve
l/
bl
oo
d
co
nc
.
Pi
ll
co
un
ts
M
EM
S
Pa
ti
en
t
re
po
rt
/
in
te
rv
ie
w
M
G
LS
BM
Q
(H
or
ne
)
BM
Q
(S
va
rs
ta
d)
M
A
R
S
1
K
at
on
et
al
.,3
8
19
94
✓
2
K
at
on
et
al
.,2
3
19
96
✓
✓
3
Sa
un
de
rs
K
.,2
4
19
98
✓
✓
4
Pe
ve
le
r
et
al
.,2
5
19
99
✓
✓
5
Bu
lt
m
an
an
d
Sv
ar
st
ad
,4
3
20
00
✓
6
C
la
xt
on
et
al
.,4
0
20
00
✓
7
G
eo
rg
e
et
al
.,2
6
20
00
✓
✓
✓
✓
8
Si
re
y
J.
A
.,2
7
20
01
✓
✓
9
A
ke
rb
la
d
et
al
.,2
8
20
03
✓
✓
✓
10
K
w
on
et
al
.,2
9
20
03
✓
✓
11
Sl
ea
th
et
al
.,4
1
20
03
✓
12
C
ap
oc
ci
a
et
al
.,4
4
20
04
✓
13
A
ik
en
s
et
al
.,3
0
20
05
✓
✓
✓
14
Br
oo
k
et
al
.,3
1
20
05
✓
✓
15
Br
ow
n
et
al
.,3
2
20
05
✓
✓
16
R
ic
kl
es
et
al
.,3
3
20
05
✓
✓
✓
17
R
us
se
ll
an
d
K
az
an
tz
is
,3
4
20
08
✓
✓
18
Y
eh
et
al
.,3
9
20
08
✓
19
Te
n
D
oe
ss
ch
at
e
et
al
.,1
2
20
09
✓
20
Te
n
D
oe
ss
ch
at
e
et
al
.,1
5
20
09
✓
21
G
ab
ri
el
an
d
V
io
la
to
,4
7
20
10
22
In
te
ri
an
,3
5
20
10
✓
✓
23
Le
e
et
al
.,3
6
20
10
✓
✓
✓
24
Pr
uk
ka
no
ne
et
al
.,4
2
20
10
✓
25
In
te
ri
an
et
al
.,3
7
20
13
✓
✓
26
G
ab
ri
el
,4
8
20
15
Su
m
m
ar
y
(2
6)
6
2
1
3
2
7
10
7
2
4
1
In
it
ia
ti
on
5
1
0
1
1
3
5
1
0
2
0
Im
pl
em
en
ta
ti
on
6
2
1
3
2
7
10
7
2
4
1
D
is
co
nt
in
ua
ti
on
2
1
0
2
1
4
4
7
0
2
0
N
o
Su
bj
ec
ti
ve
da
ta
N
a
R
el
ia
bi
lit
y
V
al
id
it
y
A
gr
ee
m
e-
nt
b
A
dh
er
en
ce
ph
as
ec
Se
lf
-r
ep
or
t
C
lin
ic
ia
n
ra
ti
ng
sc
al
e
A
A
S
Pr
ov
id
ed
re
lia
bi
lit
y
da
ta
R
ef
er
re
d
to
ot
he
r
N
o
da
ta
Pr
ov
id
ed
va
lid
it
y
da
ta
R
ef
er
re
d
to
ot
he
r
N
o
da
ta
In
it
ia
ti
on
Im
pl
em
en
ta
ti
on
D
is
co
nt
in
ua
ti
on
1
1
✓
✓
✓
✓
2
2
✓
✓
✓
✓
✓
✓
3
2
✓
✓
✓
✓
✓
4
2
✓
✓
✓
✓
✓
5
1
✓
✓
✓
✓
✓
6
1
✓
✓
✓
7
4
✓
✓
✓
✓
✓
8
2
✓
✓
✓
✓
✓
9
3
✓
✓
✓
10
2
✓
✓
✓
✓
✓
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
P. Srimongkon et al. Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
5 55
Ta
bl
e
2
(c
on
tin
ue
d)
N
o
Su
bj
ec
ti
ve
da
ta
N
a
R
el
ia
bi
lit
y
V
al
id
it
y
A
gr
ee
m
e-
nt
b
A
dh
er
en
ce
ph
as
ec
Se
lf
-r
ep
or
t
C
lin
ic
ia
n
ra
ti
ng
sc
al
e
A
A
S
Pr
ov
id
ed
re
lia
bi
lit
y
da
ta
R
ef
er
re
d
to
ot
he
r
N
o
da
ta
Pr
ov
id
ed
va
lid
it
y
da
ta
R
ef
er
re
d
to
ot
he
r
N
o
da
ta
In
it
ia
ti
on
Im
pl
em
en
ta
ti
on
D
is
co
nt
in
ua
ti
on
11
1
✓
✓
✓
12
1
✓
✓
✓
✓
✓
✓
13
3
✓
✓
✓
✓
✓
14
2
✓
✓
✓
✓
15
2
✓
✓
✓
✓
✓
16
3
✓
✓
✓
✓
✓
17
2
✓
✓
✓
18
1
✓
✓
✓
19
1
✓
✓
✓
✓
20
1
✓
✓
✓
✓
21
✓
1
✓
✓
✓
✓
22
2
✓
✓
✓
✓
23
✓
4
✓
✓
✓
✓
24
1
✓
✓
✓
✓
25
2
✓
✓
✓
✓
26
✓
1
✓
✓
✓
✓
2
1
–
6
7
14
9
8
9
8
10
26
15
0
0
–
1
1
7
3
2
5
–
–
–
2
1
–
6
7
14
9
8
9
–
–
–
2
0
–
3
3
9
6
5
4
–
–
–
A
bb
re
vi
at
io
ns
of
m
ed
ic
at
io
n
ad
he
re
nc
e
m
ea
su
re
s.
A
A
S:
th
e
A
nt
id
ep
re
ss
an
t
A
dh
er
en
ce
Sc
al
e.
4
7
BM
Q
by
H
or
ne
:B
el
ie
fs
ab
ou
t
M
ed
ic
in
es
Q
ue
st
io
nn
ai
re
.4
5
BM
Q
by
Sv
ar
st
ad
:B
ri
ef
M
ed
ic
at
io
n
Q
ue
st
io
nn
ai
re
.4
9
M
A
R
S:
M
ed
ic
at
io
n
A
dh
er
en
ce
R
ep
or
t
Sc
al
e,
6
3
M
EM
S:
M
ed
ic
at
io
n
Ev
en
t
M
on
it
or
in
g
Sy
st
em
.
M
G
LS
:F
ou
r-
it
em
M
or
is
ky
,G
re
en
,
an
d
Le
vi
ne
Se
lf
-R
ep
or
te
d
M
ed
ic
at
io
n
Ta
ki
ng
Sc
al
e,
1
4
al
so
re
po
rt
ed
as
M
ed
ic
at
io
n
A
dh
er
en
ce
Q
ue
st
io
nn
ai
re
(M
A
Q
)1
2
,1
5
an
d
Se
lf
-r
ep
or
te
d
M
ed
ic
at
io
n
Ta
ki
ng
Sc
al
e
(S
M
TS
).
3
5
,3
7
a
N
=
nu
m
be
r
of
ad
he
re
nc
e
m
ea
su
re
s.
b
A
gr
ee
m
en
t
be
tw
ee
n
di
ﬀ
er
en
t
ad
he
re
nc
e
m
ea
su
re
s.
c
A
dh
er
en
ce
ph
as
e
ca
te
go
ri
ze
d
by
th
e
re
se
ar
ch
er
s
un
de
r
th
e
A
BC
de
ﬁ
ni
ti
on
.
P. Srimongkon et al. Research in Social and Administrative Pharmacy xxx (xxxx) xxx–xxx
6 56
3) Pill counts
Pill counts were used to evaluate medication adherence in 2 stu-
dies.26,36 George et al. reported a signiﬁcant correlation between pill
counts and percentage of days on which openings were detected by
MEMS (r=0.616; P < 0.001). However, when the authors compared
data with the MGLS and serum concentration of antidepressant medi-
cines, they concluded that some patients may open the container and
discard the medicine, rather than take it, hence the poor correlation
between MEMS and pill counts in this study.26 Another study reported a
signiﬁcant but low correlation between pill counts and MEMS of 0.419
(95% conﬁdence interval: 0.254, 0.561).36 The kappa value between
the two measures was 0.38, which reﬂected a fair to poor agreement.
3.4. Subjective adherence measures
Self-report was the most commonly used subjective measure of
adherence. Prior to 2004, researcher developed self-report measures
were commonly used. Kwon et al. reported high agreement between
claims data and the researchers' developed self-report scale, especially
at 4-months.29 However, the self-report measure used was imprecise as
all values were dichotomized. Katon reported an agreement between
prescription reﬁlls with a self-report scale for long-term treatment (4-
months) but did not specify the questions asked.23 Saunders reported
high agreement (91% agreement with kappa= 0.80) between pre-
scription reﬁll and self-report data on both the premature dis-
continuation of antidepressants and adequate dose consumption.
Agreement regarding dosage adequacy was also higher later in treat-
ment, but the kappa values were quite low: 0.52 at 1 month and 0.65 at
4 months.24
After 2004, established self-report measures such as MGLS became
more widely used.
1) Four-item Morisky, Green, and Levine Self-Reported
Medication Taking Scale (MGLS)
The MGLS is a well-established adherence measure with a
Cronbach's alpha value of 0.61 as reported from the original research in
patients with hypertension.14 The MGLS consists of 4 items to assess the
forgetfulness, carelessness, and stopping due to feeling worse or feeling
better interferes with medication adherence. It is noteworthy that one
of the ways in which the MGLS diﬀers conceptually from the Morisky
Medication Adherence Scale-4 (MMAS-4)46 is in the second item; with
the former assessing carelessness, and the latter assessing problems
remembering to take medicines. In this review, the MGLS was used in 7
studies, mostly for the implementation and discontinuation
phase.12,15,26,30,32,35,37 It has been shown to have adequate reliability
when assessing adherence to antidepressant medicines, speciﬁcally for
the implementation phase of adherence, with a Cronbach's alpha of
0.6232 and 0.70.35 The MGLS scale also has a good correlation with
MEMS for detecting poor adherence, with sensitivity 72.2%, speciﬁcity
74.1% for ≥80% adherence.26 Interian also reported a correlation be-
tween MGLS and MEMS, however, the correlation was only moderate
(r=−0.43).35 The scale was also shown to have high agreement with a
3-month medication possession ratio (72% agreement), which was
computed from pharmacy reﬁll data.30
2) Antidepressant Adherence Scale (AAS)
The AAS was developed based on the MGLS scale. The AAS consists
of four items to assess the degree to which forgetting, carelessness, and
stopping due to feeling worse or feeling better interferes with medica-
tion adherence in the last 4 weeks. Responses are converted to a
continuous numerical score as opposed to a categorical response (yes or
no). In this review, the AAS was used in 2 studies for the im-
plementation phase of treatment.47,48 Both studies reported acceptable
levels of internal consistency reliability (Cronbach's alpha 0.52–0.86),
content, convergent and construct validity (see Table 3).
3) Beliefs about Medicines Questionnaire (BMQ by Horne, 1999)
The BMQ by Horne comprises two parts, namely the BMQ-speciﬁc
and the BMQ-general.45 It assesses both necessity beliefs and concern
beliefs about medicines. The psychometric properties have been eval-
uated using conﬁrmatory factor analysis. The BMQ has been tested in
patients with psychiatric conditions, asthma and diabetes. For psy-
chiatric conditions, the internal consistency reliability (Cronbach's
alpha) of the BMQ has been reported at 0.74 for speciﬁc-necessity be-
liefs, 0.63 for speciﬁc-concern beliefs, 0.73 for general-overuse beliefs,
and 0.70 for general-harm beliefs.45
In this review, the BMQ by Horne was used in 2 studies for both
implementation and discontinuation phase of treatment.32,34 However,
only one of these studies reported statistical evidence of reliability and
validity of the measure.32 Brown et al. reported adequate internal
consistency and good construct validity of the BMQ (Cronbach's alpha
of 0.80 for BMQ speciﬁc-necessity beliefs, 0.75 for BMQ speciﬁc-con-
cern beliefs, 0.71 for BMQ general-overuse beliefs and 0.67 for BMQ
general-harm beliefs). Brown et al. found that beliefs about medications
for depression were signiﬁcantly related to self-report adherence.32
Using conﬁrmatory factor analysis, the BMQ was shown to have con-
struct validity in consumers with depression. The hypothesized 4-factor
model provided a fair to good ﬁt (RMSEA=0.056, 90% conﬁdence
interval for RMSEA=0.041–0.070, CFI= 0.95, GFI= 0.89).32
4) Brief Medication Questionnaire (BMQ by Svarstad, 1999)
The BMQ by Svarstad consists of two parts. The ﬁrst part contains 3
main items that ask patients how they took each medicine in the past
week and assesses beliefs about drug eﬃcacy and bothersome eﬀects. It
detects repeat non-adherence (patients who take ≥20% more or less
than the prescribed number of doses), sporadic non-adherence (patients
who take 1–19% under or over prescribed number of doses) and no
non-adherence (patients who take 100% of doses). The second part
contains 11-items that ask patients about the diﬃculties in re-
membering medication-taking behaviour. It assesses physical and cog-
nitive barriers to adherence and self-eﬃcacy. Validity of the BMQ by
Svarstad has been demonstrated with the regimen and belief screens
having 80–100% sensitivity for ‘‘repeat’’ non-adherence and the recall
screen having 90% sensitivity for ‘‘sporadic’’ non-adherence.49
The ﬁndings of this review showed that the BMQ by Svarstad has
been evaluated in 4 studies.30,33,41,43 One study reported signiﬁcant
correlation when it evaluated one question which was similar to the
question in BMQ by Svarstad, with the true rate of dose omission by
MEMS over a 7-day or 30-day period.33
4. Discussion and conclusion
4.1. Discussion
This is the ﬁrst systematic review to comprehensively evaluate the
psychometric properties of all measures of medication adherence used
to assess medication taking behaviour in consumers with unipolar de-
pression. For this review, the measures of adherence were mapped to
the three phases of adherence in accordance with the ABC framework,
that is, the initiation, implementation and discontinuation of pharma-
cotherapy.1 According to the continuous process of adherence, the
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capability of some adherence measures to capture more than one ad-
herence phase (i.e. MGLS, AAS, and BMQ by Svarstad can capture both
implementation and discontinuation of treatment), and incomplete data
reported from recruited studies, led to diﬃculty in diﬀerentiating the
diﬀerent adherence phases. Although some studies assessed medication
adherence from initiation of treatment, the psychometric properties of
adherence measures were mainly evaluated at the implementation
phase. Therefore a large proportion of results reported in this study
were categorized at the implementation phase. None of the studies
assessed medication adherence nor reported the psychometric proper-
ties of adherence measures at the initiation phase.
At implementation, MEMS was the most commonly used objective
measure followed by pharmacy records. MEMS is generally recognized
as a “gold standard” of adherence. Although observing actual medica-
tion ingestion (Directly Observed Treatment or DOT) is recognized as
the true gold standard of adherence measurement,50 it has not been
used in patients with depression. This is probably because DOT is an
impractical measure in the clinical setting, where chronic therapy for
unipolar depression is indicated. Therefore, MEMS was selected as the
criterion measure in this review, to which other measures of adherence
could be validated. Similar to previous studies in other conditions,
pharmacy records and prescription claims data have been used at each
phase of adherence and have been reported to be somewhat “accurate”
as long-term adherence measures.23,24 Longitudinal assessment of pre-
scription reﬁll data can capture (indirectly) the changes in medication
taking behaviours over time from initiation to discontinuation.51 The
review ﬁndings showed a strong positive relationship between phar-
macy records and MEMS (r= 0.760; P≤ 0.001),33 in line with another
study in patients with hypertension or heart failure.52 Pill counts have
been used almost exclusively for the implementation of adherence, but
their “accuracy” has been questioned by some especially when the time
of the pill count is known by the patient.26 Unannounced and random
home-based pill counts present a possible solution to improve the va-
lidity of the measure.50
Self-report measures were the most commonly used subjective
measure of adherence and were used at each phase of adherence. They
are regarded as the most practical and least costly method for assessing
medication adherence in clinical settings but the reliability and validity
of these measures have not always been considered. However, since
2004 there has been an emphasis on reporting the psychometric
properties of self-report measures, particularly the MGLS and BMQ by
Horne.
A commonly used self-report measure, the MGLS scale, demon-
strated acceptable reliability (Cronbach alpha range 0.62 and 0.70)32,35
sensitivity and speciﬁcity when compared to MEMS.26 It has also been
shown to have signiﬁcant agreement with 3-month medication pos-
session ratio data,30 suggesting that the MGLS scale may be considered
as an acceptable measure for assessing medication adherence for the
implementation phase of treatment. This scale has been useful in de-
tecting non-adherence during the implementation and discontinuation
phases of adherence in both unipolar depression12,34 and other chronic
conditions.53 However one study in hypertensive patients commented
that the MGLS scale does not fully assess the diﬀerent dimensions of the
ABC taxonomy.51 Whilst Nguyen et al. reported that the MGLS eval-
uated the implementation and discontinuation phases of adherence, by
identifying barriers to adherence such as forgetfulness, poor medication
taking behaviours and adverse eﬀects.53 Similarly, Tan et al. reported
that it was a useful measure for screening and monitoring medication
taking behaviour.54 In addition, the MGLS can identify intentional and
unintentional medication nonadherence. However, the limitations of
the MGLS scale should be considered, as it only assesses barriers to
adherence (medication underuse or omission) and not self-eﬃcacy,
which has been found to be an important predictor of medication
adherence.55 Another limitation of the MGLS scale is that it does not
assess adherence over a speciﬁc time frame.50 To counter this, a mod-
iﬁed Morisky (eight-item Morisky Medication Adherence Scale or
MMAS-8)56 has been developed, which shows better reliability and
validity albeit in hypertensive patients (Cronbach's alpha value is 0.83,
sensitivity and speciﬁcity are 93% and 53% respectively) when con-
sidering a speciﬁc time frame of 2 weeks.54
The Antidepressant Adherence Scale (AAS) represents another
modiﬁcation of the MGLS scale. The psychometric properties of the AAS
in unipolar depression are comparable to the MGLS scale,47,48 hence it
may be used as an alternative measure to the MGLS scale. The AAS is
considered as a useful measure to detect medication non-adherence at
the discontinuation phase.47 A positive correlation between non-ad-
herence scores of the AAS and the perceived stigma subscale has been
reported. This positive correlation was also related to the discontinua-
tion of antidepressant treatment when the patients felt better.47
The Beliefs about Medicines Questionnaire (BMQ by Horne, 1999) is
another commonly used self-report measure of medication adherence.
The sub-scales have “acceptable” to “good” internal consistency relia-
bility and “fair to good” construct validity when used as a measure of
medication adherence in depression.32 A systematic review of validated
self-report adherence scales in many health conditions (such as asthma,
diabetes, and other psychiatric conditions) also reported signiﬁcant
correlations with the Reported Adherence to Medication Scale, the
Medication Adherence Report Scale (MARS-5), and MGLS.53 Although
the BMQ by Horne is not a stand-alone comprehensive adherence scale,
it may be used to reveal the drivers behind patients' non-adherence by
identifying barriers and beliefs that inﬂuence medication adherence
rather than measuring medication-taking behaviour itself.53
The Brief Medication Questionnaire (BMQ by Svarstad, 1999), an-
other self-report measure, has been recommended for use in individuals
taking antidepressant medicines for depression as well as for other
medicines/conditions.55 It has been used during the implementation
and discontinuation phases of adherence. It is noteworthy that the
psychometric properties of BMQ by Svarstad have also been tested and
reported in other chronic conditions (e.g. hypertension, diabetes, and
hypercholesterolemia), however, only weak correlations with phar-
macy reﬁll records have been demonstrated.17
The majority of included studies evaluated concurrent validity of
adherence measures via correlating the measures with a standard
measure such as MEMS.25,26,31,35,36 Among self-report measures, the
AAS demonstrated higher levels of validity (convergent and construct
validity), while BMQ by Horne demonstrated acceptable construct va-
lidity.32,47 and MGLS and AAS showed acceptable reliability.35,48
It is notable that whilst older studies of medication adherence used
single measures, most contemporary studies now apply multiple mea-
sures of adherence,16,50,57 recognizing that individual measures eval-
uate diﬀerent aspects of adherence. This is the case for both depression
as well as other chronic conditions such as heart failure and hy-
pertension.52 Speciﬁcally a combination of both subjective (self-report)
and objective adherence measures is recommended.
The majority of studies included in this review evaluated medica-
tion adherence during the implementation and discontinuation phases
of therapy. It is noteworthy that no study has speciﬁcally assessed
medication adherence at the initiation phase of therapy. This indicates
a signiﬁcant gap in the literature because data on the proportion of
consumers, who have been prescribed an antidepressant medicine, for
the ﬁrst time, but not had it dispensed or had it dispensed but not
commenced taking the medicine (primary non-adherence), is not
known.58 That is, studies have focused on the period after an anti-
depressant medicine has been dispensed and the ﬁrst dose taken.58
Some studies have evaluated the initiation of antidepressant medi-
cines (i.e. starting therapy) as an inclusion criterion,23–26,31,33,38,42–44
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using pharmacy records or self-report or MEMS as a measure. However,
determining whether consumers actually commenced management
with antidepressant medicines is not known.
There are several strengths and limitations of this systematic review.
Firstly, this systematic review is the ﬁrst to evaluate the psychometric
properties of medication adherence measures used in consumers taking
antidepressant medicines for depression without comorbidity.
Knowledge of whether the adherence measures are reliable and valid is
critical to informing and determining the eﬀectiveness of anti-
depressant medicines. It is likely that in some cases, the assumption of
“good” adherence, in consumers who are non-adherent, may contribute
to the conclusion that a particular antidepressant medicine is not ef-
fective for the individual. Hence the importance of knowing the psy-
chometric properties of measures of adherence. Secondly, this review is
based on an established framework for medication adherence which
conceptualizes medication taking behaviour as the initiation, im-
plementation, and discontinuation of therapy. This is important be-
cause depending on the phase of adherence, diﬀerent evaluation mea-
sures (for adherence) and strategies to address non-adherence may be
required.
There are also some potential limitations. Firstly, this systematic
review required the assessment of the adherence phase being evaluated,
and the evaluation of adherence measures used at these diﬀerent
phases. Most studies did not conceptualize adherence in the same way
nor did they include comprehensive details about the statistical pro-
cedures used to determine the psychometric properties of the measures.
Although any assumptions were kept to a minimum when extracting
data, the researchers did not attempt to contact authors for clariﬁca-
tion, in cases of incomplete or missing data. This is because the re-
searchers acknowledge that the focus of this review was diﬀerent to the
focus of most of the included studies. Secondly, although a standardized
framework was used for adherence, lack of standardized deﬁnition for
adherence in the included articles and the use of diﬀerent terms (e.g.
compliance, concordance), sometimes used interchangeably, meant
that it was challenging to extract data from some papers. Similarly,
some papers used the terms - reliability and validity – without further
explanation or details about the type of reliability or validity measured
(Table 1) or the statistical procedures. Hence the data extracted from
some of the articles were based on the researchers' interpretation of the
articles. Lastly, although the initial search for the relevant articles and
results extraction was conducted by one researcher, twenty percent of
included articles were cross-checked by a second researcher.
This study focuses on people with unipolar depression without co-
morbidity, in order to enhance the internal validity of ﬁndings. The
external validity of the ﬁndings may be limited, for example, consumers
with unipolar depression and co-morbidity.
4.2. Conclusion
A range of objective and subjective measures have been used to
assess antidepressant adherence in consumers with unipolar depression,
mainly during the implementation and discontinuation phases of ad-
herence. No measure exclusively assessed medication adherence at the
initiation phase, which is especially critical for consumers with de-
pression. Self-report measures were the most commonly used and were
also practical measures of medication adherence for consumers with
depression in the clinical setting. Although the psychometric properties
of various measures of medication adherence have been evaluated, a
standout measure with strong reliability and validity was not apparent.
Practice implication
In the absence of a gold standard measure which captures adherence
across the three phases of adherence or instruments with strong psy-
chometric properties across the diﬀerent phases of adherence, a range
of diﬀerent subjective and objective measures of adherence should be
combined, as a practical approach to assessing adherence in consumers
with depression. This systematic review provides a practical compre-
hensive evaluation of measures of medication adherence which can be
used to assess antidepressant medication taking in consumers with
depression. These data may be used to guide patient care with the view
to improving outcomes in depression. It is also recommended that fu-
ture studies clearly indicate the phase of adherence being assessed, in
order to better understand the complexities associated with the use of
antidepressant medicines for the management of unipolar depression.
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PART C - FACTORS INFLUENCING TO MEDICATION 
ADHERENCE TO ANTIDEPRESSANT MEDICINES IN 
UNIPOLAR DEPRESSION 
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CHAPTER FOUR – Consumer related factors influencing 
antidepressant adherence in unipolar depression: A qualitative 
study 
 
Chapter introduction 
 
It is important to realise that adherence to antidepressant medicine is crucial to the 
treatment of unipolar depression; this is because depression requires long-term 
treatment from acute to maintenance phases. In general, regular consumption of 
antidepressant medicine is recommended for at least of 6–9 months after the alleviation 
of depressive symptoms for the first episode of depression, and even longer in people 
with recurrent episodes. Nevertheless, a low rate of adherence is often reported after 
six months of treatment initiation, in particular during the maintenance phase in which 
the person is symptom-free. As discussed in Chapter Three, it is not only the right 
measure that is required to yield a reliable adherence rate, but a better understanding 
of the potential causes of non-adherence from the consumer perspective in order to 
improve medication adherence in unipolar depression. Despite many studies that have 
explored factors pertaining to medication adherence in unipolar depression, none have 
employed the ABC taxonomy. In addition, the existent information of the facilitators of 
and barriers to medication adherence throughout the adherence process is fragmented. 
Therefore, this part of the thesis (Chapters Four and Five) aimed to collect and explore 
the facilitators of and barriers to medication adherence at each adherence phase 
(initiation, implementation, and discontinuation) from the consumer’s perspective.  
 
  
72
73
© 2018 Srimongkon et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Patient Preference and Adherence 2018:12 1863–1873
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1863
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S160728
Consumer-related factors influencing 
antidepressant adherence in unipolar depression: 
a qualitative study
Pornchanok Srimongkon 
Parisa Aslani 
Timothy F chen
The University of sydney school of 
Pharmacy, sydney, nsW, Australia
Purpose: To explore factors which facilitate and negatively impact adherence, at initiation, 
implementation and discontinuation phases of adherence to antidepressant medicines.
Patients and methods: Semi-structured, face-to-face interviews were conducted with patients 
suffering from unipolar depression. The digitally audio-recorded and transcribed verbatim 
were used. Transcripts were thematically content analyzed and data managed using N-Vivo 
software.
Results: Twenty-three interviews were conducted. The predominant factors facilitating initia-
tion of therapy included self-motivation and severity of depression. Factors aiding persistence 
with therapy included belief in, and effectiveness of, antidepressants. Stigma and fear of adverse 
events inhibited initiation of therapy, whilst adverse events and ineffectiveness of antidepressants 
contributed to discontinuation. Patients with strong perceptions of the necessity and few concerns 
about antidepressants were more likely to adhere to treatment at all phases of adherence.
Conclusion: Different factors influence medication adherence at the different phases of adher-
ence. These factors were based on individual perceptions about depression and its treatment, 
and actual experiences of antidepressant treatment. This information should be considered by 
health care professionals in delivering targeted and tailored interventions to foster adherence. 
Strategies to address medication non-adherence in unipolar depression patients should consider 
the phase of adherence and individual perceptions about depression and its treatment, along 
with previous experiences with treatment for depression.
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Introduction
The most frequently cited definition of medication adherence, developed by the World 
Health Organization, is “the extent to which a person’s behavior-taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recom-
mendations from a health care provider”.1 More recently, medication adherence has 
been defined by a European consortium of researchers (ABC project: the Ascertaining 
Barriers for Compliance of medicines) as a continuous process, comprising three 
phases: initiation, implementation and discontinuation of therapy.2 Initiation occurs 
when the patient takes the first dose whilst discontinuation occurs when the patient 
stops taking the prescribed medication. Implementation of therapy refers to the actual 
dosing of medication consumption from initiation until the last dose.2
Globally, the total number of people living with depression was estimated to exceed 
300 million in 2015, equivalent to 4.4% of the world’s population.3 This estimation 
increased by 18.4% between 2005 and 2015.3 Depression is ranked by the WHO as 
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the single largest contributor to global disability and suicide 
deaths.3 However, medication adherence rates in depression 
are low. Approximately 30% of patients with depression do 
not complete their treatment.4 The average length of treatment 
in unipolar depression has been reported as ,6 months, with 
50%–60% discontinuation rates within the first 10–16 weeks 
of treatment.4–7 In one study, only 20% of patients reported 
good adherence (adherence rate above 80%) at 4 months 
after treatment initiation,5 while most treatment guidelines 
recommended continuation of antidepressant treatment for 
6–9 months after recovery.8,9
Depression itself is a risk factor for non-adherence.10,11 
A meta-analysis showed that medication non-adherence was 
three times higher in patients with depression compared to 
other conditions.11 Antidepressant non-adherence may lead to 
unnecessary switches in antidepressant medications, super-
fluous instructions to increase the dose, initiation of unwar-
ranted adjuvant treatments, and misclassification of patients 
as treatment resistant.12 One study in the USA reported that 
4.8% of patients did not initiate antidepressant treatment at 
6 months after an antidepressant was prescribed, and 12.2% 
reported ceasing therapy within the first 6 months.13 The 
most important reason for those who did not commence 
antidepressants was concern about potential adverse drug 
reactions (ADRs), while the most important reason for 
ceasing antidepressant treatment was that the antidepres-
sant was not helping.13 Other factors contributing to early 
discontinuation of antidepressant medicines include adverse 
effects, severity of illness, comorbidity, personality traits, and 
lack of support from health providers.14,15 Previous studies 
have shown that the symptoms of depression improving or 
becoming worse, the uncertainty about the usefulness of 
antidepressants, experience of side effects or adverse events, 
perceived stigma, peer pressure, adverse media stories, pre-
existing beliefs, difficulties with cost and the availability 
of care, and preference for other interventions, particularly 
counseling, are common reasons for individuals to stop 
taking antidepressant medicines.16–19 While some studies 
have shown that personal experiences with antidepressant 
medicines have a major impact on treatment continuation, 
such as belief in and acceptance of antidepressant medicines 
as a treatment option, acceptance of their condition, no side 
effects, fear of recurrence of symptoms of depression if 
antidepressant medicines are ceased, positive attitudes and 
interaction with doctors directly influence whether consumers 
take antidepressant medicines.19,20
Medication adherence is a continuous and dynamic pro-
cess that can change over time and is an individual patient 
behavior which is complex and is simultaneously influenced 
by several factors.21,22 Moreover, non-adherence may occur 
more frequently during a particular phase of treatment.23 
To maximize treatment outcomes, it is crucial to consider 
the potential factors influencing adherence at each phase of 
adherence. Although existing studies have discussed a range 
of factors influencing medication adherence, most of them 
have focused on the implementation and discontinuation 
phases16–20 or have not specified the phase(s) of adherence 
assessed. For this reason, a qualitative approach which 
focuses on the way people interpret their lived experiences24 
was employed in this study. The aim of this study was 
therefore to explore the facilitators or positive influencing 
factors which promote medication adherence at three phases 
of adherence (ie, initiation, implementation, and discontinua-
tion) in unipolar depression from patients’ perspectives; and 
to explore the barriers or negative influencing factors which 
reduce medication adherence at all phases of adherence.
Patients and methods
This was a qualitative study which used a phenomenological 
approach, to explore individual lived experiences of antidepres-
sant medicine taking (the phenomenon of interest) in consumers 
with unipolar depression who lived in the Sydney metropolitan 
area. This approach allowed for the collection of detailed 
self-reported information relating to individual attitudes and 
perceptions while also providing a basis for disclosure and 
comparison between responses. This study was approved by 
the Human Research Ethics Committee of the University of 
Sydney and has been reported in accordance with the consoli-
dated criteria for reporting qualitative studies (COREQ32).25 
The inform consent and relevant information had been given 
to the participants, therefore the consent form was signed prior 
to the commencement of an interview process.
study participants
A purposive sample of consumers with unipolar depression 
was recruited to ensure mix of gender, age, duration of current 
and previous use of antidepressants. The inclusion criteria for 
this study were: 1) age 18 years, 2) able to speak English 
fluently, without needing a translator, and 3) antidepressant 
medicine prescribed for unipolar depression currently or 
consumers who had ceased antidepressants in the 6 months 
prior to recruitment.
recruitment
A three-pronged recruitment strategy was employed which 
included recruitment of participants from community 
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pharmacies located within 15 km of the University of Sydney, 
through advertising on Internet websites and via a market 
research company. For the first strategy, 27 pharmacies were 
approached and 19 agreed to participate. Of those who did 
not participate, five did not respond and three refused to 
participate (one pharmacy did not have a policy to participate 
in research, one did not agree with the recruitment process 
and another did not give a reason). Participating community 
pharmacies displayed study advertisements and provided 
flyers to potential participants who were collecting a repeat 
prescription for an antidepressant for unipolar depression. 
Potential participants who were interested in taking part in 
the study were then directly contacted by the researchers via 
e-mail, text message, or phone.
Interview guide
A semi-structured interview guide was developed to address 
the specific study objectives. The interview guide was based 
on the ABC conceptual framework for adherence, published 
literature and the experience of research team members. Key 
topics included personal experiences of depression, previous 
experiences of taking antidepressants and side effects, effec-
tiveness of antidepressants, support network, relationship with 
doctors and other health care professionals, stigma experi-
enced, alcohol consumption, smoking behavior and lifestyle.
Data collection
Individual, face-to-face interviews were conducted. The 
interviews were digitally audio-recorded and transcribed 
verbatim. Participants fulfilling the inclusion criteria were 
interviewed by one of the researchers, P.S. (n=16) or T.C. 
(n=7). Participants gave written consent for interview 
recording and for publication of de-identified data. The 
study participants’ names were replaced by a code number 
once the interviews were transcribed. The transcripts were 
also checked for accuracy against the original recordings by 
P.S. The interviews lasted between 20 and 69 minutes and 
were carried out between February and August 2015. Data 
analysis was performed during July 2015 to February 2016. 
Interviews were conducted until data saturation,26 which was 
reached at the 21st participant. An additional two partici-
pants were interviewed to ensure that there were no further 
emergent themes.
Data analysis
Coding of the transcripts was carried out using iterative the-
matic analysis, with NVivo10 program for data management. 
The codes were extracted and grouped according to the 
themes and subthemes.24 Themes were derived from data 
extraction and grouped under the ABC framework for posi-
tive and negative factors at the three phases. Initial coding 
was performed by the first author (P.S.). Findings were 
cross checked by the other two investigators, experienced 
in qualitative data analyses.
Results
Twenty-three participants were recruited. Of these par-
ticipants, eight were recruited from community pharmacies, 
and 15 were recruited via a market research company. No 
participants were recruited via online advertising. No data 
on the response rate for participants recruited by the market 
research company or through community pharmacies were 
available. Participant characteristics and the current use of 
antidepressant medicines are presented in Table 1.
This research focused on patient-related factors, derived 
from their actual experiences, which were reported to influ-
ence medication adherence, from initiation to discontinua-
tion. The results obtained related to the first antidepressant 
Table 1 characteristics of the participants (n=23)
Characteristics N
Demographic data
Age range (years): 19–63, median: 37, mean: 40
gender: females/males
Self-report ethnic group
– Oceania (Australia or new Zealand)
– Others (Americas, south-east Asia, north- 
West europe, south African, southern and  
eastern europe)
Living circumstances
– Living with partner or family
– Living with roommate/housemate
– Living alone
Highest level of education completed
– secondary
– Diploma
– Bachelor
– Postgraduate 
– Other*
Prescription of antidepressant:  ,5/5 years
15/8
16
7
10
5
8
6
3
9
3
2
13/10
current antidepressant medicines prescribed
SSRIs: citalopram, escitalopram, fluoxetine,  
paroxetine, sertraline
snris: desvenlafaxine, duloxetine, venlafaxine
TcA: amitriptyline
Others: mirtazapine, phenelzine, reboxetine
Most recently ceased antidepressant medicines  
prescribed
9
7
1
3
ssris: escitalopram, sertraline 3
Note: *Primary school, certificate.
Abbreviations: ssri, selective serotonin reuptake inhibitors; snri, serotonin-
norepinephrine reuptake inhibitors; TcA, tricyclic antidepressants.
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ever prescribed through to the most recent one for the 
participant. Most participants had tried a range of different 
antidepressant medicines over a period of time in order 
to find the “right one”. A few participants had recently 
ceased taking their antidepressant medicine or reported 
intermittent consumption. Some of those who had ceased 
their antidepressant medicine were looking for an afford-
able and effective medicine with less or no ADRs. The 
majority of participants had chronic depression, and so had 
experience of restarting new treatment cycles with differ-
ent antidepressant medicines. Some participants tried to 
cease their antidepressant medicines to see if they could 
cope without them. Most participants realized the need for 
antidepressant medicines in order to boost their mood and 
day-to-day function.
At initiation, participants were more likely to commence 
antidepressants once they accepted that their depression was 
real and if they valued antidepressant treatment. Belief in 
and awareness about the need for antidepressants, as well as 
positive treatment effects, encouraged participants to adhere 
to antidepressant medicines. Although, fear of possible 
ADRs was not common, it was a strong barrier at initiation. 
Unpleasant ADRs, unsatisfactory treatment outcomes and 
depressive symptoms were common barriers which led to 
discontinuation of treatment. The index of the terms used 
in this study, in relation to influencing factors is shown in 
Table S1.
Positive factors
A broad range of positive influencing factors at the three 
phases of adherence were identified. Self-motivation; self-
management; and belief in and awareness about the need 
for, the importance of, and the effectiveness of antidepres-
sant medicines were main facilitators reported at all phases. 
At initiation, the predominant factors were self-motivation, 
patient perception that depressive symptoms were real and 
manageable, and willingness to follow doctor’s order. During 
the implementation phase, positive effect of antidepressant 
treatment with minimal ADRs experienced, and the ability 
to self-manage were reported as the main facilitators. To 
prevent discontinuation of therapy, positive influencing 
factors included self-motivation and belief in antidepres-
sant therapy. Figure 1 shows a schematic representation of 
positive factors reported to influence medication adherence 
at all phases.
Positive factors at initiation of therapy
Multiple factors were reported to encourage medication 
adherence at initiation: self-motivation, the acceptance of 
depression diagnosis, willingness to follow doctor’s orders, 
the severity of depressive symptoms, and recognition of anti-
depressant medicines. The majority of participants revealed 
that they wanted to feel better. Some participants wanted to 
be “cured” or “feel like normal” and that was the main factor 
that motivated them to commence antidepressant therapy 
Figure 1 Factors which positively influenced medication adherence at the three phases of adherence: initiation, implementation, and discontinuation of therapy.
Abbreviation: ADRs, adverse drug reactions.
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(quote no 1, Table 2). Once participants realized that they 
were experiencing depressive symptoms, they were more 
likely to start an antidepressant. When patients believed in 
and valued antidepressant medicines, they were more likely 
to take them regularly. Some participants mentioned that the 
severity of depressive symptoms compelled them to com-
mence antidepressants. More severe depressive symptoms 
provided a greater motivation to commence the treatment. 
However, in a few cases when patients were too ill to make 
a critical decision about their treatment, they relied more on 
their doctor rather than their own decision. Some participants 
indicated that they believed in their doctor’s judgment, and 
therefore followed their doctor’s advice.
Most participants suggested a variety of strategies which 
might encourage adherence to antidepressants such as early 
detection of depression and providing more education about 
the value of antidepressant medicines to target population.
Positive factors at implementation of therapy
A range of predominant factors were identified as positively 
influencing adherence at the implementation phase: positive 
effect of antidepressant therapy, belief in and realizing the 
need for antidepressant medicines, self-management, and fear 
of the effects if antidepressant therapy is ceased. The majority 
of participants reported that positive effects of antidepressant 
treatment, particularly the effectiveness of antidepressant 
medicines was the main reason to adhere to antidepressants. 
Participants were likely to continue their antidepressant 
medicine if depressive symptoms were lessened with few 
or no undesirable ADRs.
Self-management was a predominant positive factor 
for the majority of participants for persisting with therapy. 
A number of participants revealed that once they realized 
the importance of antidepressant therapy and believed in 
them, they organized a routine for taking their medicine 
regularly. The majority of participants reported a variety of 
techniques that they used to remind themselves to take their 
antidepressant regularly, for example, using a pill box, or 
setting an alarm (on their phone), putting their antidepres-
sant medicine in a noticeable spot (such as next to the cof-
fee maker or on a bedside table), choosing a regular time to 
take their antidepressant (such as the first thing to do in the 
morning, after breakfast, or before going to bed). In one case, 
a participant used a diary to remind herself to take her anti-
depressant routinely. Self-management was also important 
at this phase. Some participants indicated that they believed 
Table 2 Indicative quotes of positive and negative factors influencing the three phases of adherence
Factors Themes Quotes
Positive self-motivation  1. [i wanted] to lessen some of the symptoms that i had […] i was down, really down and 
upset [no 9/M/30 Y; Adherence phase: i/P/D]
 2. I’ll just keep going down and down and down until I feel I’ve got to get back up again. 
I’ll start that [antidepressant] again. [No 5/F/57 Y; Adherence phase: I/P/D]
Fear of negative consequences of 
ceased antidepressant medicines
 3. It took nearly a week [for them] to work and since then I’ve had a fear of stopping them 
so I’ve never really done it because I am too scared to stop and get those feelings back. 
[no 20/F/53 Y; Adherence phase: P/D]
Belief in and the effectiveness of 
antidepressant medicines
 4. i’m a little bit doubtful, but, […] i’ve seen medication [used] in family and friends, and 
i’ve seen it work. [no 15/M/44 Y; Adherence phase: i/P/D]
Negative Fear of anticipated ADrs  5. I was really worried about weight gain and I didn’t want to take medication that would 
make me gain weight. [No 22/F/28 Y; Adherence phase: I]
Self-stigma  6. I really didn’t want to [take them] in the beginning. I think it’s just […] embarrassing […] 
I felt like there’s something wrong with me […] [but] I could just talk myself into being 
happy instead of having to take it. [No 22/F/28 Y; Adherence phase: I/P/D]
Experiencing unpleasant ADRs  7. The Avanza® [mirtazapine], it was prescribed to me, I was in a pretty difficult position 
and with Avanza it helps you sleep but I didn’t like it because I stacked on the weight 
[no 21/M/45 Y; Adherence phase: i/P/D]
economic issue  8. The newest one that i tried which i went off was Valdoxan® [agomelatine] because it 
was so expensive [no 5/F/57 Y; Adherence phase: P]
Forgetfulness  9. First thing I’ll do is just put that [antidepressant] in my hand and take it. I made the 
mistake of putting my tablet two days ago into my dressing gown pocket, and that’s 
where it stayed. I found it the next day. Forgetfulness is also a symptom of depression 
and I find that I do suffer [No 19/F/60 Y; Adherence phase: P]
Previous negative experiences of 
antidepressant medicines
10. When I read the symptoms or side effects of it, I thought, yeah, I’ve had this before. 
I’m not going on it. [No 18/M/28 Y; Adherence phase: D]
Abbreviations: M, male; F, female; Y, years old; i, initiation; P, implementation; D, discontinuation.
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in antidepressant medicines, and trusted and were willing to 
follow doctor’s order.
Some participants stated that they feared the effect if they 
ceased their antidepressant medicine, as they had previously 
had experienced or heard about negative outcomes in other 
people (quote no 3, Table 2). Some participants observed 
positive results of antidepressant treatment from other people, 
which effectively motivated them to continue therapy.
A few participants mentioned that they wanted better health 
outcomes and so this motivated them to continue their antide-
pressant medicine. Two participants revealed unusual feelings 
when they missed a dose (one explained an electric shock-like 
feeling, another one reported a “zapping” sensation), and this 
reminded them to continue to take their medicine.
Comorbidity can affect medication adherence in differ-
ent ways. One participant had depression along with chronic 
pain, and was willing to take antidepressant medicines 
regularly, because they relieved both conditions. While 
another participant reported some difficulties in adherence 
to antidepressant medicines because of attention deficit 
hyperactivity disorder.
Most participants realized the benefits of commencing 
and maintaining some activities or lifestyles that improved 
depressive symptoms such as meditation, gentle exercise, 
hobbies and social activities. In a few cases, although partici-
pants stated that they believed more in alternative treatments 
such as acupuncture or herbal medicines, they decided to 
stay on antidepressant treatment.
Positive factors at discontinuation of therapy
The discontinuation phase of adherence occurred when an 
individual stopped taking their antidepressant medicine 
of their own accord. Unlike initiation and implementa-
tion, which are “positive” behaviors, discontinuation is a 
“negative” behavior. Therefore, in contrast to initiation and 
implementation, positive factors contribute to discontinu-
ation, whilst negative factors stop discontinuation. Hence, 
positive factors at this phase were similar to negative factors 
at the implementation phase.
Negative factors
Participants reported a wide range of factors that could 
adversely influence adherence to antidepressant medicines, at 
all phases of adherence. This included stigma associated with 
the use of antidepressant medicines, experiencing or antici-
pating ADRs, and personal issues such as not believing in 
the effectiveness of antidepressant treatment and unwilling to 
rely on medicine. At initiation, negative factors were mainly 
related to fear of or anticipating ADRs and self-stigma. At 
implementation, experiencing ADRs and ineffective treat-
ment played a significant part in negatively influencing 
adherence. Other negative factors included forgetfulness, 
feeling better, and the existence of depressive symptoms. 
At the discontinuation phase, previous negative experiences 
with taking antidepressant medicines led to discontinuation 
of therapy and failure to start a new cycle of antidepressant 
therapy. Figure 2 shows a schematic representation of nega-
tive factors reported to influence medication adherence.
Figure 2 Factors which negatively influence medication adherence at the three phases of adherence: initiation, implementation, and discontinuation of therapy.
Abbreviation: ADRs, adverse drug reactions.
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Negative factors at initiation of therapy
A number of factors were identified: unwillingness to rely on 
medicine, denial of depression diagnosis, fear of anticipated 
ADRs (eg, concern about weight gain) and self-stigma (eg, 
the feeling of being embarrassed when getting their prescrip-
tion dispensed). Two participants reported that they did not 
want to rely on medicines, another one identified herself as an 
“anti-medication” type person, and one participant indicated 
lack of support from family, which resulted in delayed initiat-
ing antidepressant therapy. Two participants who revealed the 
hesitation to commence an antidepressant at the initial diagnosis, 
hence the initiation phase was delayed, and later, they reported 
experiencing recurrent episodes of depression. However, most 
of them were on their antidepressant at the time of interview.
Negative factors at implementation of therapy
A range of negative factors were identified: experiencing 
unpleasant ADRs, ineffectiveness of antidepressant medicines, 
uncertainty about the effectiveness of antidepressant medi-
cines, forgetfulness, clinical improvement in depressive symp-
toms, and having depressive symptoms. These factors meant 
that participants did not persist with antidepressant therapy and 
this sometimes led to discontinuation of antidepressant medi-
cines. In most cases, unpleasant ADRs and the ineffectiveness 
of antidepressant treatment were mentioned as reasons for not 
persisting with antidepressant medicines. Some participants 
mentioned that after they started to feel better, they were more 
likely to discontinue their antidepressant medicine. Depressive 
symptoms such as forgetfulness, lethargy and laziness were 
reported in some cases as negative influencing factors, which 
interfered with medication taking behavior. A few participants 
doubted the effectiveness of antidepressant treatment and 
conducted their own trials to cease their medicine to see how 
they would be without it. In some cases, excessive alcohol 
consumption and illicit drug use interfered with adherence to 
antidepressant therapy. A few participants revealed that they 
denied both their diagnosis of depression and the necessity of 
antidepressant treatment. In other cases, self-stigma, inability 
to afford antidepressant medicines, concern about long-term 
effects of taking antidepressant medicines, an inconvenient 
dosage regimen, and lack of education about antidepressant 
medicines were noted as negative factors which adversely 
influenced medication adherence.
Negative factors at discontinuation of 
therapy
As described above, discontinuation is a “negative” behavior. 
Therefore, negative factors at discontinuation stop discon-
tinuation of antidepressant therapy.
Discussion
The results of this study are based on participants’ self-
reported actual experiences of antidepressant treatment 
as well as their perceptions and beliefs towards the use of 
antidepressant medicines for unipolar depression. This study 
comprehensively discussed factors influencing antidepressant 
adherence, and was able to capture information about facilita-
tors of, and barriers to, antidepressant adherence at the three 
phases of medication taking (initiation, implementation, and 
discontinuation). Although there have been previous qualita-
tive studies investigating medication adherence, this study is 
different because it uses the conceptual framework provided 
by the ABC consortium to allow for a more comprehensive 
analysis. This study therefore has the potential to inform 
tailored-interventions, based on the phase of adherence, for 
people prescribed antidepressant medicines.
The findings emphasized that consumers traded off the 
pros and cons of taking antidepressant medicines from initia-
tion to discontinuation of therapy, based on the integration of 
their own experiences, beliefs about their health conditions 
and perceptions of antidepressant treatment effectiveness, 
observing the experiences of other consumers taking antide-
pressants, specifically close family and friends, and concerns 
about the ability to afford antidepressant treatment, before 
making their own decision.20 Similarly, Schofield et al have 
reported that patients learn to trade off the risks and benefits of 
antidepressant treatment based on trial and error.16 The major-
ity of participants who continued antidepressant treatment 
in this study acknowledged the advantages of the treatment 
over the disadvantages, although some were burdened by their 
experiences with ADRs.27 In line with the Necessity-Concerns 
Framework,20,28–34 higher adherence rates were also reported by 
participants when they held stronger beliefs of the necessity of 
treatment than they did for concerns about treatment.28,35
Although participants identified a range of strategies 
that helped their medication adherence, it is noteworthy that 
the factors which may influence medication adherence in 
people with depression are likely to be both condition and 
medicine-related. For some, depressive symptoms drove 
participants to seek help and commence antidepressant medi-
cines. Thompson et al also found that increasing depressive 
symptoms prompted participants with depressive symptoms 
to seek help.36 Once participants had decided to seek help, 
they could participate in the decision-making process by 
weighing up the necessity to take the antidepressant medi-
cines against their concerns of taking them.17,37
At initiation, personal attitude and acknowledgement 
of their depressive condition and belief in antidepres-
sant medicines were key factors facilitating medication 
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adherence.38 Conversely, a negative attitude toward their 
depressive condition and lack of belief in antidepressant 
medicines inhibited medication adherence.39 Previous 
studies have also indicated that knowledge about disease 
and treatment combined with faith in the doctor motivates 
patients to start using medicines.39,40 Hence, strategies which 
may aid medication adherence in people recently diagnosed 
with depression and prescribed antidepressant medicines 
should include and emphasize, at the outset, education about 
depression and antidepressant treatment at the early stage.36 
This process should also include accurate and consistent 
information from health care professionals, including the 
pros and cons of antidepressant treatment. Specifically, edu-
cation should include discussion about the condition itself 
(depression) as well as the use of antidepressant medications. 
Participants indicated that the symptoms of depression such 
as constantly feeling sad, forgetfulness, loss of motivation, 
or a sense of hopelessness, may themselves inhibit adher-
ence, such as delaying the initiation of treatment, or reducing 
motivation to persist with antidepressant medicines once 
prescribed.12,23 Hence education about depressive symptoms 
and their impact on daily activities was important. In terms 
of specific education about the use of medicines, participants 
reported the need for specific counseling on the delayed onset 
of antidepressant medicine effects and anticipated short and 
long-term ADRs especially at initiation of therapy.12,23 It is 
noteworthy that fear of anticipated ADRs, unwillingness to 
rely on medicines, and uncertainty about the effectiveness 
of antidepressant medicines could delay the initiation of 
therapy. Although only some had a fear of anticipated ADRs, 
this fear played a strong role in delaying the commencement 
of antidepressant medications.
Once the treatment was initiated, participants reported 
constantly balancing the positive and the negative impact of 
taking antidepressant medicines. If the benefit outweighed the 
harm, most participants were motivated to remain adherent. 
For example, when they felt better (clinical improvement) 
and/or believed in and perceived the need for antidepressant 
treatment over unpleasant ADRs and stigma. In contrast, 
when harm exceeded the perceived or actual benefit, they 
became non-adherent. If negative factors significantly out-
weighed the positive factors, such as the unbearable ADRs 
and unsatisfactory treatment outcome, they would consider 
ceasing or having a break in therapy.
Treatment efficacy, belief, and perceptions about the anti-
depressant were major influencing factors during the imple-
mentation phase of adherence. Belief in and perceived need 
for medications have been previously linked to medication 
adherence.31,41 Similarly, Ho et al have also found that clini-
cal improvement was the major reason for patients to adhere 
to antidepressant treatment.42 Although positive effects of 
antidepressant therapy was one of the most powerful facili-
tators, paradoxically it also led to discontinuation, in some 
cases, as individuals felt they no longer needed treatment, 
as they were “better”.17,43 From a different perspective, fear 
of the effect when ceasing an antidepressant medicine was 
a major facilitator for persisting with treatment. In contrast, 
ineffectiveness of antidepressant treatment and experienc-
ing unpleasant ADRs, specifically sexual dysfunction, have 
been previously identified as the major barriers leading to 
discontinuation.13,20,44–48 Our study findings were therefore 
in line with previous findings which have also reported that 
perceived potential harmfulness (concerns) were significantly 
related to prior experience of ADRs.31,41
At discontinuation, new or recurrent depressive episodes 
prompted the majority of participants to seek out and com-
mence the new treatment cycle of antidepressant medicines. 
In some cases, unsatisfactory treatment outcome and expe-
riencing ADRs meant that consumers preferred alternative 
treatments (to antidepressants) such as acupuncture, herbal 
remedies, and counseling.
Many factors facilitated adherence at more than one phase. 
These included self-motivation, medication self-management 
for antidepressants, and trust in the doctor, whilst troublesome 
ADRs, self-stigma, and economic issues were significant 
barriers from initiation to discontinuation of therapy. Most 
of them were considered as modifiable factors (eg, attitudes, 
perceptions, beliefs about effectiveness of depression treat-
ment, patient/provider communication, including stigma).49 
Although, stigma was reported as a well-known barrier,23,38,50,51 
we found that it was manageable once the consumer realized 
the need of antidepressant treatment.13
Strengths
Our research design specifically focused on the different 
phases of adherence to medicines (ie, initiation, implemen-
tation, and discontinuation) using the ABC framework. It 
comprehensively covered both facilitators of and barriers 
to medication adherence at these different phases. In taking 
this approach, we gained important insights into consumer 
perspectives, which are often overlooked by health care pro-
fessionals. The recruitment process resulted in a wide range 
of experiences of depression and antidepressant treatment, 
duration of antidepressant treatment, age and background 
which likely reflects many consumers prescribed antidepres-
sant treatment for depression management.
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limitations
A relatively small number of participants was included in this 
study, as is the case with all qualitative studies. However, 
the sample size allowed us to reach theme saturation. Also, 
the participants in this study may not be representative of all 
people with unipolar depression. Specifically, all participants 
in this study acknowledged, recognized and had lived expe-
rience of depression. However, our study did not or could 
not include individuals (or groups) who do not acknowledge 
depression as a condition, and consequently the place of 
antidepressant medicines for the management of depression. 
Additionally, our initial recruitment approach of identifying 
consumers with depression through community pharmacy 
was low. Recruitment of participants for in-depth interviews 
about a potentially sensitive topic is challenging. Specifi-
cally for this study, the stigma associated with depression,52 
in both consumers and society, may have contributed to the 
recruitment process. Hence, we added an alternative method 
of recruitment via a market research company to identify 
consumers.
Directions for future research
Since medication adherence is a multidimensional and com-
plicated process, numerous factors typically affect the use of 
antidepressant medicines among people with unipolar depres-
sion. More specific aspects should be further explored such 
as antidepressant class-specific factors, and cultural-related 
factors in future studies.
Conclusion
Different factors influence medication adherence at the 
different phases of adherence. These factors were based on 
individual perceptions about depression and its treatment, 
and actual experiences of antidepressant treatment. This 
information should be considered by health care profession-
als when advising patients about adherence to antidepressant 
medicines, at the different phases of adherence, to ensure that 
targeted and tailored interventions are delivered to facilitate 
medication-taking behavior.
In order to optimize the use of antidepressant medicines, 
health care professionals should consider both positive 
and negative influencing factors at the different phases of 
adherence. To facilitate medication adherence, health care 
professionals should facilitate and encourage tailored use of 
positive influencing factors, and similarly address the nega-
tive influencing factors, at each of the phases of adherence. 
This approach is (more) likely to enhance treatment outcomes 
in people living with unipolar depression.
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Table S1 Index of the terms used in this study, in relation to influencing factors
Influencing factors Definition in the study
Positive factors
education about antidepressant 
treatment
Patient’s knowledge about the use of antidepressant medicines in depression treatment, including 
health literacy.
Willingness to follow doctor’s order Willingness and ability to follow doctor’s order pertaining to the use of antidepressant medicines 
in treatment of depression.
Acceptance of depression diagnosis Acceptance that one has a diagnosis of depression.
Recognition of antidepressant medicine The recognition of the importance of antidepressant medicines in the treatment of unipolar 
depression.
Positive effects of antidepressant 
treatment
Experiencing or beliefs about experiencing positive effects form the use of antidepressant 
medicines, such as, the effectiveness of antidepressant, clinical improvement, recovery, feeling 
better, few or no ADrs, and the observation of positive treatment outcomes from family 
members and/or friends.
self-motivation The reliance on one’s own powers and resources rather than those of others. This includes a 
desire to feel better and achieve better clinical outcomes as well as self-reliance.
Self-management The management of oneself pertaining to the consumption of antidepressant medicines; the 
taking of responsibility for regular consumption. This includes routines for taking antidepressant 
medicines, use of reminders or alarms, pill box, Webster-pak®, diary etc.
Negative factors
Unwillingness to rely on medicine The reluctance to use antidepressant medicines.
Denial of depression diagnosis Belief that one does not have depression.
Denial of the need for antidepressant 
treatment
Belief that one does not need an antidepressant medicine for treatment of depression.
Disorganized life Relevant factors pertaining to everyday living that negatively influence medication adherence such 
as running out of antidepressant medicine, excessive alcohol consumption, illicit substance use, etc.
Concern about long-term 
antidepressant treatment
Negative thoughts and concerns about long-term use of antidepressant medicines including fear of 
addiction, interference with natural functions of the brain or body, etc.
Self-stigma The process of an individual accepting society’s negative evaluation and incorporating it into his or 
her own personal value system and sense of self.1
Negative effects of antidepressant 
therapy
Experience or beliefs about experiencing negative effects from the use of antidepressant 
medicines; including ineffective antidepressant treatment, feeling worse, unsatisfactory treatment 
outcome, the existence of depressive symptoms, etc.
Trial cessation of antidepressant Personal experiment to cease antidepressant medicine without the guidance of health 
practitioners. 
Abbreviation: ADR, adverse drug reaction.
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CHAPTER FIVE – The influence of the health care system and 
society on adherence to antidepressant medicines: consumer 
perspective 
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Title: The influence of the healthcare system and society on adherence to 
antidepressant medicines: consumer perspectives 
Abstract 
Background: Non-adherence to antidepressant medicine is a major barrier to successful 
treatment in consumers living with unipolar depression. Understanding potential factors 
influencing medication adherence from the consumer perspective is a crucial step to 
improve adherence. The taxonomy proposed by the ABC project team, which 
conceptualises adherence into three phases: initiation, implementation, and 
discontinuation, was adopted in this study to elaborate potential factors influencing 
medication adherence.  
Objective: To explore influencing factors related to healthcare system and society which 
facilitate and negatively impact adherence, at initiation, implementation and 
discontinuation phases of adherence to antidepressant medicines in consumer with 
unipolar depression. 
Methods: Semi-structured, face-to-face interviews were conducted in consumers with 
unipolar depression. Interviews were digitally audio-recorded and transcribed verbatim. 
Transcripts were thematically content analysed and data managed using N-Vivo 
software.  
Results: Twenty-three interviews were conducted. At initiation, family and friends 
played an important role in encouraging consumers to seek help for depression and 
commence antidepressant medicines. At implementation, health care professional 
manner and support from government (Medicare) were central to good adherence. Lack 
of good bedside manner by health care professionals and an inability to support 
antidepressant medicine were major causes contributing to the discontinuation phase. 
Some factors such as stigma (e.g. societal stigma, stigma among health care 
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professionals) inadequate information about depression treatment from health care 
professionals, and difficult access to mental health specialist, negatively influenced 
adherence, but are modifiable.      
Conclusions: A number of factors influence medication adherence across the three 
phases. Health care professionals should consider distinct factors at each of the phases 
in order to deliver targeted and tailored interventions to foster adherence. Strategies to 
address medication non-adherence in consumers with unipolar depression should 
consider the phase of adherence, along with greater support from health care 
professionals and understanding of the healthcare system. 
 
Keywords: Depression, Adherence, Influencing factors, Facilitators, Barriers  
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The influence of the healthcare system and society on adherence to antidepressant 
medicines: consumer perspectives. 
 
INTRODUCTION  
Medication adherence is considered as a key to successful treatment in chronic 
conditions, including unipolar depression. In 2012, a new concept of medication 
adherence was proposed by a European consortium of researchers, known as the ABC 
project, which defined medication adherence as a continuous process, comprising 3 
elements: initiation, implementation, and discontinuation of medicines. “Initiation 
occurs when the patient takes the first dose of a prescribed medication. Implementation 
of the dosing regimen [is] defined as the extent to which a patient’s actual dosing 
corresponds to a prescribed dosing regimen, from initiation until the last dose is taken. 
Discontinuation marks the end of therapy, when the next dose to be taken is omitted and 
no more doses are taken thereafter”.1  
Unipolar depression is a highly prevalent mental health disorder globally. In 2015, more 
than 300 million people around the world were reported to be living with unipolar 
depression.2 The consequences of depression are huge. The World Health Organization 
has reported it as the major contributor to suicide deaths for approximately 800,000 
persons per year, and unipolar depression was the single largest contributor to global 
disability.2, 3  Depression is a unique mental health condition that lowers medication 
adherence in itself 4-6, due to demotivating symptoms such as lack of motivation and 
constantly feeling sad with a sense of hopelessness. Those with depression both delay 
commencement and have reduced adherence during treatment.7, 8 Non-adherence to 
antidepressant medicines has a significant impact on both clinical and economic 
outcomes. This includes the increased risks of relapse and/or recurrence, emergency 
department visits, and hospitalisation rates.9 Also, non-adherence in depression has led 
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to unnecessary switches in antidepressant treatment, unneeded instructions to increase 
doses, initiation of unwarranted adjuvant treatments, and misclassification of treatment 
resistant.7 
Antidepressant medicines are considered a major modality of treatment for 
depression.10-12 Most clinical practice guidelines recommend antidepressant medicines 
for a minimum course of 6-9 months after symptom recovery.11, 13 However, the 
adherence rate to antidepressant medicines has been reported to be relatively low. 
Generally, good medication adherence has been defined as an adherence rate greater 
than or equal to 80% as measured by dispensing records.14 However an estimated 50-
60% of people living with depression have ceased antidepressant medicines within the 
first 10-24 weeks of treatment 15-19 with the most common reasons given as ‘feeling 
better’ followed by ‘adverse events’ and ‘fear of drug dependence’.19 Nearly 25% of 
people have reported to have stopped antidepressant treatment without informing their 
doctor.15, 19, 20 In one study, 5% of patients reported to have never commenced 
antidepressant medicines.21 
Adherence is simultaneously influenced by several factors. WHO has categorized these 
factors into 5 dimensions; social and economic, healthcare team/system, characteristics 
of the disease, therapies and patient-related factors.3 Patient-related factors have been 
well studied, however, there has been little research conducted on the impact of the 
healthcare system (HCS) and healthcare professionals (HCPs) on adherence to medicines 
from the consumer’s perspectives. This study therefore focused on HCPs, HCS and social-
related factors that impact adherence from the consumer perspective. Many studies 
have indicated that HCPs, specifically general practitioners (GPs) play an important role 
in patient management including medication adherence in unipolar depression, within 
the first 3 months of starting antidepressants.22-24 Patients who experienced 
unsatisfactory interactions with HCPs were more likely to stop taking their 
antidepressant and vice versa.24 Family and peer support were recognised as supportive 
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factors for consumers with a mental illness.25 While stigma among HCPs and stigma in 
the society were reported as significant barriers to depressive treatment.26, 27 
Although a range of reasons related to HCPs and HCS have been reported as factors 
influencing medication adherence in unipolar depression, most studies appear to have 
focused on medication adherence at the implementation phase, while some were 
unclear about the phase(s) of adherence studied.24, 26, 28-34 Some studies focused on one 
aspect, either the facilitators of or the barriers to adherence.27, 32, 35, 36 The ABC 
framework emphasises that medication adherence is a dynamic, sophisticated, 
continuous and modifiable process.1 Hence, it changes over time. It is therefore crucial 
to better understand how HCPs and society influence medication adherence at each 
phase, from initiation to discontinuation, through the views of consumers with 
depression. This would likely provide a useful guide for HCPs in order to create tailored 
interventions to encourage medication adherence at each specific phase. The aim of this 
study was to explore the strategies or positive influencing factors related to the family 
and society, HCPs, and HCS which promote medication adherence at the three phases of 
adherence (i.e. initiation, implementation, and discontinuation) in unipolar depression 
from the consumers’ perspectives; and to explore the barriers or negative influencing 
factors related to the family and society, HCPs, and HCS which reduce medication 
adherence at all phases of adherence.  
METHODS  
Individual semi-structured, face-to-face interviews were conducted to collect detailed 
information relating to individuals’ attitudes, perceptions, and actual experiences about 
antidepressant treatment while also providing a basis for comparison between 
responses. This study is the second part of a research project exploring consumer-related 
factors influencing adherence to antidepressant medicines in unipolar depression from 
the consumers’ perspective. Approval for the conduct of this study was obtained from 
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the human research ethics committee of the University of Sydney, protocol number 
2014/967. The study has been reported in accordance with the consolidated criteria for 
Reporting Qualitative studies (COREQ32).37  
Recruitment 
A purposive sample of consumers with unipolar depression was recruited from 
community pharmacies located in the Sydney Metropolitan area, via on-line advertising 
(such as gumtree and locanto.com.au), and via a market research company, until data 
saturation was reached, i.e. when no new information or themes were observed.38-41 For 
purposive sampling, the basic elements for metathemes tend to be generally present at 
six interviews, and saturation can occur within the first twelve interviews.38 
Overall, 27 pharmacies were approached and 19 agreed to participate. Twenty-three 
participants took part in the study. Of these participants, 8 were recruited from 
community pharmacies, 15 were recruited via a market research company, and none via 
the Internet.  
Participants  
Participants were consumers who had been diagnosed with unipolar depression, were 
either on a recently prescribed antidepressant medicine or had ceased an antidepressant 
medicine in the 6 months prior to recruitment, were aged 18 or above, and spoke English 
fluently. The interviews were conducted at the School of Pharmacy, Faculty of Medicine 
and Health, The University of Sydney and audio-recorded with the participant’s 
permission. Participants gave written consent for audio-recording and to publish the 
data without any identifiable information, prior to the interview starting.  
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Interviews 
Semi-structured qualitative interviews were selected for data collection as they are well 
suited for the exploration of perceptions and opinions of respondents regarding complex 
and sensitive issues and to enable probing for more information and clarification of 
answers.42 Open-ended questions were used to explore consumers’ views about 
facilitators and barriers which influenced medication adherence at all phases. The 
interview guide was developed to address the study objectives and was based on the 
ABC conceptual framework for adherence, published literature and the experience of 
the research team.  
Participants fulfilling the criteria were interviewed by one of the researchers, P.S. or T.C., 
who have been trained in qualitative research. Seven participants were interviewed by 
T.C. and sixteen participants by P.S. Interviews were conducted until data saturation,38, 
43 which was reached at the 21st interview. Two additional participants were interviewed 
to ensure that there were no further emergent themes. 
Data presentation and analysis 
Thematic analysis was used to describe, identify, and analyse the key issues, and 
categorise data in ways that can be summarised, and reported as themes or patterns 
within data.44, 45 Verbatim transcripts of the interviews were iteratively analysed, using 
Nvivo10 program to assist with the data management for coding and thematic analysis. 
The codes were extracted and grouped according to the themes and grouped under ABC 
framework for positive and negative factors at all phases. Initial coding was performed 
by the first author (P.S.). Findings were cross checked by the two other investigators, 
experienced in qualitative data analysis. An Ishikawa model was created to visually 
display data. These models depict a “cause-and-effect diagram” which is useful way to 
illustrate multiple influencing factors across different constructs (family, society, and 
economy; health care professionals; and healthcare system) and the three phases of 
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adherence (Figure 1).46 The model was colour coordinated to represent different phases 
of medication adherence (e.g. factors influencing initiation in green).  
The operational definitions and theme descriptors used in this study is presented in 
Table 1. 
 
Table 1 Operational definitions and theme descriptors used in this study 
  Operational definition 
Family and social-
related factors 
Factors which indicated how family, friends, and society 
(e.g. neighbourhood, workplace, work colleagues) 
influenced medication taking behaviour from the consumer 
perspective. 
Health care 
professionals-related 
factors 
Factors which related to GPs, psychiatrists, pharmacists, 
and nurses, generated from the consumer perspective. 
Healthcare system-
related factors 
Factors which related to health care system, generated 
from the consumer perspective. 
Positive factors at 
initiation  
Any thoughts or events which encourage consumers to 
commence the first dose of an antidepressant medicine. 
Positive factors at 
implementation 
Any thoughts or events which encourage consumers to 
adhere to antidepressant medicines on a daily basis. 
Positive factors at 
discontinuation  
Any thoughts or events which encourage consumers to 
cease their antidepressant medicine.  
Negative factors at 
initiation  
Any thoughts or events which discourage or prevent 
consumers from commencing the first dose of an 
antidepressant medicine. 
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  Operational definition 
Negative factors at 
implementation 
Any thoughts or events which discourage or prevent 
consumers from continuing with their antidepressant 
medicine and leads to discontinuation. 
Negative factors at 
discontinuation  
Any thoughts or events which discourage or prevent 
consumers from discontinuing their antidepressant 
medicine. 
 
RESULTS 
This research focused on how family, society, HCPs, and HCS impact medication taking 
behaviour from the perspectives of consumers with depression. The participants spoke 
about their experiences and opinions pertaining to the first antidepressant medicine 
they had ever been prescribed to the most recent one. Twenty-three participants were 
involved in the study with an age range from 19 to 63; fifteen were female; and sixteen 
were Australian born. The majority of participants were prescribed selective serotonin 
reuptake inhibitors (SSRIs) followed by serotonin and noradrenaline reuptake inhibitors 
(SNRIs). The time since depression diagnosis ranged from 3 months to 42 years, while 
the duration of antidepressants treatment ranged from 6 weeks to 40 years. A number 
of participants had tried a range of antidepressants over several years in order to find 
the “right” one for them. Although, few participants had successfully ceased 
antidepressant medicines due to socioeconomic issues (e.g. unable to afford the 
medicines, unstable life conditions), one participant wanted to recommence 
antidepressant medicines when he could afford it.  
Family and society, HCPs, and HCS all influenced medication adherence from the 
initiation to discontinuation phases and were both facilitators of and barriers to 
adherence. However, their influence varied for different individuals. At initiation, once 
95
the participants were able to access health services, the bedside manner of HCPs played 
a major role either to support or discourage participants to commence an antidepressant 
medicine and adhere to it in the long-run. Support from the HCS was another key factor 
especially at the implementation phase, to facilitate consumers throughout their 
treatment journey. An Ishikawa model was created to present potential factors 
influencing medication adherence at the three phases (Figure 1). Example quotes have 
been provided indicated in Table 2.     
Three broad themes relating to the influencing factors were identified: the role of family 
and society in depression treatment, health professional’s manner towards the 
consumer, and the role of the HCS in depression treatment. Findings have been 
described below, together with illustrative quotations for the themes and sub-themes 
identified.  
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1 
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Role of family and society in depression treatment 
Family and society influenced medication adherence differently for different individuals. 
Approximately half of the participants perceived the need for support from family 
members, friends, teachers, and counsellors. At the initiation phase, the detection of 
depressive symptoms by family and community was important and assisted the 
participants in receiving the initial consultation from HCPs. At implementation, support 
was more related to monitoring depressive symptoms and encouraging regular medicine 
taking (Quote No.4, Table 2). At the discontinuation phase, where no further doses of 
antidepressant medicine were taken, the main facilitator was convincing the participant 
to recommence antidepressant medicines under the supervision of their physician. 
Family support played an important role for participants who were diagnosed with 
depression at a young age. In this respect, parents’ support was crucial to arrange the 
treatment plan, organise a medication taking schedule, and administer medicines (e.g. 
crush up the pill and give them every morning) (Quote No.18, Table 2). In turn, lack of 
family support was also reported. One participant noted that his parents believed that 
his depression was made up, and this led to delayed medication initiation (Quote No. 5, 
Table 2). Although lack of family support was a barrier to medication adherence, in most 
cases, it was not strong enough to hinder the participants to commence and adhere to 
antidepressant medicines once they realised the necessity of the treatment. A few 
disclosed that their family members had become very supportive right after a serious 
circumstance such as a suicidal attempt. Since then, their family seemed to realise the 
impact of depression and the importance of taking an antidepressant medicine. It was 
notable that family members living with depression played a strong role across the three 
phases for both direct and indirect support. First-hand experiences from family and 
friends with depression apparently facilitated a number of participants to adhere to their 
antidepressant. Family members learnt from the actual experiences of participants 
about the importance of medication adherence. For example some observed the 
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consequences of early discontinuation of antidepressant medicines (such as withdrawal 
symptoms and worsening depression) which emphasised the importance of adherence 
to antidepressant medicines. Participants reported that family members also observed 
a significant improvement in health outcomes when participants consistently consumed 
antidepressant medicine. This reassured participants and family members about the 
benefits of the medicine (Quote No.19, Table 2). Direct support from family members 
and/or friends who lived with depression such as advice about the use of antidepressant 
medicines was also mentioned as a strong facilitator of adherence at the implementation 
phase. Support from family and people around them was essential to encourage and 
maintain good adherence in particular cases in which the participants needed extra 
support, for example people with immobility, and disability. In some cases, unstable 
family situations (e.g. moving out of home, frequent moving) was a major reason to 
discontinue antidepressant medicines, for both intentional and unintentional 
discontinuation. 
Because of stigma, a number of participants were ashamed of their diagnosis and related 
depression to personal weakness, hence they did not want to disclose their depression 
to others especially to their employer. Most participants hid their medicines and only 
took their medicines at home, in private 
Mental health support groups were acknowledged as a helpful resource in some cases 
such as in an emergency situation, however, most were did not directly influence 
medication adherence. Some argued that support groups could be both useful and 
stressful at the same time. A few participants refused to join support groups as they had 
enough support, they did not want to listen to others’ stories of their depression, and 
they did not believe that support groups could help them. In one case, a meditation 
group at a Buddhist temple was reported as a beneficial choice in terms of effectiveness 
and cost savings.  
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Health care professional’s manner to the consumer 
All participants mentioned that HCPs’ manner directly influenced medication adherence, 
whether or not to take antidepressant medicines throughout the adherence process, 
particularly during implementation. HCPs with good bedside manner encouraged 
participants to commence, adhere to antidepressant and detect when they needed to 
resume treatment. Practitioners with good bedside manners displayed altruism  and 
accountability (e.g. an open supportive understanding relationship, good 
communication and listening skills and trust, provided enough time to discuss 
information about antidepressant medicines) facilitated  participants to commence and 
adhere to their antidepressant (Quote No.3, Table 2). At initiation, most participants 
were too ill to make a rational decision about their treatment. Hence, they relied more 
on their HCPs, especially GPs to make a decision on their behalf. At the implementation 
phase, experienced HCPs in mental health and good bedside manner (e.g. good 
relationship, open discussion, understanding) were critical and closely linked to the 
continuation of antidepressant medicines (Quote No. 10, Table 2). Having a regular HCPs 
also encouraged them to commence and adhere to their antidepressant medicine. A few 
revealed that they had more confidence to persist with their antidepressant medicine 
when they were treated by an experienced doctor rather than a young one. Close 
monitoring, having a good healthcare team with access to needed services, adequate 
information about the treatment plan and antidepressant medicines provided to 
consumers also encouraged participants to adhere to antidepressant medicines (Quote 
No.13, Table 2). Supportive services form pharmacy were additional key factors at the 
implementation phase (Quote No.15 and 16, Table 2). Some participants admired 
pharmacy support in terms of ease of access, as well as the pharmacist providing enough 
consultation time and information, and their willingness to answer questions. In one 
case, the pharmacist provided spare antidepressants to cover a gap while the participant 
was waiting for a new prescription from their doctor. Another participant reported the 
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helpfulness of a short message reminder to refill their prescription from the local 
pharmacist. 
On the other hand, potential barriers were strongly related to lack of good bedside 
manner (e.g. one-way/passive communication, rushed doctor, lack of understanding, 
insufficient information provided to the participant) especially at the implementation 
phase (Quote No.11 and 14, Table 2). A few participants revealed that they did not 
receive enough information about antidepressant medicines at the initial dose. 
Consequently, they ceased it right after side effects occurred. A paternalistic approach 
to healthcare, limited experience, and limited competency in mental illness were also 
mentioned as main barriers which contributed to discontinuation of treatment in some 
cases. A few participants indicated that the pharmacist did not influence their treatment 
because the pharmacist could not access their full treatment history (Quote No.17, Table 
2). This reflected the fragmentation of the HCS and health services. Furthermore, some 
participants did not have a regular pharmacy, and therefore could not establish good 
rapport with a pharmacist. A few participants reported experiencing stigma when they 
refilled their prescription at a pharmacy, and in some situations when they needed to 
disclose their current use of medicines, therefore their antidepressant, when visiting a 
pharmacy. As they felt uncomfortable and embarrassed, they felt that they were treated 
differently by pharmacists (Quote No.12, Table 2) which negatively influenced their 
adherence.  
Healthcare system role towards depression treatment 
Easy access to health services was the most important facilitator at the initiation phase, 
while the government subsidy for antidepressant medicines was a major factor 
supporting the implementation phase of adherence. In many cases, financial issues were 
considered paramount. Most participants acknowledged the benefits from the 
Australian government subsidy provided through Medicare Benefits Schedule (MBS). 
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The prescribed medications were supported through the Pharmaceutical Benefits 
Scheme (PBS) and Repatriation Pharmaceutical Benefits Schedule (RPBS). Medicare 
offers free treatment as a public patient in a public hospital, refunds for professional 
health services under the MBS, and subsidies for prescription medicines under the PBS. 
These factors were key facilitators supporting participants’ access to the HCS and 
promoting adherence to long-term treatment. All participants highlighted that they 
appreciated less out-of-pocket costs for antidepressant medicines as well as partial 
support to see mental health specialists (Quote No.7, Table 2). The subsidy made the 
price of their antidepressant reasonable and therefore the treatment was judged to be 
affordable. While a few participants gratefully received financial support in the form of 
a pension for other conditions (Quote No.6, Table 2). Collectively these factors were 
considered to be important positive influencing factors for facilitating medication 
adherence Likewise, private health insurance was mentioned as a facilitator in one case 
due to a significant reduction in out-of-pocket costs along with better services provided. 
A few participants disclosed a preference for receiving generic brand antidepressants as 
they were cheaper.  
Difficult access to mental health specialists and HCS were mentioned as a major barrier 
at the initiation phase in one case. As the participant was not an Australian citizen, there 
were unable to obtain Medicare support, and struggled to commence the treatment 
(Quote No.2, Table 2). Despite Medicare support, at the implementation phase, a few 
participants reported that they could not afford the out-of-pocket costs to consult with 
mental health specialists regularly. Additionally, some antidepressant medicines were 
not fully covered by the PBS, hence patients had to pay the full price. As a consequence, 
this led to premature cessation of the antidepressant medicine due to being 
unaffordable (Quote No.8, Table 2). Another issue was related to the need of pension to 
support people with depression when they were unable to work during severe 
depressive episode (Quote No.9, Table 2). In a few cases, lack of continuity of care in the 
public system due to high doctor rotation (every couple of months), long waiting times 
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at primary health centres, and long waiting period for an appointment with mental 
health specialists were also reported as barriers. At the implementation phase, clearly, 
affordable treatment was a key for good adherence. Although high cost unaffordable 
antidepressant medicines were not common, this was a powerful factor contributing to 
early discontinuation.   
Table 2 Example quotes throughout medication adherence process 
Themes Positive influencing quotes Negative influencing quotes 
At the Initiation 
Health care 
System: Medicare 
services 
• “I think once I get my health
insurance or Medicare, I might
also try other antidepressants,
see if it works out for me, like
the more expensive brands I
couldn’t afford back in my
country.” Quote No.1,
Participant No.7 (Male, age
19)
• “At the moment, I can’t
afford the price (of
depressive treatment) here.
It’s too expensive. If I get the
Medicare (card) I’d love to
try other antidepressants.”
Quote No.2, Participant No.7
(Male, age 19)
Health care 
professionals: 
Medical 
professionalism 
and expertise in 
mental health 
• “The first time I didn’t know I
had to take them until the
doctor explained why he’d like
to send me to the psychiatrist
and why do I need to take
antidepressant. I was so
desperate, so desperate that I
wanted anything that was
going to help me at that
moment.” Quote No.3,
Participant No.20 (Female,
age 53)
- 
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Themes Positive influencing quotes Negative influencing quotes 
Family and society: 
Initiate organise 
health care 
professional 
consult by family 
members 
• “What started me in the
beginning? I was depressed. I
was struggling to get up in the
mornings. I'd been taking a lot
of cocaine before I went in. It
probably was chemical
depression as well as the
other behavioural depression
or whatever it is. My Mum
and the woman who ran the
rehab knew each other very
well. My Mum works in
health. They decided that I
should be on
antidepressants.” Quote No.4,
Participant No.8 (Female, age
30)
• “With the antidepressants,
they (my parents) actually
didn’t believe in my
depression because I was
kind of hiding it for the most
part… they didn’t really
believe me about how
depressed I was. They
thought I was just acting
up.” Quote No.5, Participant
No.7 (Male, age 17)
At the Implementation 
Healthcare 
System: 
Affordability of 
health care system 
under Medicare 
and PBS 
• “Well, I’m very lucky. I am a
pensioner. That means that I
don’t have to pay very much
for my pills, $5.60 per
packet….. With my pharmacy, 
if you get blister packs and 
you get the generics, they 
don’t charge you for your 
medication. I am blessed. I get 
about $80 worth of meds for 
nothing a month.” Quote 
• “That last one, probably the
newest one that I tried
which I went off was the
…(the name of
antidepressant)… because it
was so expensive…and it was
not covered by the PBS”
Quote No.8 , Participant
No.8 (Female, age 57)
• “..I’m lucky that I’m legally
blind because it’s a lot
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Themes Positive influencing quotes Negative influencing quotes 
No.6, Participant No.17 
(Female, age 63) 
• “Cost would have been a big
one. If it was really expensive
and I wasn’t sure if I need to
be on it, I might have tried to
take myself off early, but it is
so cheap. Makes a big
difference.” Quote No.7,
Participant No.1 (Female, age
31)
harder to get a pension for a 
mental health issue 
condition…. You go to 
Centrelink and say I need a 
pension because I’m 
depressed. They tell you to 
just get on with it. Everyone 
gets sad - deal with it and it’s 
not that easy. I think what 
makes it worse is people 
that have depression, it’s not 
all the time that you are 
depressed.” Quote No.9, 
Participant No.22 (Female, 
age 28) 
Health care 
professionals: 
Bedside manner 
• “My new psychiatrist likes to
have a conversation first and
figure out recommendations
to do. …The appointment that
I usually have has 20 minutes
(as) a kind of update on my
thoughts and feelings about
how things are going and then
if I want (to) change anything.
The next 20 minutes is kind of
his ideas of what to do on it.
And 25-30 minutes are like the
final results of what is
continue” Quote No.10,
• “I feel like my doctor was
not listening to me when I
tried to explain what’s going
on but she just seemed to 47
say ‘we’ve got the best
which is working with me
anyway’ so I switch over to
another doctor” Quote
No.11, Participant No.6
(Female, age 24)
• “I felt that I was treated
differently at the clinic when
they (health care
professionals) knew that I’m
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Themes Positive influencing quotes Negative influencing quotes 
Participant No.6 (Female, age 
24) 
on …(the name of 
antidepressant). They stared 
at me and I felt really 
uncomfortable.” Quote 
No.12 , Participant No.22  
(Female, age 28) 
- GPs:
Accountability,
altruism,
bedside
manner,
professionalism
and expertise
• “We’ve got the support 24/7
of the nurses and doctor and
also the fact that if you go
through the washout period
of changing from one
medication to another, you’ve
got that support. If you do it in
the community, that might be
very hard for you… He’s (GP)
doing such a really good job
he will call me in the middle of
the night for results, if it was
urgent. He’s really
wonderful… I feel that I could
pretty much contact him any
time if I had any difficulties.
And his staff are really
wonderful too.” Quote No.13,
Participant No.4 (Female, age
38)
• “I had a doctor before then.
As soon as I mentioned stuff
like this (depressive
symptoms), his hands were
already on the script. I'm like
come on. What's going on
here? I can't talk to him in
detail. I think that's more the
busyness of him. He's just
rushing all the time. Now, I
changed to another doctor. I
think he's got more time to
talk, about anything. I think
that's good.” Quote No.14,
Participant No.9 (Male, age
30)
- Pharmacy:
Service
• “Occasionally Mum would
forget to order a new script
for me from my psychiatrist
• “No I don't really think
talking to pharmacists is
useful because they don't
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Themes Positive influencing quotes Negative influencing quotes 
but our pharmacist was really 
nice and would give me a bit 
of medication to tide me over 
while we got the script ... 
Which was really good 
because if I stopped this 
medication, I had really bad 
experience with that before.” 
Quote No.15, Participant 
No.11 (Female, age 26) 
• “They (the pharmacy) keep
your scripts for 4 or 5 of my
repeat (medicines) and they’ll
send you a message to come
and pick up your medicines.
It’s not that beneficial for me
but for other people I thing
that would help.” Quote
No.16, Participant No.3
(Female, age 30)
know your full background 
and history and everything. 
So they are kind of just 
guessing.” Quote No.17, 
Participant No.22 (Female, 
age 37) 
Family and society: 
Support and 
understanding 
• “I used to not be able to
swallow tablets so every
morning my mother would
crush up the pill and put it in
honey on a teaspoon and give
it to me with my breakfast.
Yeah, certainly until I was
about 17, 18 my Mum was the
one who gave it to me every
• “I still do think I don't really
want anyone at my work
knowing particularly,
because of the negative
stigma that is associated.
Because I know people that
probably should be on
medication that criticize
people that are on
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day.” Quote No.18, 
Participant No.11 (Female, 
age 26) 
• “She’s (his partner) been quite
encouraging and educated as
well, to sharing the
importance of staying on
something (antidepressant),
and committing to it until the
end. Because she was on
antidepressants as well”
Quote No.19, Participant
No.15 (Male, age 44)
• “At the moment I've got my
Mum, and she has an alarm
on her phone. She sends me a
text message twice a day to
say, take your meds. And I've
got an alarm on my phone,
but I still forget to take the
meds.” Quote No.20,
Participant No.3 (Female, age
30)
medication. It's, yeah. It 
does have a little bit of, I like 
to keep it secret.” Quote 
No.21, Participant No.15 
(Male, age 44)   
• “Not many of my friends
know the full story (of
depression). They might not
understand. And because I
don’t want them to look at
me like this, something sad
and wrong with me. Also
because depression is …
someone who wakes up,
sometimes feel like crying
every day.” Quote No.22,
Participant No.8 (Female,
age 30)
At the Discontinuation 
Health care 
professionals: 
GPs: bedside 
manner 
• “I trust him more than I trusted
the other doctor and he's
known me already. I saw him
immediately, as soon as I got
to the area and I've been there
• “I think I got scared because
of how I spiralled (down)
when he took me off it
quickly. I think I got a fear of
the tablets themselves. He
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now since 2007. When I felt 
the depression I knew I could 
tell him. He said, "I want to talk 
to you about it too. Because I 
know how you've been prior 
and I've noticed this slowly but 
surely change within you, so 
I'm glad you brought it up." 
Quote No.23, Participant No.16 
(Female, age 56) 
apologized at the end when 
he finally finished, he said, 
"I'm really sorry." I said to 
him, "You're a doctor, you 
should've known that you 
shouldn't take people off 
them immediately like that." 
Quote No.24, Participant 
No.16 (Female, age 56) 
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DISCUSSION 
Medication adherence is an inherently dynamic and complicated behaviour 
influenced by multidimensional factors. This study explored consumers’ view of the 
external factors (HCPs, HCS, and family and society) influencing medication 
adherence at specific phases of medication taking. These factors build on our 
previously published research which has reported on the influence of consumer-
related factors on medication adherence to antidepressant medicines. 
Participants reported that the people around them such as family members and 
friends played an important role for the initial detection of depressive symptoms and 
encouragement to seek help from HCPs. Hence accessibility to HCS and HCPs were 
main factors which facilitated or hindered participants in accessing and initiating 
treatment for their depressive symptoms. Specifically, once consumers had 
consulted with their doctor, the health care professional’s manner was a key to 
encourage them to commence and adhere to the treatment. Health care 
professionals with good bedside manner and who built trust and rapport with their 
patients using good communication skills facilitated the initiation of antidepressant 
medicines and ongoing implementation. Specifically for pharmacists, good service 
which included Webster paks provided by the pharmacy which also supported 
consumers to consistently use antidepressant medicines. During the implementation 
phase, Medicare services also played a major in role in supporting adherence in terms 
of the subsidy for medicines and specialised treatment. Affordable medicines was 
emphasised by the majority of participants and was mentioned as a crucial factor for 
good adherence in the long run. Private health insurance also positively influenced 
adherence in some cases as it facilitated access to quality care with lower out-of-
pocket expenses. On the other hand, consumers who could not detect depressive 
symptoms and/or were unable to access the HCS reported poorer medication 
adherence.  
The findings highlighted that distinct factors played a strong role at specific phases. 
At the initiation phase, early detection and the ability to access HCS are crucial 
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especially in severe cases. Among the consumers who had commenced 
antidepressant medicines, many reasons prompted them to cease treatment early, 
especially when they did not share a good relationship with HCPs or their HCPs lacked 
a good bedside manner.22, 24, 33, 48-50  For some this poor bedside manner was manifest 
as a paternalistic approach which lacked accountability and a sense of altruism. This 
negatively influenced adherence to antidepressant medicines. In other cases when 
consumers realised the advantages of antidepressant medicine over those negative 
factors, they traded-off these negative factors and consistently took antidepressant 
medicines. For example, stigma-related issue regarding the employment is a well-
accepted factor that was negatively influencing medication adherence.22, 26 It was 
manageable once the consumers perceived need of antidepressant medicines over 
concern of the stigmatisation. In the same way, some factors (e.g. the fragmentation 
of HCS, stigma among HCPs, stigma in family and society, the retirement of HCPs, 
HCPs with less expertise in mental health, lack of public awareness about depression, 
and lack of education about depression in society) negatively influenced adherence 
but these factors did not necessarily stop individuals from taking their antidepressant 
medicines. In part this may be explained by the Necessity-Concerns framework (NCF 
framework).51 The NCF states that higher adherence was associated with stronger 
perceptions of necessity of treatment and fewer concerns about treatment.51 
However in some cases, these potential barriers also has the potential to lead to early 
discontinuation of antidepressant medicines. One of the stronger negative 
influencing factors was the ongoing cost of antidepressant medicines as higher cost-
sharing is a significant barrier to medication adherence.31 Some factors often 
influence adherence/non-adherence at all phases of medication taking such as 
stigma (societal stigma and stigma among HCPs), access to HCS, health services, 
Medicare support, and constant support from HCPs and family members. Not 
surprisingly, mental health stigma about depression also presented challenges for the 
recruitment of participants to this study.  
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For participants, the support of their family was linked to monitoring the progress of 
depressive symptoms and to encouraging regular consumption of antidepressant 
medicines. Building on previous studies, support from family members with 
depression was highlighted as an important facilitator from the initiation to the 
discontinuation phases, for both direct and indirect support (e.g. second-hand 
experience). This is may be due to full understanding about the condition and its 
treatment. In contrast, lack of family support was associated with low health literacy 
about depression (non-acceptance as a medical condition) and the consequent 
stigma attached to the person and the family as a result. Mental health advocacy 
organizations were helpful in some cases, specifically in emergency situation.  
The findings from this study about the views of HCPs aligned with those of previous 
research which pointed to the need for more collaboration (shared decision making 
with a patient-centred approach) between patients and HCPs, in order to improve 
adherence and treatment outcomes.49 At the discontinuation phase, once consumers 
ceased their medicines, early detection of recurrent symptoms had to be prompted 
by HCPs and/or family members, highlighting the importance of family support and 
access to HCPs. Notably, the majority of negative factors that contributed to the early 
discontinuation of antidepressant medicines were modifiable, such as lack of public 
awareness about depression, HCPs manners in practice, and better health services.  
Participants commented that some modifications to health care systems were 
required in order to improve medication adherence and health outcomes. This has 
previously been reported.31 Practical changes from the consumer perspective 
included increasing the number of subsidised mental health specialist visits per year, 
increasing the number of mental health specialists actively working in the HCS, and 
government social support for those with depression. Specifically for medicines, and 
in line with previous studies, an even greater range of subsidised antidepressant 
medicines and continued and increased use of more affordable generic medicines 
were reported by participants as aiding medication adherence.52, 53 Interestingly, 
participants also reported on fragmentation within the health care system caused by 
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lack of a shared patient medical record amongst HCPs which inhibited a 
multidisciplinary health care team approach. 
 Strengths and limitations of the study 
This study focused on both facilitators for and barriers to medication adherence at 
specific phases of medication taking from initiation to discontinuation of therapy. 
Detailed first-hand experiences of people with unipolar depression provided 
meaningful insights into the impact of HCPs, HCS and family on adherence to 
medicines .  
One notable limitation was that it was not possible to recruit consumers with primary 
non-adherence, that is those who had been provided treatment with an 
antidepressant medicine but who did not initiate therapy or those who did not 
acknowledge that they had a depressive disorder. Individuals who did not have access 
to the health care system were also not able to be recruited to this study. It should 
be noted that the participants in this study were those who were willing to share their 
treatment experiences and maybe more likely to adhere to antidepressant 
medicines. Additionally, the majority of recruited participants were unemployed or 
pensioners receiving government support who lived in the Sydney metropolitan area. 
Comparisons with those residing in in rural or remote areas was not possible and 
might present other factors which may positively or negatively influence medication 
adherence.  
CONCLUSION  
This study examined the influence of HCS, HCPs, and society on adherence to 
antidepressant medicines, across the different phases of medication taking, in people 
with unipolar depression. This study demonstrated that there are substantial factors 
which go beyond the more commonly reported consumer-related factors which 
influence medication adherence. Strategies to address medication adherence should 
consider the broader impact of the HCS, HCPs and society if medication adherence 
and health outcomes for people with depression are to improve. This study identified 
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that specific factors influence medication adherence at particular phases of 
medication taking. At initiation, easy access to HCS and HCPs, HCPs with good bedside 
manner, and early detection of depressive symptoms were the greatest influencing 
factors. At the implementation, constant support from HCPs and financial support via 
Medicare played a major role in maintaining adherence to antidepressant medicines 
in the long run. However, increased support from HCS and HCPs was also identified, 
predominantly through a stronger patient-centred focus and better integration of the 
health system. Participants identified a number of factors which are potentially 
modifiable such as the bedside manner of HCPs, pharmacy services, and 
communication between HCPs and consumer with unipolar depression.   
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The findings of Chapters Four and Five highlighted the complexity of medication 
adherence in consumers with unipolar depression. Many factors can influence 
consumer behaviour across adherence phases, in terms of either positive or negative 
impact, particularly as these may be linked to personal beliefs about and perceptions 
of depression and antidepressant medicines. For example, clinical improvement 
contributes to good adherence in many cases once the consumers realises that the 
effectiveness of antidepressant medicines over the disadvantages. However, it may 
also lead to the discontinuation of treatment due to recovery in certain cases. The 
implication here is that consumer beliefs should be a key element of medication 
adherence. Therefore, it is important to engage in a patient-centred shared-decision 
making approach in order to improve adherence to medicines in people with unipolar 
depression. In addition, patient engagement is necessary for successfully 
encouraging behaviour change and maintain adherence in long-term treatment.  
This part of the thesis has highlighted factors specific to the condition of depression 
and antidepressant medicines. Because the inherent symptoms of depression (e.g. 
trouble concentrating, remembering details, and making decisions) generally 
decrease adherence to antidepressant medicines as well as the pharmacological 
properties of antidepressants negatively impacted medication adherence (e.g. 
unbearable ADRs, particularly sexual dysfunction and delayed onset of the actions of 
antidepressant medicines). In general, depressive symptoms may commonly 
influence adherence at the initiation and discontinuation phases, whereas the 
consequences of using antidepressant medicines largely influence medication 
adherence across the three phases, particularly at the implementation phase. 
Furthermore, these factors may be interlinked and therefore influence other factors. 
For example, in most cases, although the effectiveness of antidepressant medicines 
played a major role in medication adherence at the implementation phase, other 
factors such as its ADRs and belief about the need of antidepressant medicines should 
also be considered concurrently. 
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Although many factors influence medication adherence across the three phases, the 
impact of each factor at each phase of adherence may be different. For example, 
despite the education on antidepressant medicines playing a role towards 
medication adherence from the initiation to the discontinuation phases, it had the 
strongest impact at the initiation of the treatment, as the decision of whether or not 
to commence taking antidepressant medicines was directly related to the initial 
decision-making process. A lower impact was discovered at the implementation and 
discontinuation phases. These findings emphasise the need for health professionals 
to clearly understand potential factors influencing medication adherence at specific 
phases, as it is a crucial step to effectively solve non-adherence problems.  
Because medication adherence is a multidimensional process, this thesis classified 
the influencing factors into five categories: consumer-related factors 126; factors 
related to health care professionals; factors related to health care systems; 
depression-related factors; and family-, society-, and economy-related factors. The 
operational definitions and theme descriptors used in this thesis are presented in 
Chapter Five, Table 1. 
The Ishikawa model is a commonly used method for visually depicting complex 
processes or behaviours such as medication adherence. Here this method has been 
used to combine the data presented in Chapters Four and Five. Specifically, different 
colours in the model represent the factors influencing medication adherence at each 
phase of medication taking behaviour (e.g. green for the initiation phase) (Figure 3). 
In the Ishikawa model, factors specific to unipolar depression have been marked with 
an asterisk (e.g. severity of depressive symptoms, new or recurrent depressive 
episode, whilst it is acknowledged that other factors may apply to other health 
conditions. Factors which positively influence adherence are depicted in the top half 
of the Ishikawa model and those which negatively influence medication adherence 
are depicted in the lower half of the model. 
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PART D - DEVELOPMENT AND VALIDATION OF 
MEDICATION ADHERENCE FRAMEWORK IN 
CONSUMERS WITH UNIPOLAR DEPRESSION 
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CHAPTER SIX – The development and validation of 
medication adherence conceptual framework in consumers 
with unipolar depression 
 
Chapter introduction 
 
Medication adherence is a multidimensional process which involves not only 
consumers, but also health professionals, family, society, and the health care system. 
For this reason, the above-mentioned aspects must be integrated when dealing with 
the non-adherence problem. Therefore, it is crucial for health care professionals to 
clearly understand what would happen to their patients once antidepressant 
medicines have been prescribed, including potential factors influencing medication-
taking behaviour across the adherence process from the patient’s viewpoint. 
Consequently, there must be appropriate interventions to enhance medication 
adherence, while all possible barriers should be restricted. 
The proposed framework has been developed in order to illustrate the adherence 
process and factors influencing medication-taking behaviours in consumers with 
unipolar depression at specific phases of adherence, based on the consumer’s 
perspective. The framework aimed to guide the physician to better understand their 
patients when antidepressant medicines were prescribed, from the first dose to the 
last dose of treatment. This proposed framework has been based on the research 
presented earlier in this thesis, specifically the review of the literature (Chapter 
Three), distillation of the qualitative studies (Chapters Four and Five), and the 
experience of the research team.  
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The development and validation of medication adherence conceptual framework 
in consumers with unipolar depression 
 
 
Introduction 
Depression is a common mental illness that affects approximately 300 million people 
around the world, equating to 4% of world population in 2015. It contributes to a 
significant in global health loss including suicide death.1 Depression may then require 
long-term treatment. Most treatment guidelines recommended continuous use of 
antidepressant medicines for 6-9 months after recovery from depressive symptoms, 
for the first episode.2-7 The duration of treatment is longer for recurrent depression. 
However, adherence to antidepressant medicines was reported to be relatively low 
at approximately 50-80% after 4-6 months of treatment.8-10 Reasons for non- 
adherence in people with depression are numerous and multifactorial.11-13 Notable 
influencing factors are related to clinical characteristics of depression and 
pharmacological properties of antidepressant medicines. Depression itself is a well-
known risk factor for non-adherence as depressive symptoms negatively influence 
medication adherence.14-16 Common causes of non- adherence are adverse drug 
reactions (ADRs), unsatisfactory interactions with health care professionals (HCPs), 
and ineffective clinical response to antidepressant medicines.11, 17-19 Non- adherence 
to antidepressant medicines increases the risk of relapse and/or recurrence of 
depression, emergency department visits and hospitalization rates, and can increase 
the severity of depression.20, 21 
In 2012, a taxonomy for medication adherence was established by a European 
Consortium who conceptualised the ABC framework for medication adherence.22 This 
taxonomy divides medication adherence into 3 components: initiation, 
implementation, and discontinuation.22 Initiation starts when the consumer 
commences the first dose of medication. The process continues with the 
implementation of the dosing regimen, until the last dose is taken and no further 
doses are taken. The latter marks the discontinuation phase.22 Adherence is a 
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complex and dynamic process that can change over time.12, 22 The factors which 
influence adherence at the different phases of adherence differ.11 For example, more 
intensive contact with and support from HCPs are particularly helpful to consumers 
who have just commenced antidepressant medicines.11 Furthermore, 
multidisciplinary and multilevel approaches are necessary to optimise adherence.12, 
23-25 A recent systematic review and meta-analysis of medication adherence 
outcomes of over 700 intervention trials suggested that HCPs should focus 
intervention content on behavioural strategies, especially habit-based interventions, 
more than cognitive strategies designed to change knowledge and beliefs.26 In order 
to do so, a solid understanding of the entire process of medication adherence, a crucial 
fundamental for tailored-interventions, is necessary. 
A conceptual frameworks is ‘a network of interlinked concepts that together provide 
a comprehensive understanding of a phenomenon or phenomena’.27 They outline28 
the relationships between the concepts presumed to account for the phenomenon, 
by fitting the explanations into a set of categories.28 Conceptual frameworks have 
been applied to a variety of health conditions (e.g. HIV, heart failure, hypertension) 
to elucidate relationships between concepts of interest, including medication 
adherence. 29-33 Most of the existent frameworks in unipolar depression are mainly 
created to improve quality of treatment in people with depression.34-36 Nevertheless, 
no existing frameworks has been created specifically to solve non-adherence 
problem in people with depression. 
Much of the focus of existing frameworks aimed at improving medication adherence 
has been the perspective of HCPs.24 Existing frameworks have not necessarily focused 
on the characteristics of depression or antidepressant medicines which may impact 
adherence. Nor have they considered the consumer perspective or health care 
system related factors. A detailed understanding of the factors influencing 
medication adherence at the specific phases of medication taking behaviour 
(initiation, implementation, and discontinuation) may be important for HCPs to aid 
better management of their patients. This may facilitate the implementation of 
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tailored interventions designed to improve medication adherence.37-44 
This study aimed to develop and validate a conceptual framework that illustrates 
potential factors influencing medication taking behaviour in consumers with unipolar 
depression. This conceptual framework was intended to describe the adherence 
process and identify factors influencing medication adherence at specific phases (i.e. 
initiation, implementation, and discontinuation) in people with unipolar depression, 
from the perspective of consumers. 
 
Methods 
This study consisted of 2 main parts: the development of a medication adherence 
conceptual framework for people with unipolar depression and the content 
validation of this framework. The development phase was created in accordance with 
Lynn (1986) method, and was undertaken by the research team.45 The face and 
content validation involved an internet-based survey using an expert panel. This 
study was approved by the Human Research Ethics Committee of The University of 
Sydney. 
1. The development of a medication adherence conceptual framework for 
people with unipolar depression 
The ABC taxonomy was used to guide the development of the framework.22 The 
framework aimed to document potential factors which influence adherence to 
antidepressant medicines at the three phases of medication taking, from the 
consumer perspective. Item generation (i.e. factors influencing medication 
adherence/ non-adherence) at the three phases of the adherence process was 
informed by multiple sources. The specific content of the framework was generated 
from qualitative studies conducted by the research team (Part C, Chapters Four and 
Five), published literature on factors known to influence medication taking behaviour 
and the experience of the research team. This content was used to build an item bank 
of statements pertaining to factors which may influence medication adherence 
(Appendix Four, Table A). The items were then grouped into 5 domains and mapped 
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onto the ABC taxonomy. Figure 1 presents the conceptual framework of medication 
adherence in people with unipolar depression. The operational definitions and theme 
descriptors used in the framework are presented in Table 1. T.C. conceptualised the 
framework and constructs and P.S conducted the item generation process. 
Following internal review by the authors, items were transferred to Survey Monkey, 
for face and content validation via an expert panel. 
 
Figure 1: conceptual framework of medication adherence in consumers with 
unipolar depression 
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Table 1: The operational definitions and theme descriptors used in the framework 
 
 
Domain  
Health care 
professionnals 
Factors pertaining to health care professionals, 
such as GPs, psychiatrists, pharmacists, and nurses, 
which may impact medication adherence, 
generated from the consumer perspective. 
Consumers Factors pertaining to the consumer experience 
of taking antidepressant medicines, both 
physical and emotional aspects, which may 
impact medication adherence. 
Health care system Factors pertaining to the health care system which 
may impact medication adherence, generated from 
the consumer perspective. 
Family, society, and 
personal finance 
considerations 
Factors pertaining to family, friends, and society (e.g. 
neighbours, workplace, community) which may 
impact medication adherence. 
Depression Factors pertaining to unipolar depression which may 
impact medication adherence, generated from the 
consumer perspective. 
Facilitators at the 
initiation phase 
Any factors which encourage consumers to commence 
(initiate) the first dose of an antidepressant medicine. 
Facilitators at the 
implementation phase 
Any factors which encourage consumers to adhere to 
antidepressant medicines. 
Factors leading to 
early discontinuation 
Any factors which lead to the early discontinuation of an 
antidepressant medicine. 
Barriers at the 
initiation phase 
Any factors which discourage or prevent consumers 
from commencing the first dose of an antidepressant 
medicine. 
Barriers at the 
implementation phase 
Any factors which discourage or prevent consumers 
from continuing with their antidepressant medicine and 
lead to early discontinuation. 
Factors preventing 
early discontinuation 
Any factors which discourage or prevent the early 
discontinuation of an antidepressant medicines. 
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The framework starts when a consumer first consults with their health care 
professional and receives a prescription for an antidepressant medicine. Following 
the receipt of a prescription for an antidepressant medicine, consumers may or may 
not choose to have their antidepressant medicine dispensed. When the first dose of 
the antidepressant medicine is taken, medication adherence commences. This point 
is recognised as the initiation phase of medication adherence. In contrast primary 
non-adherence occurs when a consumer does not have their antidepressant 
medicine dispensed or does not initiate therapy with the medicine. The ongoing 
process of consistently taking and having their antidepressant medicine dispensed 
refers to the implementation phase. Discontinuation occurs when the last dose of the 
antidepressant medicine is taken without any further doses consumed. Secondary 
non-adherence occurs if the implementation phase of antidepressant medicine 
taking is sub-optimal or with the early discontinuation of the medicine. The 
adherence cycle resumes when a consumer decides to recommence their 
antidepressant medicine for a different episode of management. The main focus for 
this framework is the reporting of factors which may impact medication adherence 
(facilitators of and barriers to) at the specific phase of adherence. 
2. Validation of conceptual framework 
Face and content validity are primary assessments when a new tool or framework is 
developed.46 Face validity has been defined as validity conferred by a layperson’s 
acceptance that the tool or framework appears to be sound or relevant.45 Content 
validity is a crucial process for the development of any form of tool or framework to 
assess the representativeness of its content and appropriateness of the development 
process.45, 47 Hence, it is considered a fundamental part of the validation assessment 
process.47 Content validations follows a two-step process with the first step 
pertaining to the development process followed by second step which is the 
judgement-quantification process  
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using a panel of experts to evaluate the instrument elements.45, 47, 48 In this study, an 
internet-based survey using an expert panel was employed to assess both of face and 
content validity of the framework due to the convenience for both researchers and 
expert panel, as it provides rapid feedback, ease of data management, and the 
possibility of recruiting international panel members.49-51 
The expert panel was asked to rate their opinion towards the items bank generated 
for the framework. Specifically, the relevance and importance of the influencing 
factors (items) at each phase of adherence were evaluated.52, 53 In this study, 
relevance refers to the extent to which the statement is relevant to practice at the 
specified phase of medication adherence. Importance refers to the extent to which the 
statement is important for the specified phase of medication adherence. Blank space 
was also provided for each item to allow expert panel members to provide further 
comments such as the clarity of items (Figure 2). Five-point Likert scales, which 
included the following options: ‘strongly agree’, ‘agree’, ‘neither agree nor disagree’, 
‘disagree’, and ‘strongly disagree’, were employed in this study.47, 52, 54 When 
compared to four-point scales, they reduce the risk of losing critical information and 
chance agreement.47 
Figure 2: The example of item provided on internet platform 
 
 
 
 
131
The Content Validity Index (CVI) is the most widely used method used to quantify 
experts’ degree of agreement regarding the content relevance and importance of an 
instrument.47, 55, 56 The CVI is a basic index of interrater agreement that expresses the 
proportion of agreement among the expert panel.55 Two main types CVI adopted for 
this study were for individual items (I-CVIs) and content validity of the overall scale (S-
CVI/Ave). I-CVIs is a proportion of agreement about relevance for each item, it is 
computed as the number of experts giving a rating of either ‘agree’ or ‘strongly 
agree’, divided by the number of experts.56 S-CVI/Ave refers to the proportion of items 
given rating ‘agree’ or ‘strongly agree’ by the raters involved for the whole scale. In 
general, both I-CVIs and S- CVI/Ave of 0.80 or higher are acceptable.55, 56 Items are 
categorised as having moderate level of consensus when the I-CVIs score are 
between 0.70- 0.79, and low when <0.70. 
The expert panel members were chosen based on their extensive experience in 
medication adherence and/or depression and/or health services research. A 
purposive sample57 was used to recruit the panel under the following criteria: 1) 
belonging to one of the following professions: general practitioners (GPs), 
pharmacists, or academic researchers 2) currently involved in or working in mental 
health, medication adherence, or medication taking behaviour. A set of specific 
instructions were provided to expert panel members to facilitate the content 
validation process. Initially, an email invitation including all relevant information and 
link to survey host was sent to 19 potential experts. Twelve responded, 2 declined to 
participate due to their bust scheduled, while 5 did not respond to the invitation. In 
this respect, it is difficult to state the reason for those who did not respond. 
Nevertheless, 2 experts who agreed to participate did not complete the survey. 
Therefore, overall, 10 experts fully participated in this study. 
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Results 
• Expert panel members
Ten multidisciplinary expert panel participated in the validation process and were 
recruited from (Australia, Canada, Nepal, United Kingdom, and Switzerland) as 
showed in Table 2. 
Table 2: Overview of panel member characteristics 
Disciplines General 
practitioners 
Pharmacists Academic 
Researchers* 
Number 2 4 4 
Years in practice 27 (15-39) 24 (20-30) 22.5 (10-35) 
Countries 
• Australia
• Switzerland
• Nepal
• Canada
• United Kingdom
2 
- 
- 
- 
- 
2 
1 
- 
1 
- 
1 
1 
1 
- 
1 
*University lecturer and researcher in pharmacy practice
• Face and content validity
Seventy-two items were evaluated (Table 3) with forty-six items (63.9%) reaching 
80% agreement or more for both relevance and importance. The S-CVI/Ave for 
relevance and importance were 0.7 and 0.76 respectively, indicating moderate 
consensus for the overall conceptual framework. The I-CVI and clarity data for all 
items under the framework were presented in Table 3. 
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Table 3: I-CVIs of all items under the conceptual framework 
Domain Item I-CVIs Clarity Level of 
agreement R I
At the initiation phase 
1. Health care
professionals
1. Following the diagnosis of a
consumer with depression, GPs
can influence whether
consumers commence therapy
with antidepressant medicines.
1 1 Y High 
2. Following the diagnosis of a
consumer with depression,
psychiatrists can influence
whether consumers commence
therapy with antidepressant
medicines.
1 1 Y High 
3. Following the diagnosis of a
consumer with depression,
community pharmacists can
influence whether consumers
commence therapy with
antidepressant medicines.
0.8 0.8 Y High 
4. Good relationships between
GPs and consumers can
influence whether consumers
commence therapy with
antidepressant medicines.
0.9 1 Y High 
5. Good relationships between
psychiatrists and consumers can
influence whether consumers
commence therapy with
antidepressant medicines.
0.8 0.9 Y High 
6. Good relationships between
community pharmacists and
consumers can influence
whether consumers commence
therapy with antidepressant
medicines.
0.9 0.9 Y High 
7. Good support from the GP is
critical to whether a consumer
with depression commences
therapy with an antidepressant
medicine.
0.8 0.8 Y High 
8. Good support from a
psychiatrist is critical to
whether a consumer with
depression commences therapy
with an antidepressant
medicine.
0.7 0.8 Y Moderate 
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Domain Item I-CVIs Clarity Level of 
agreement R I
9. Good support from the
community pharmacist is
critical to whether a consumer
with depression commences
therapy with an antidepressant
medicine.
0.9 0.9 Y High 
10. Any perceived stigma
displayed by healthcare
professionals toward
depression can inhibit a
consumer from commencing an
antidepressant medicine.
1 1 Y High 
11. GPs beliefs about the
efficacy of antidepressant
medicines influences whether a
consumer commences therapy
with an antidepressant
medicine.
0.8 0.8 Y High 
12. Psychiatrist beliefs about
the efficacy of antidepressant
medicines influences whether a
consumer commences therapy
with an antidepressant
medicine.
0.8 0.8 Y High 
13. Community pharmacist
beliefs about the efficacy of
antidepressant medicines
influences whether a consumer
commences therapy with an
antidepressant medicine.
0.7 0.5 Y Low 
2. Consumers 1. Self-motivation of a
consumer is a factor in whether
they commence therapy with
an antidepressant medicine.
0.9 0.9 Y High 
2. Consumers who acknowledge
their depressive condition, tend
to commence therapy when
prescribed an antidepressant
medicine.
0.5 0.5 Y Low 
3. Consumers who are involved
in the treatment decision-
making process are more likely
to commence therapy with an
antidepressant medicine.
0.9 0.9 Y High 
4. Consumers who have
previous unfavourable
experiences with
0.9 0.9 Y High 
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Domain Item I-CVIs Clarity Level of 
agreement R I 
antidepressant treatment are 
less likely to commence therapy 
with antidepressant medicines. 
5. Consumers who have 
previous unfavourable 
experiences with 
antidepressant treatment are 
less likely to commence therapy 
with antidepressant medicines.  
0.6 0.6 Y Low 
6. Stigma about depression can 
be a barrier to a consumer to 
commence antidepressant 
therapy.  
1 1 Y High 
7. Consumer beliefs about the 
efficacy of antidepressant 
medicines influences whether 
they commence therapy with 
an antidepressant medicine.  
1 1 Y High 
8. Concern about possible 
adverse drug reactions can 
influence whether a consumer 
commences therapy with an 
antidepressant medicine. 
1 1 Y High 
9. Consumers with higher levels 
of education are more willing to 
commence antidepressant 
therapy.  
0.2 0.2 Y Low 
3. Health care 
system 
1. The accessibility of the health 
care providers affects when a 
consumer commences therapy 
with an antidepressant 
medicine. 
0.8 0.8 Y Accept 
2. Private health insurance 
influences whether a consumer 
commences therapy with an 
antidepressant medicine. 
0.4 0.4 Y Low 
4. Family, 
society, and 
economy  
1. Consumers who live with a 
partner are more likely to 
commence antidepressant 
therapy.  
0.3 0.3 Y Low 
2. The cost of antidepressant 
medicines influences whether a 
consumer commences taking 
antidepressant therapy. 
0.8 0.7 Y Moderate 
3. The cost of health care 
influences when a consumer 
0.5 0.6 Y Low 
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Domain Item I-CVIs Clarity Level of 
agreement R I 
commences therapy with an 
antidepressant medicine. 
 4.  Consumers who have family 
support are more likely to 
commence antidepressant. 
0.5 0.5 Y Low 
 5. Consumer who have peer 
support are more likely to 
commence antidepressant 
therapy. 
0.7 0.5 Y Low 
 6. Any perceived stigma 
displayed by a family member 
or carer toward mental health 
can be a barrier to a consumer 
commencing antidepressant 
therapy. 
0.9 0.9 Y High 
 7. Stigma in society can be a 
barrier to a consumer 
commencing antidepressant 
therapy. 
0.9 0.8 Y High 
 8. Mental health advocacy 
organizations such as 
BeyondBlue influence whether 
a consumer commences 
therapy with an antidepressant 
medicine.  
0.6 0.5 Y Low 
5. Depression 1. Consumers who have more 
severe depressive symptoms 
are more willing to 
commence antidepressant 
medicines. 
0.4 0.5 Y Low 
At the implementation phase 
1. Health care 
professionals 
1. Following the diagnosis of a 
consumer with depression, GPs 
can influence whether 
consumers continue to take 
antidepressant medicines. 
0.9 0.9 Y High 
2. Following the diagnosis of a 
consumer with depression, 
psychiatrists can influence 
whether consumers continue to 
take antidepressant medicines. 
0.9 0.9 Y High 
3. Following the diagnosis of a 
consumer with depression, 
community pharmacists can 
influence whether consumers 
continue to take antidepressant 
medicines. 
0.9 0.9 Y High 
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Domain Item I-CVIs Clarity Level of 
agreement R I 
4. Experienced GPs can 
influence whether consumers 
continue to take antidepressant 
medicines. 
0.8 0.6 Y Low 
5. Experienced psychiatrists can 
influence whether consumers 
continue to take antidepressant 
medicines. 
0.8 0.6 Y Low 
6. Experienced community 
pharmacists can influence 
whether consumers continue to 
take antidepressant medicines. 
0.9 0.7 Y Moderate 
7. Good relationships between 
GPs and consumers can 
influence whether consumers 
continue to take antidepressant 
medicines. 
1 1 Y High 
8. Good relationships between 
psychiatrists and consumers can 
influence whether 
consumers continue to take 
antidepressant medicines.  
1 1 Y High 
9. Good relationships between 
community pharmacists and 
consumers can influence 
whether consumers continue to 
take antidepressant medicines. 
1 1 Y High 
10. Collaboration between GPs, 
psychiatrists, and pharmacists 
in a mental healthcare team can 
influence whether consumers 
continue to take antidepressant 
medicines. 
1 0.9 Y High 
11. Interactive communication 
and open dialogue between 
healthcare professionals and 
consumers can influence 
whether consumers continue to 
take antidepressant medicines. 
1 1 Y High 
12. Lack of adequate 
information about depressive 
treatment from healthcare 
professional can inhibit a 
consumer from continuing to 
take antidepressant medicines. 
1 0.9 Y High 
13. Stigma about depression 
from healthcare providers 
0.9 0.8 Y High 
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Domain Item I-CVIs Clarity Level of 
agreement R I 
can inhibit a consumer from 
continuing to take 
antidepressant medicines. 
      
2. Consumers  1. Consumers who believe in 
antidepressants are more likely 
to continue to take 
antidepressant medicines. 
0.9 0.9 Y High 
2. Consumers who are more 
able to self-manage are more 
likely to continue to take 
antidepressant medicines.  
0.7 0.6 Y Moderate 
3. Consumers who are involved 
in the treatment decision-
making process are more likely 
to continue to take 
antidepressant medicines.  
0.9 0.8 Y High 
4. Consumers who have 
previous unfavourable 
experiences with 
antidepressant treatment are 
more unlikely to continue to 
take antidepressant medicines. 
0.9 0.9 Y High 
5. Consumers who are 
concerned about the effect of 
stopping antidepressant 
therapy are more likely 
continue to take antidepressant 
medicines.  
0.9 0.9 Y High 
6. Consumers who feel better 
after taking antidepressants 
tend to continue to take 
antidepressant medicines. 
0.6 0.5 Y Low 
7. Consumers who have trust in 
their healthcare professional 
are more likely to continue to 
take antidepressant medicines.  
1 0.9 Y High 
8. Consumers who have 
knowledge about depression 
and antidepressant therapy are 
more likely to continue to take 
antidepressant medicines. 
0.7 0.7 Y Moderate  
9. Forgetfulness can inhibit a 
consumer from continuing 
therapy with an antidepressant 
medicine. 
0.9 0.9 Y High  
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Domain Item I-CVIs Clarity Level of 
agreement R I 
10. Consumers with higher 
levels of education are more 
willing to continue to take 
antidepressant medicine. 
0.9 0.9 Y High  
11. Consumers who have 
positive experiences from 
antidepressant therapy are 
more likely to continue to take 
antidepressant medicine.  
1 1 Y High  
12. Consumers who have few 
adverse drug reactions from 
antidepressant medicines are 
more likely to continue to take 
them. 
0.9 0.9 Y High  
 13. Ineffectiveness of 
antidepressant treatment can 
inhibit a consumer from 
continuing therapy with an 
antidepressant medicine.  
1 1 Y High  
3. Health care 
system 
1. Consumers who have private 
health insurance are more likely 
to continue to take 
antidepressant medicines.  
0.3 0.2 Y Low 
2. The accessibility of the health 
care services effects whether a 
consumer continues to take 
antidepressant medicines. 
0.8 0.9 Y High  
3. The accessibility of 
antidepressant medicines 
effects whether a consumer 
continues to take 
antidepressant medicines. 
0.9 0.9 Y High  
4. Lack of continuity of care in 
the public system can inhibit a 
consumer from 
continuing therapy with 
antidepressant medicines. 
0.9 0.8 Y High  
4. Family, 
society, and 
economy 
1. Consumers who live with a 
partner are more likely to 
continue to take antidepressant 
medicines.   
0.4 0.3 Y Low 
2. Consumers who can afford 
antidepressants are more likely 
to continue antidepressant 
medicines. 
0.9 0.8 Y High  
3. Societal stigma about 
depression can inhibit a 
0.8 0.7 Y Moderate  
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Domain Item I-CVIs Clarity Level of 
agreement R I 
consumer from continuing 
therapy with an antidepressant 
medicine.  
 4. Lack of support from family 
can inhibit a consumer from 
continuing therapy with an 
antidepressant medicine. 
0.9 0.9 Y High  
 5. Stigma about depression by 
family members can inhibit a 
consumer from continuing 
therapy with an antidepressant 
medicine.  
0.9 0.8 Y High  
 6. Mental health organizations 
such as BeyondBlue influence 
whether consumers continue to 
take antidepressant medicine.  
0.6 0.5 Y Low 
5. Depression  1. Consumers who have more 
severe depressive symptoms 
are more likely to continue to 
take antidepressant medicines. 
0.6 0.5 Y Low 
2. Depressive symptoms can 
inhibit a consumer from 
continuing therapy with an 
antidepressant medicine. 
0.8 0.9 Y High 
3. Long term treatment of 
depression can inhibit a 
consumer from continuing 
therapy with an antidepressant 
medicine.  
0.6 0.6 Y Low 
R= Relevance, I= Importance, Y = Yes, N = No 
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Framework sub-component at the initiation phase   
At initiation, the majority of items related to HCPs were rated with high agreement 
such as items pertaining to ‘good support from HCPs’ and ‘good relationship between 
HCPs and consumer with unipolar depression’. This means that the agreed that these 
factors serve as facilitators of adherence to antidepressant medicines. A few items 
related to the psychiatrist and pharmacist were rated as moderate and low 
agreement. This could be explained by the fact that many consumers do not receive 
specialist psychiatrist management for their depression; also, pharmacists do not 
always have access to the full health picture (e.g. diagnosis and treatment history). 
In light of consumer-related factors, consumer self-motivation to receive treatment, 
being involved in the decision making process about treatment, and personal belief 
about the efficacy of antidepressant medicines were rated with high agreement as 
facilitators of adherence at the initiation phase. Stigma issues and unfavourable 
experience of antidepressant use were rated as relevant and import barriers. 
Whereas, having more severe symptoms, family and peer support, adequate 
information about depression and antidepressant medicine, higher level of 
education, and people who acknowledge their depressive condition received low 
agreement, as those factors are not routinely related to adherence to antidepressant 
medicines, although they could be for some people. 
At this phase, the majority of factors relating to family, society, and personal financial 
consideration were rated low with a low level of agreement for both relevance and 
importance. Cost of antidepressant medicines was rated as relevant but not an 
important factor. Similarly, mental health organisation and private health insurance 
factors also received low agreement scores, although they could be for some people. 
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Framework sub-component at the implementation phase   
When compared to the initiation phase, a similar pattern of ratings was obtained for 
both facilitators of and barriers to medication adherence. For HCPs-related factors, 
collaboration between HCPs in a mental health care team, and interactive 
communication between HCPs and consumers were rated with a high level of 
agreement for both relevance and importance. Consumer-related factors including 
belief in antidepressant medicine, concern about the effect of stopping 
antidepressant medicine, trust in their HCPs, ability to support antidepressant 
medicine, positive experiencing antidepressant medicine, and fewer ADRs were also 
rated as facilitators of adherence. Whereas, lack of adequate information about 
depressive treatment from HCPs, forgetfulness, lack of continuity of care in health 
system, ineffective antidepressant medicine, and depressive symptoms were rated 
as additional barriers of medication adherence at the implementation phase. 
Experienced HCPs were rated relevant but not import for assisting medication 
adherence. In line with the initiation phase, the role of mental health organisations 
was also rated low with low agreement for the implementation phase. This is because 
the influence of advocacy organisations was predominantly aimed at the population 
or community level rather than a direct provider role Private health insurance was 
noted as relevant to National health plans.  
The expert panel also provided additional written comments. These covered co-
decision making between HCPs and patients as being dependent on personality; and 
some people not wanting to take responsibility of shared decision making with their 
HCPs. 
The expert panel highlighted the need for trust and a good relationship between HCPs 
and people with unipolar depression. GPs were especially important for both 
initiation and implementation phases of medication taking. Consistent and on-going 
communication of messages was also noted as an important facilitator of medication 
adherence at all phases. 
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Other comments from expert panel members pertained to health beliefs regarding 
medicines (such as benefits and harms) and cultural beliefs (such as the experiences 
and perceptions of friends and family members toward antidepressant medicines). 
Discussion  
This framework developed and content validated in this research adopted the ABC 
taxonomy. It aimed to comprehensively evaluate potential factors influencing 
medication adherence at the specific phases of medication taking by consumers with 
unipolar depression. This framework may be used to guide HCPs to identify know 
facilitators of and barriers to medication adherence at the different stages of 
medication adherence. In turn this may inform the implementation of targeted 
individualised strategies to facilitate medication adherence. 
For both phases, the results indicate that most of items related to HCPs and HCS were 
rated with high agreement (I-CVIs >0.8) except for an item which related to private 
health insurance. In contrast, the majority of factors related to family, society, and 
personal financial consideration were rated lower for both phases (I-CVIs range 0.3-
0.7). This suggests that expert panel members valued professional/clinical issues 
more highly than other issues (e.g. family, society) which were beyond their own 
direct scope of influence. This results also points to the need to conduct a content 
validation process with non-health care professionals to further explore this issue. 
This point is important as the majority of items were generated directly from 
consumer perspectives. This misalignment between consumer perspectives and the 
assessment provided by the expert panel members points to a significant challenge 
in the delivery of a patient-centred, shared decision making approach to health care 
for people with unipolar depression. 
With regard to the clarity of the items, the majority were assessed as clear, with >80% 
agreement. Notwithstanding this, some expert panel members commented on the 
ambiguity of adjectival descriptors such as ‘critical’, ‘tend to’, ‘experienced GPs’, and 
‘accessibility’. However, most of these terms were not keywords for the individual 
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items concerned, thus the essence of the item would remain, even if these terms 
were removed. Additionally, some statements may not be mutually exclusive, for 
example, ‘supportive’, ‘role’ and ‘relationship’. Nonetheless, those terms express 
different meanings as ‘supportive’ was used in a non-specific way whereas ‘role’ and 
‘relationship’ were used to refer to interactions between HCPs and patients. Overall, 
the researchers therefore believe that the framework items yielded adequate clarity 
and validity. 
It should be noted that some factors such as feeling better and severity of depression, 
have the ability to be either positive or negative influencer for individuals. Hence 
there was variability in the assessments made by expert panel members for these 
items as they can be both facilitators of and barriers to adherence. Furthermore, 
some factors were individualised such as ‘support from peers, family members, and 
a partner’ where the outcomes may either facilitate or hinder adherence. This 
explained why the Hence, the CVI scores for these items were relatively low, but 
points to a rationale for keeping them in the item bank, given the aim of producing a 
comprehensive framework for aiding medication adherence. In our study, a few items 
received low agreement among the panel which was in contrast to other studies e.g. 
more severe depression and cost of antidepressant medicines.13, 58-63 This may be due 
to their own perspective which may need further clarity.61 
Our framework has some similarities with other frameworks developed to aid 
adherence in other conditions such as diabetes Jaam (2017). However it is broader in 
the sense that it includes both facilitators of as well as barriers to adherence across 
the different phases of medication taking. 29 
Strength limitations and future directions 
In light of the validation process, both of the size and scope of expertise of the panel 
members were important for the assessment of content validity. Lynn (1986) 
recommends a minimum of three panel members for content validation45, 47 with ten 
participating in this study, increasing the credibility of the content validation 
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process.54, 64 However, the inclusion of non-expert consumer panel is recommended 
to provide greater balance to framework validation. 
The framework was created based on everyday practice in which the dispensing 
function is separated from physician function. Therefore, the implementation of the 
framework may be limited to other types of the health care system. 
This framework did not provide influencing factors at the discontinuation phase. This 
is because medication adherence is a continuous process. The discontinuation phase 
is defined as the point when the last dose of medicine was taken; therefore, the 
barriers at this stage were similar to those factors that prevent the consumer to cease 
their medicine. In other words, the barriers at the discontinuation phase were similar 
to influencing factors at the implementation phase. 
Conclusion 
Factors identified under the ABC taxonomy indicated the complexity of adherence 
process in consumers with unipolar depression. This framework emphasised that 
greater attention should be provided at particular phases to increase adherence to 
antidepressant medicines along treatment process. This framework can be used as a 
guide to develop more efficient strategy to improve medication adherence based on 
consumer-specific intervention. Future study should consider to integrate other 
perspectives such as the payer and nonprofessional panels in order to complete the 
framework form multiple views. 
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CHAPTER SEVEN: Discussion 
The research included in this thesis aimed to explore and examine issues pertaining 
to medication adherence in people living with unipolar depression with a particular 
focus on factors influencing adherence at specified phases from the consumer 
perspective: initiation, implementation, and discontinuation of therapy. Specifically, 
this thesis focused on obtaining a greater understanding of medication-taking 
behaviour in people with unipolar depression. This research developed a conceptual 
framework of medication adherence and identified facilitators of and barriers to 
adherence at each of the phases of medication-taking. The research included in this 
thesis involved a comprehensive identification and evaluation of these factors, with 
the proposed framework intended as a guide for health care professionals when 
individualising strategies to facilitate medication adherence in people with unipolar 
depression.  
In this chapter, the research findings are discussed in five main sections: [1] 
implementation of the proposed framework, [2] framework development and 
framework components, [3] face and content validity of the framework, [4] selection 
of valid measurement(s) at specific phases of medication adherence, and [5] strength 
and limitation of the research presented in this thesis  
7.1 Implementation of the proposed framework 
Medication-taking is a complex behaviour and can change over time. Hence, an 
understanding of the factors that influence adherence to antidepressant medicines 
is likely to be multifaceted and different for individual patients and at different times. 
For these reasons, a framework which identifies different strategies to facilitate 
medication adherence to antidepressant medicines at different stages of medication-
taking for individuals is important. It is unlikely that a single intervention will work for 
all consumers. Moreover, tailored interventions are likely to provide the best solution 
for individuals in whom medication adherence is a sub-optimal. Therefore, to develop 
a framework for medication adherence in consumers with depression, an in-depth 
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understanding of the adherence process and possible factors influencing medication-
taking behaviour from the consumer’s viewpoint is required. This framework was 
developed for the purpose of guiding health care professionals in facilitating 
adherence to antidepressant medicines in clinical practice, particularly in primary 
care where the majority of patients with depression are managed. 
It is noteworthy that several conceptual frameworks have been created to improve 
medication adherence and help understand the barriers to medication adherence.47, 
94, 95, 108, 109, 117, 160 Related conceptual frameworks in the area of medication 
adherence have been specifically designed for other conditions which require long-
term treatment, such as hypertension, AIDS, diabetes, and chronic heart failure; 
however, this has not been done for depression.94, 95, 108, 109 Croghan et al. (2006)98 
developed a framework for the management of depression in primary care, but not 
with a specific focus on medication adherence. Building on this research, our 
conceptual framework was developed as an important part of depression treatment 
in primary care, with particular focus on medication adherence. Specifically, our 
framework identifies potential factors influencing medication adherence at specific 
phases of medication-taking, from the initiation to the implementation and 
discontinuation phases of adherence. In addition, the systematic review presented in 
Chapter Three identified specific measures of adherence for specific phases 
(initiation, implementation, and discontinuation) in order to evaluate the capability 
of the framework in optimising medication adherence. The selection of appropriate 
measures of medication adherence with good reliability and validity is critical if 
tailored strategies designed to facilitate adherence are implemented. Hence, the 
conceptual framework can be used as a guide to inform health care professionals to 
carefully monitor their patients and effectively tailor interventions for them. In 
addition, it is possible to integrate the framework with existing frameworks, such as 
the conceptual model developed by Croghan et al, in order to provide more 
individualized care for the management of depression. 
154
The framework developed and presented in this thesis is the first conceptual 
framework that has been created specifically to understand the medication 
adherence process in people with unipolar depression, with a particular focus on 
consumer-related factors. As the major outcome of this doctoral research, the 
holistic framework of medication adherence was created to elucidate the entire 
process of adherence and potential factors influencing medication-taking behaviour 
at the different phases of adherence. The framework includes factors related to 
health care professionals; consumer-related factors; factors related to the health 
care system; family-, society-, and economy-related factors; and depression-related 
factors.  
Our conceptual framework is similar to the one proposed by Jaam et al. (2017), which 
represented the complex network of factors associated with medication adherence 
in consumers with diabetes mellitus.94 Specifically, both frameworks investigate a 
broad range of domains which might influence medication adherence. Although the 
barriers to and facilitators of medication adherence were stated in the same manner, 
a distinction between the frameworks is that we integrated the ABC taxonomy in our 
proposed framework. Hence, the factors influencing adherence were specifically 
mapped to particular phases of medication adherence. That is, comprehensive 
information pertaining to potential factors influencing medication adherence are 
included, from the first dose of antidepressant medicine to the last dose taken. 
Various conceptual and theoretical behavioural models have also been used to 
support and facilitate medication adherence in consumers with unipolar depression. 
These include the Health Belief Model (HBM), theory of planned behaviour, the 
transtheoretical model of behaviour change, self-regulatory model, etc.47, 109, 116-118 
However, none of the existing conceptual frameworks or behavioural models are 
specifically focused on depression. There are many unique characteristics of 
depression and specific characteristics of antidepressant medicines which warrant 
the development of a specific framework for depression. These include the 
pharmacological properties of antidepressant medicines such as unbearable ADRs 
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and delayed onset of action. In addition, the inherent characteristics of unipolar 
depression, such as loss of interest in activities, cognitive dysfunction and 
forgetfulness, as well as the severity of depression are also closely connected to non-
adherence to antidepressant medicine.17, 23, 64, 173 Therefore, it is important to 
establish a clear and comprehensive conceptual framework that captures potential 
factors which may impact medication adherence to antidepressant medicines. This 
framework, based on a better understanding of consumer views on adherence to 
antidepressant medicines, may aid the implementation of strategies to optimise 
medication adherence and treatment outcomes. 
The COM-B framework is a comprehensive framework which is intended to explain 
individual health-related behaviour based on three domains: capability, opportunity, 
and motivation.116 This framework is generally applied in health science pertaining to 
behavioural issues including medication adherence.116 However, it is difficult to map 
depression to the COM-B framework or the COM-B framework to depression because 
the effects of depression towards medication adherence can be explained by a 
number of different factors. Therefore, the COM-B framework may not be ideal for 
medication adherence in people with depression.116 This issue emphasises the 
complexity of depression itself. This finding also indicates the need for a specific 
framework for medication adherence in unipolar depression.  
Another well-known framework, the Necessity-Concerns Framework (NCF) 
postulates that adherence is influenced by implicit judgements of personal need for 
the treatment. This framework is closely related to personal belief (necessity beliefs) 
and concerns about the potential adverse consequences of taking it.125 The NCF has 
been proven as a useful model for understanding patients’ evaluation of prescribed 
medicines; therefore, it has been commonly used to explain non-adherence to 
prescribed medicines in patients with long-term conditions like depression.110, 124, 125 
However, the implementation of this framework is limited to the particular issue 
relevant to beliefs and concerns, as it does not intend to explain other aspects of 
adherence. 
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In terms of the implementation of the (our) conceptual framework to other chronic 
conditions, this framework can be used as a prototype for developing an adherence 
model in other chronic conditions. In practice, our framework is suitable for 
application in depression with comorbidities, as many factors also influence 
medication adherence in other chronic diseases. However, the application of the 
framework in this case should be done carefully. 
7.2 Framework development and framework components 
Mainstream approaches which support the role of patients to manage their health 
issues, such as patient-centred care, are being increasingly encouraged in practice.174, 
175 As is evident, the patient-centred approach (including shared-decision making, 
physician-patient communication, etc.) has contributed to significantly improved 
clinical outcomes in chronic conditions.174-177 In addition, it also can enhance 
adherence to antidepressant medicines in people with unipolar depression.178-182  
Our conceptual framework focuses on consumer behaviour with patient autonomy 
as the core principle.98, 99, 101, 116 We acknowledge that the consumers have the choice 
to decide whether or not to take the medicines prescribed for them. Medication 
adherence may be influenced by a range of different patient-specific factors including 
the individual’s perception of depression and towards antidepressant medicines 
themselves. It may also be influenced by the consumer relationship with their health 
care professionals, particularly when a co-decision is made about treatment options, 
and self-management practice with respect to medication-taking. This principle is in 
accordance with the global shift in the direction of health care from focusing on 
health care professionals (with the particular focus on disease) to patient and family 
or patient-centred care.183 The concept of patient-centeredness refers to the care 
that is respectful of and responsive to individual patient preferences, needs, and 
values. Moreover, patient values should guide all clinical decisions. In essence, this 
concept highlights the importance of clinicians and patients working together to 
produce the best outcomes possible.183 Similarly, this is evident from the shift of 
compliance terminology (focus on health care professionals, with patients somewhat 
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subservient to prescribers) to adherence terminology (the cooperation between 
prescriber and patient) which constructively aligns with the concept of patient-
centred care and shared decision making.2, 177, 179, 184-186 In essence, the active 
involvement by the patients in treatment decision-making is increasingly 
implemented in everyday practice and is an important strategy for enhancing 
treatment engagement and achieving successful treatment in long-term 
conditions.179, 180 Further, the implementation of shared-decision making to improve 
medication adherence and depression outcomes in people with unipolar depression 
has been shown to be successful.187, 188 However, we also acknowledge other 
important factors which may impact medication adherence, including the patients 
themselves, health care professionals, the health care system, family, and society. 
With regard to framework development, the proposed conceptual framework was 
rigorously developed based on the integration of existing information from multiple 
sources. A process of triangulation was applied at this stage to ensure the 
comprehensiveness of the framework. Further, facilitators of and barriers to 
medication adherence at each phase were extensively generated from various 
sources, including a review of the literature, in-depth qualitative interviews, and the 
experience of our research team. A schema depicting the framework development is 
presented in Figure 4. 
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Figure 4 The triangulation of multiple sources to develop the framework of 
adherence to antidepressant medicine.  
 
 
 
 
The framework has been developed as a pragmatic approach to medication-taking 
behaviour. It is known that many health care systems are fragmented and that this 
fragmentation can affect medication adherence. For example, the separation and 
lack of coordination between doctor and pharmacist may lead to specific and 
nuanced advice on treatment, which may appear to be conflicting from the 
consumer’s perspective. That is, there may be inconsistency or conflict in the 
information conveyed to consumers. Furthermore, pharmacists do not always have 
timely access to relevant treatment history and diagnostic data, which may 
contribute to providing incomplete key information to consumers. Ideally, the 
adoption of an interprofessional approach to patient care combined with a patient-
centred approach is preferred in order to improve patient outcomes, including 
adherence to medicines.178, 187-189 
Another key aspect which directly impacts medication adherence is the relationship 
between consumers and health care professionals at each stage of the treatment 
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process.178, 186, 190, 191 This includes the relationship between the GPs and consumers 
at the beginning of the process, which impacts primary non-adherence. Primary non-
adherence refers to consumers who fail to have a new prescription dispensed within 
a defined number of days (commonly 30 or 60 days) after the medicine was 
ordered.192  
The relationship between the pharmacist and consumer, commences when the 
prescription is dispensed for the first time or refilled, which impacts secondary non-
adherence. Secondary non-adherence refers to consumers who do not begin taking 
their medicines as intended after they have had their prescriptions dispensed; this 
behaviour can range from not following the frequency or dose instructions of the 
prescription (e.g. skipping doses, taking medicines at incorrect times or in incorrect 
doses, taking more than prescribed), forgetfulness, errors of purpose, or use of 
inadvertent combinations.3, 8, 46-49 The framework has the capability of elucidating the 
entire process of medication adherence in consumers with unipolar depression. In 
addition, facilitators of and barriers to adherence at specific phases were also 
illustrated. Because our framework focuses on the stage of adherence to medicines, 
all interactions between the consumers and health care professionals, health care 
system, and society were therefore delineated in the framework subcomponents. 
These considerations highlighted the endeavour to create a practical framework 
which elaborates on potential factors influencing medication adherence from the 
consumer’s perspective. Consequently, a better understanding of the medication 
taking process can be achieved, which is an important step to establish effective 
strategies to promote medication adherence in consumers with depression. 
Although there have been previous studies which have explored factors influencing 
medication adherence in unipolar depression, they have generally not focused on the 
ongoing nature of medication adherence, that is, the factors which may influence 
medication adherence may change over time for individuals.80, 193-195 For example, 
during the early phase of treatment, early medication adherence may be enhanced 
by the provision of educational information concerning the nature of depression, 
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medicines used, and possible ADRs. Whereas, facilitators of adherence at six months 
of the treatment were more related to the previously used antidepressants and the 
consequence of using antidepressant medicines.196 This point is crucial as it 
acknowledges the dynamic nature of medication adherence in unipolar depression. 
It is also noteworthy that none of the existing studies have conducted a detailed 
evaluation of factors mapped to the different phases of adherence identified by the 
ABC framework. Nor have most studies provided clear information pertaining to the 
adherence phase in their studies. Another point concerns the diverse results when 
one factor influences medication adherence in individuals in different ways due to 
their personal experiences and different perspectives. For example, stopping a 
medicine may be commonly interpreted as negative factor. On the other hand, the 
cessation of medicine due to unbearable ADRs should not be interpreted as negative 
factor. In this study, stopping a medicine was perceived as a negative factor because 
we were interested in the consumers’ decision to cease antidepressant medicines 
without informing their doctor. For this reason, the interpretation and clarification of 
influencing factors should be undertaken carefully. Therefore, we conducted in-
depth semi-structured interviews to identify factors influencing medication 
adherence at each phase of medication-taking.  
When comparing the development process of our framework with other frameworks 
in medication adherence, most of the existent frameworks have been developed on 
the basis of review of the literature.8, 94, 95, 98 Furthermore, a number of them did not 
provide detailed information about the development process;8, 95, 98 therefore, it is 
difficult to evaluate the initial step between the frameworks.  
7.3 Face and content validity of the framework  
Validation of the framework is an important process which establishes scientific 
evidence that the proposed framework is capable of consistently delivering credible 
results. For the validation process, content validation using an expert panel was 
adopted because it is a well-accepted and widely used technique to evaluate content 
validity when new tool is established. In accordance with the purpose of the 
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framework, health care professionals were the target group which may directly apply 
the framework in practice. Therefore, they were selected as panellists to evaluate 
face and content validity of the framework.172 An internet-based survey was selected 
to disseminate the survey link to ease storage and management of data, including 
data from international panel members.197-199  
It was noted that expert panel members tended to prioritise their own professional 
views as health care professionals rather than focusing on patient-related factors. 
These findings point to the need to include a non-professional panel members (such 
as consumers and caregivers) in future studies to further support a patient-centred 
approach.172 Inclusion of non-health care professional panel members may help 
refine the framework further resulting in improved CVI score (the overall instrument 
CVI or CVI/Ave). This is likely because the initial items (influencing factors at specific 
phases of adherence) were generated from multiple resources, but mainly extracted 
from consumer views. In addition, evaluations from non-health care professional 
panel members may enhance the reliability of the framework. Notwithstanding the 
composition of expert panel members in this study, the findings confirm that the 
proposed framework had acceptable content validity for the relevance and 
importance of the influencing factors (S-CVI/Ave for relevance and importance were 
0.79 and 0.76, respectively). 
With regard to framework subcomponents, some items were inconsistently rated by 
panel members when compared to the findings of our qualitative study and review 
of the literature. This may be because panel members based their responses on their 
expertise. Secondly, there may be differences due to the potential for interactions 
between influencing factors, which may impact consumers and health care 
professionals differently in different circumstances.  
When comparing the validation process with existing frameworks in the area of 
medication adherence, the overall process of framework development and 
framework validation in the research included in this thesis is similar to the 
framework created by Jaam et al. (2006).94 The validation process was a little 
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different in that Jaam et al applied the Delphi technique to finalise their model.94 
However most existent studies did not provide details pertaining to the validation of 
the framework, nor did they validate their framework.94, 95, 108 Although one 
adherence model in hypertension verified feedback from patients as a part of model 
creation, the sample size was small and limited to the specific group of patients.109 
Therefore, it is difficult to present a detailed discussion about the validation process 
for existing adherence frameworks.  
7.4 Selection of valid measurement at specific phases of medication 
adherence 
The framework of adherence to antidepressant medicines was created with the 
particular focus of understanding adherence at each of the phases of medication 
taking behaviour. This was coupled with an understanding of the selection of a 
credible assessment of adherence to medicines for each of these phases, which is 
essential for both treatment evaluation and follow-up care. Critically this framework 
acknowledges that medication adherence is a dynamic process for individuals. 
Further, in clinical settings, there is a lack of a gold standard of an adherence 
measure. This indicates the need to identify valid and reliable measurement to 
evaluate medication adherence in chronic conditions.  
The selection of valid tool(s) at a specific phase of adherence is important. This will 
aid clinicians to yield an accurate evaluation measure which is crucial for treatment 
evaluation and modification of the treatment plan. Hence we conducted a systematic 
review to identify appropriate measures of medication adherence for the different 
phases of adherence. The following two main aspects will be discussed in accordance 
with the identification and evaluation of the measures: 1) identification of the 
measure at a particular phase of adherence, and 2) the evaluation of the 
psychometric properties of each measure.  
First, it was crucial to identify the measures that have been used to assess medication 
adherence at specific phases of adherence in accordance with the ABC taxonomy. At 
163
this stage, no measure had been used to assess medication adherence at the 
initiation phase, as most studies focused on antidepressant consumption at the 
implementation and discontinuation phases. Similarly, all the psychometric tests 
have been done and reported at the implementation phase.  
Because of the lack of a gold standard to assess medication adherence, multiple tools 
are suggested to assess medication adherence. In the initiation phase, it seems 
impractical to directly investigate the consumption of the first dose of the prescribed 
medicine. One possible solution, however, is that physicians and other health care 
professionals could ask their patients whether or not they have taken the first dose 
of medicine as well as explain to them any side-effects, if any, for the medicine 
prescribed. In the implementation phase, multiple tools are recommended. The most 
practical strategy is to use a standardised self-report tool, for example, the four-item 
Morisky, Green, and Levine Self-reported Medication-taking Scale (MGLS)77 or the 
Antidepressant Adherence Scale in conjunction with pharmacy records (or 
prescription claims data),34, 201 as they can capture both short and long-term 
adherence with acceptable reliability and validity (page xx, Table 3, Chapter 3). In 
addition, some of the standardised self-report measures such as the MGLS are able 
to capture both the implementation and discontinuation phases, where the patients 
intend to cease taking their medicines.202 The Beliefs about Medicines Questionnaire 
(BMQ by Horne)76 is another useful self-report measure at the implementation 
phase. It provides acceptable reliability and validity (page xx, Table 3, chapter 3) 
which considers an individual’s beliefs, which in turn may prove useful in 
understanding the rationale underlying one’s decision pertaining to medication 
adherence behaviour. 
For the evaluation of the psychometric properties of each measure at the particular 
phases of adherence, we found that missing information and unclear data obtained 
from the existing studies contributed to difficulty in interpretation the psychometric 
properties of instruments. For example, unclear methods and ambiguous terms that 
have been used for the evaluation of measures (e.g. agreement, correlation, and 
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concordance between measures). In addition, the Kappa statistic, an important 
reliability test was commonly reported. However, specific types of Kappa statistics 
were often unspecified. Although a rigid procedure pertaining to the identification of 
the adherence phase has been determined by researchers, many studies did not 
detail information about the phase of adherence being evaluated. In other words, 
adherence processes were not conceptualized in the same manner, using the ABC 
framework.2 That is, relevant information pertaining to the timeline when adherence 
was evaluated was limited. In this respect, we acknowledge that the original studies 
reviewed had a different purpose to our systematic review. This explains the limited 
and somewhat fragmented information presented in discussion part of Chapter 3 and 
table 1A (page xx, chapter 3). 
With regard to the use of standardised patient self-report adherence measures, the 
interchangeable and inconsistent use of the terminology may also have contributed 
to challenges in extracting data about the medication adherence measures. In this 
respect, three main aspects will be discussed here: the similarity of abbreviated 
names of the tools, several names used for the same tool/s, and the inclusion of 
similar items among different tools.  
First, two “BMQ” patient self-reports were identified. One was the BMQ, created by 
Horne et al (1999).76 This tool comprises two sections: the BMQ-specific which 
assesses representations of medicine prescribed for personal use and the BMQ-
general which assesses beliefs about medicines in general.136 Further, another BMQ, 
the Brief Medication Questionnaire was created by Svastad et al. (1999).203 This is a 
patient self-report tool for screening adherence and barriers to adherence. It includes 
a five-item regimen screen that asks patients how they took each medicine in the 
past week, a two-item belief screen that asks about drug effects and bothersome 
features, and a two-item recall screen about potential difficulties remembering. 
Therefore, it is important that the full name of the tool is clearly defined when it is 
employed.  
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Secondly, one tool can be called by different names. For example, the MGLS was also 
called the Medication Adherence Questionnaire (MAQ) and Self-reported Medication 
Taking Scale (SMTS).19, 204-206 Although the most common terminology use was the 
MGLS, it could be the case that some researchers have used different names for the 
same instrument. 
Lastly, some measures were created based on a previous version or were modified in 
some way, for example, the four-item Morisky Medication Adherence Scale (MMAS-
4) was created via the modification of the MGLS.207 The MMAS-4 comprises four 
items, similar to the MGLS. The only distinction is that the second question has been 
revised from the notion of ‘the carelessness of taking medication’ to ‘the problem of 
remembering to take your medication’, with the other three items being identical.207 
Furthermore, the study prior to 2011 often used the term ‘Morisky’ to represent the 
MGLS.58, 208, 209 Therefore, the interpretation and implementation of the obtained 
information relevant to these slightly different measures should be performed 
carefully with precision. 
In order to enhance the internal validity of the understanding of measurement of 
adherence in depression, only research which pertained to adults who lived with 
unipolar depression were included. We excluded comorbidities, as certain physical 
and mental conditions can alter medication-taking behaviour such as anxiety, 
attention deficit hyperactivity disorder (ADHD), and dementia.6, 7 We also excluded 
specific age ranges as a particular population group may require specific measures 
pertaining to physical change; for example, the elderly may have greater difficulty 
when using patient self-report which is related to their memorising ability and other 
tools such as smartphone applications (Apps) may be more suitable for teenagers.210 
In addition, consumers below the age of 18 years were also excluded as the 
responsibility of medication-taking in this age group was undertaken by their parents 
or caregivers rather than the consumers themselves. 
Smartphone apps are a relatively new strategy aimed at assisting  consumers in 
better managing their chronic conditions.211 Various utilities of the apps have been 
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proved for people with unipolar depression such as screening, use as the adjunctive 
treatment in lowering depressive symptoms in mild to moderate depression and in 
refractory depression, and assisting medication adherence.210, 212-215 The apps have a 
potential to be effective in improving medication adherence as they are inexpensive, 
scalable, accessible to anyone with a smartphone, and do not require separate 
devices or packaging, which allows them to be easily implemented.211 Therefore, 
smartphone apps and other technology-based solutions are becoming an important 
part in the future of mental health care.216 However, the majority of the apps lacked 
appropriate evaluations from clinical and legal viewpoints, which is considered to be 
a significant gap.217, 218  
The findings of the research described in this thesis provide a potential solution to 
address suboptimal medication adherence in people taking antidepressant medicines 
for the management of unipolar depression. The integration of the findings from 
Chapter Six, the conceptual framework of medication adherence, may be used by 
health care professionals to improve medication adherence (Chapters Four and Five). 
If combined with the use of appropriate adherence measures for the specific phases 
of adherence, this may improve overall medication adherence in consumers with 
unipolar depression. 
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7.5 Strength and limitation of this thesis  
This is a preliminary study of the framework developed to better understand 
medication-taking behaviour in people living with unipolar depression. A pilot test of 
the face and content validity of the proposed framework was conducted among 
health care professionals, via an internet-based survey using an expert panel. In order 
to balance the framework, the addition of a non-professional panel into the 
validation process could be considered. Accordingly, the revision of the framework 
subcomponents as well as pilot testing of the implementation of the framework 
among the intended users and health care professionals might improve the likelihood 
of the uptake of this model in practice. 
This thesis has a number of strengths, which are stated below:  
Firstly, this is the first study to establish a comprehensive framework of medication 
adherence which adopted the ABC taxonomy for greater understanding of 
medication-taking behaviour in people with unipolar depression. The framework 
highlighted the need for receiving specific, individualised support at different phases 
of adherence for people living with unipolar depression. It can be applied not only to 
address non-adherence to antidepressant medicine, but also can be used as a 
guidance for various stakeholders, when health policy related to this area is reviewed. 
Secondly, this framework presents a practical model which specifically endorses the 
creation of a healthcare system in which the dispensing function is separated from 
the prescribing function. On the other hand, it may not be suitable for a health care 
system in which the dispensing function is integrated with the prescribing function or 
in a one-stop service setting.  
Lastly, rigorous methods in accordance with the standard approach to conduct 
research (the PRISMA statement for a systematic review and the COREQ for reporting 
qualitative research) were employed in the research described in this thesis to ensure 
the comprehensiveness and appropriateness of the body of the work. In addition, the 
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triangulation process of multiple sources of information was used for the framework 
development. These procedures affirmed that solid work has been done. 
Despite these strengths, there are some limitations, which are discussed below:  
Firstly, this framework does include consumers who apparently fail to recognise 
depression as a disease or diagnosis, failed to treat depression, or those who do not 
believe in the doctor. This is including those who could not access or were denied 
access to health care professionals and the health care system. Given this, the 
implementation of the framework is limited to people who can or are willing to access 
health care professionals and the health care system. Therefore, both the 
interpretation and implementation of the findings must be done carefully. 
Additionally, the framework was created for primary care where most of people living 
with unipolar depression are managed. Therefore, the implementation of the 
framework in other practice settings has not been established.   
Secondly, with regard to the validation process via internet-based survey using an 
expert panel, the researchers acknowledged the value of a non-professional panel 
arm in this study as it balanced the findings and confirmed potential factors at specific 
phases from another viewpoint. In addition, increasing the number of expert panel 
members generally enhances the credibility of results; hence, it must be considered. 
We also acknowledge that the preliminary framework requires greater clarity with 
respect to the framework’s subcomponents , perhaps in accordance with the Plan-
Do-Check-Act cycle (PDCA cycle), a quality improvement methodology that may be 
used for the continuous quality improvement of processes or elements within the 
health care system.219 For this reason, the content validation process was 
undertaken. In addition, a non-health care professional panel could be recruited to 
conduct the next stage of validation of the framework subcomponents (influencing 
factors at particular phases of medication taking behaviour), contributing to 
increased external validity. In addition, the framework did not explicitly consider the 
specific competence of health care professionals, which may also influence 
adherence to medicine.   
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CHAPTER EIGHT – Conclusions and future directions 
 
8.1 Conclusions 
Understanding potential factors influencing medication adherence and non-
adherence from the consumer perspective throughout the process of medication 
taking is a crucial principle of adherence improvement in people living with unipolar 
depression. The conceptual framework developed and presented in this thesis is the 
first that has been attempted to unpack and better understand the complicated 
process of medication adherence in people taking an antidepressant medicine for 
unipolar depression. Furthermore, it is the first to have used the ABC taxonomy as 
the broad framework. The framework focused on facilitators of and barriers to 
medication adherence at the three distinct phases of adherence: initiation, 
implementation, and discontinuation of therapy. The framework employed the core 
concept of patient-centeredness which highlights the notion of patients’ preferences, 
patient empowerment, patient autonomy, and shared-decision making approach in 
health care. As can be seen, informed understanding of consumers’ beliefs about 
medicines, self-motivation, and medication self-management are central to 
improving medication adherence in people living with depression. In turn, this 
approach may contribute to improved health outcomes via improved medication 
adherence in consumers with unipolar depression. This patient-centred approach is 
aligned with a broader global health approach which has seen a movement from a 
health care professionals focus to a consumer-centred focus.    
The proposed framework attempts to bridge the gap between health care 
professionals and patients as it aids health care professionals to better understand 
their patients from the consumer’s perspective. It is noteworthy that the 
underpinning purpose of the proposed framework was for it to be useful for clinical 
practice, hence the rigorously developed but pragmatic approach to its development.  
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Specifically, this framework may be used as a guide to inform health professionals to 
tailor and convey effective strategies to improve medication adherence for 
individuals with unipolar depression. The integration of tailored and multifaceted 
interventions in conjunction with proactive care management and the involvement 
of mental health specialist should be employed in clinical settings for the 
enhancement of medication adherence. In addition, regular follow-up across the 
different phases of medication taking behaviour is recommended, coupled with the 
use of a validated measure/s of medication adherence. Such an approach may 
improve the effectiveness of antidepressant medicine use in people with unipolar 
depression which in turn may improve health outcomes.   
8.2 Future directions 
In light of the proposed framework, it can now undergo feasibility and pilot testing in 
clinical practice in primary care. Modifications and further validity testing with non-
health care professionals would also improve the utility of the framework. Ultimately 
this framework might be used routinely in clinical practice to assist health care 
professionals and individuals being treated with antidepressant medicines for 
unipolar depression.  
The proposed framework may also be used as a prototype to develop tailored 
interventions for other chronic conditions.  
Future enhancements of the framework may be included and supported by 
technology, such as the development of a health application for people with unipolar 
depression.   
This research found that few studies focused on the initiation of antidepressant 
medicines. This is an important area for future research as little is known about 
primary non-adherence in people with unipolar depression. This is likely to be of 
importance given the stigma which surrounds mental illnesses including unipolar 
depression.  
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APPENDIX ONE – Description of journals 
 
Research in Social and Administrative Pharmacy 
Research in Social and Administrative Pharmacy (RSAP) is a bi-monthly publication 
featuring original scientific reports and comprehensive review articles in the social 
and administrative pharmaceutical sciences. Topic of interest include outcomes 
evaluation of products, programs, or services; pharmacoepidemiology, medication 
adherence, direct-to-consumer advertising of prescription medication; disease state 
management; health systems reform; drug marketing; medication distribution 
systems such as e-prescribing; web-based pharmaceutical/ medical services; drug 
commerce and re-importation; and health professions workforce issues.  
Journal impact factor: 2.403 
 
Patient Preference and Adherence  
An international, peer reviewed, open access journal that focuses on the growing 
importance of patient preference and adherence throughout the therapeutic 
continuum. The journal is characterized by the rapid reporting of reviews, original 
research, modelling and clinical studies across all therapeutic areas. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their role in 
developing new therapeutic modalities and compounds to optimize clinical outcomes 
for existing disease states are major areas of interest for the journal. 
Journal Impact Factor: 1.798 (5 year impact 1.831) 
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 Research Integrity 
Research Portfolio 
Level 2, Margaret Telfer 
The University of Sydney  
NSW 2006 Australia 
T +61 2 8627 8111 
F +61 2 8627 8177 
E ro.humanethics@sydney.edu.au 
sydney.edu.au 
ABN 15 211 513 464 
CRICOS 00026A 
 
 
Research Integrity 
Human Research Ethics Committee 
 
 
Tuesday, 30 June 2015 
 
Assoc Prof Timothy Chen 
Pharmacy; Faculty of Pharmacy 
Email: timothy.chen@sydney.edu.au 
 
 
Dear Timothy 
 
Your request to modify the above project submitted on 3rd June 2015 was considered by the 
Executive of the Human Research Ethics Committee at its meeting on 23rd June 2015. 
 
 
The additional information provided was reviewed by the Ethics Office on 30th June 2015.   
 
 
The Committee had no ethical objections to the modification/s and has approved the project to 
proceed. 
 
 
Details of the approval are as follows: 
 
Project No.:  2014/967 
 
Project Title: Factors influencing patients’ adherence to antidepressant 
medicines in unipolar depression: a qualitative study 
 
 
Approved Documents: 
 
DATE TYPE DOCUMENT NAME  
03/06/2015 Other Type attachment 1 Research data for market research company
03/06/2015 Other Type attachment 2 Antidepressant lists in Australia version 1 
03/06/2015 Participant Info Statement Appendix 1 Participant information statement version 2 
17/11/2014 Advertisements/Flyer Flyer 
17/11/2014 Participant Consent Form Participant consent form 
17/11/2014 Interview Questions Interview guide 
17/11/2014 Other Type Background information questionnaire 
17/11/2014 Telephone Scripts Telephone script 
17/11/2014 Participant Info Statement Participant information statement 
17/11/2014 Other Type Reserarch reference 
 
Special Conditions: 
 
 Please correct ‘anindividual’ under point three of your PIS 
 
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
175
 Page 2 of 2 
 
 
Yours sincerely 
 
 
 
Dr Stephen Assinder 
Chair 
Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
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CRICOS 00026A 
 
 
Research Integrity & Ethics Administration 
Human Research Ethics Committee 
 
 
Wednesday, 8 March 2017 
 
 
Assoc Prof Timothy Chen 
Pharmacy; Faculty of Pharmacy 
Email: timothy.chen@sydney.edu.au 
 
 
 
Dear Timothy 
 
The University of Sydney Human Research Ethics Committee (HREC) has considered your 
application. 
 
After consideration of your response to the comments raised your project has been approved. 
 
 
Approval is granted for a period of four years from 08 March 2017 to 08 March 2021 
 
Project title:  Face and content validity of medication adherence conceptual 
framework: factors influencing patients’ adherence to 
antidepressant medicines in unipolar depression 
 
Project no.:  2016/965 
 
First Annual Report due: 08 March 2018 
 
Authorised Personnel: Chen Timothy; Srimongkon Pornchanok; Aslani Parisa; 
 
Documents Approved:  
Date Uploaded Version number Document Name 
20/02/2017 Version 2 Telephone script-Clean version 
20/02/2017 Version 2 Invitation e-mail-clean version 
07/11/2016 Version 1 Survey 
07/11/2016 Version 1 Participant Information Statement 
 
Condition/s of Approval 
 
 Research must be conducted according to the approved proposal. 
 
 An annual progress report must be submitted to the Ethics Office on or before the anniversary 
of approval and on completion of the project.  
 
 You must report as soon as practicable anything that might warrant review of ethical approval 
of the project including: 
 Serious or unexpected adverse events (which should be reported within 72 hours). 
 Unforeseen events that might affect continued ethical acceptability of the project. 
 
 Any changes to the proposal must be approved prior to their implementation (except where 
an amendment is undertaken to eliminate immediate risk to participants). 
 
 Personnel working on this project must be sufficiently qualified by education, training and 
experience for their role, or adequately supervised. Changes to personnel must be reported 
and approved.  
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 Personnel must disclose any actual or potential conflicts of interest, including any financial or 
other interest or affiliation, as relevant to this project. 
 
 Data and primary materials must be retained and stored in accordance with the relevant 
legislation and University guidelines. 
 
 Ethics approval is dependent upon ongoing compliance of the research with the National 
Statement on Ethical Conduct in Human Research, the Australian Code for the Responsible 
Conduct of Research, applicable legal requirements, and with University policies, procedures 
and governance requirements. 
 
 The Ethics Office may conduct audits on approved projects. 
 
 The Chief Investigator has ultimate responsibility for the conduct of the research and is 
responsible for ensuring all others involved will conduct the research in accordance with the 
above.  
 
 
This letter constitutes ethical approval only.  
 
Please contact the Ethics Office should you require further information or clarification. 
 
Sincerely 
 
 
Associate Professor Michael Skilton 
Chair 
Health Review Committee 
 
The University of Sydney HRECs are constituted and operate in accordance with the National 
Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in 
Human Research (2007) and the NHMRC’s Australian Code for the Responsible Conduct of 
Research (2007). 
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APPENDIX THREE – Study instruments for qualitative study (Chapter 
Four and Five) 
 
Figure A: Poster for the recruitment process 
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Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
Interview guide, Version 1, 10th November 2014 
INTERVIEW GUIDE 
 
Factors influencing adherence to anti-depressants in unipolar depression: a qualitative study 
 
This project aims to: 
1. To explore the strategies or positive influencing factors which promote medication adherence 
(at the three stages of adherence: Initiation, Continuation and Discontinuation) in unipolar 
depression from the consumer’s perspective.   
2. To explore the barriers or negative influencing factors which reduce medication adherence (at 
the three stages of adherence: Initiation, Continuation and Discontinuation) in unipolar 
depression from the consumer’s  perspective.  
 
The identified strategies or positive factors that encourage consumers to take their antidepressant 
medicines, and negative factors or barriers to medication adherence, will be used to inform the 
development of innovative and tailored interventions to promote adherence in our target population. 
 
Factors affecting antidepressant adherence. 
1) Patient related factors (Insight* and beliefs: The specific components of Insight including awareness 
of present illness, awareness of sign and symptoms related to illness, attribution of current signs and 
symptoms to the illness, understanding the usefulness of treatment.;Impact of depression, Substance 
abuse/ comorbidity, Perceived benefits/ costs) 
a. Can you tell me a bit about your experiences of depression? 
i. How long have you been diagnosed with depression? 
ii. How long have you taken antidepressant medicines? 
b. Can you tell me how your depression has affected your life and daily activities? 
2) Condition related factors (illness related, severity of symptom, the availability of effective 
treatment, drug and alcohol abuse, co-morbidities) 
a. How effective do you find antidepressant medicines for managing the symptoms of 
depression? 
b. How effective do you find antidepressant medicines for the prevention of episodes of 
depression? 
3) Clinician related factors or Health care team and system-related factors(Therapeutic alliance, 
support, frequency of visits, clinician perception/preferences, power of suggestion, simplicity of 
explanation) 
a. Can you describe to me the relationship you have with your doctor? 
b. How does your doctor or other health care professional encourage or help you to take 
your antidepressant medicines? 
c. How often do you visit your doctor or other health care professionals? 
d. What do you think about health care team in terms of the support, it provides you to 
take antidepressant medicines?  
e. What is your opinion about health care system including health insurance groups/ 
companies in terms of support you to take antidepressant medicines?  
4) Medication related factors(Efficacy, side effects, frequency, route of administration, 
polypharmacy, cost)  
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Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
Interview guide, Version 1, 10th November 2014 
a. Can you tell me about your experiences of taking antidepressant medicines? 
i. Do you take your antidepressant medicines as prescribed? 
ii. If not: Why? 
b. What are your thoughts about how well your antidepressant medicines have worked for 
you? (Do you believe in the effectiveness of antidepressant medicines?) Can you tell me 
a little bit more about that? 
c. What do you think about treatments options or medicines for people who have 
depression? 
d. Have you had any side effects from your antidepressant medicines? (such as sexual 
dysfunction, weight gain, sleep disturbances) 
i. If yes: Can you tell me a bit about that? 
ii. If yes: How did you handle it? 
e. Can you tell me about what other people (such as friends, family, work colleagues) think 
about your using antidepressant medicines?  
Antidepressant Medicines: 
a. Can you tell me what motivates you to take your antidepressant medicines? 
b. What/why made you start your antidepressant medicines? 
c. Can you tell me what made you continue your antidepressant medicines? 
d. What are some of the steps you take every day to help you in making sure that you take 
your antidepressant medicines? 
e. In an ideal world what sort of help would encourage and help you and other people with 
depression to take antidepressant medicines on a regular basis? 
f. Have you stopped taking antidepressantmedicines for a while? Can you explain more 
about that? 
g. What or who supported you to restart your antidepressant medicines?  
h. How often have you stopped taking your antidepressant medicines? 
5) Environmental related factors or Social and Economic factors(Family support and beliefs, 
Access, Formulary considerations, Role of internet/ advertising, financial burden)  
a. Do you belong to any support group? 
i. If yes: Can you tell me about that? How helpful is the group? 
ii. If no: Would you consider joining such a group? 
b. How well would you say your family (partner, parents, friends, colleagues) support you? 
What are some of the ways that they support you?   
c. What do you think about the cost of antidepressant medicines? 
6) Can you tell me what stops you or gets in the way of youtaking your antidepressant medicines? 
7) In your view, what could be the barriersfor people with depression who are trying to take their 
antidepressant medicines on a regular basis? 
8) Can you tell me whether you drink alcohol? Does it impact on your medicine taking?  
9) How can you tell me whether you smoke cigarettes? Does it impact on your medicine taking? 
10) Do any lifestyle factors impact on your medicine taking? 
 
What other comments do you have that we have not addressed so far? 
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Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
Interview guide, Version 1, 10th November 2014 
 
 
 
 
 
INTERVIEW GUIDE FOR PARTICIPANTS 
 
TITLE: Factors influencing adherence to anti-depressants in unipolar depression: 
a qualitative study 
 
 
 
We would like to ask you about… 
 
1) Your experience with depression. 
2) Effectiveness of antidepressants. 
3) A relationship with your doctor and healthcare professional. 
4) Your experience of taking antidepressants and side effects. 
5) The environments and people who support you taking your 
antidepressants. 
6) Alcohol consumption, smoking behavior and your lifestyle.      
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Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
Demographic Questionnaire, Version 1, 10th November 2014 
 
 
Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
 
Please place a tick (√) in the box to provide your background details.   
1. Gender:  Male   Female  Transgender   Prefer not to respond 
 
2. In what year were you born? _________ 
 
3. Ethnicity: 
How do you describe your ethnicity? (please check the one option that best describes you) 
 Oceania and Antarctica (Australia, New Zealand, Melanesia, Micronesia, Polynesia and 
Antarctica)   
 North-West Europe  
 Southern and Eastern Europe 
 North Africa and Middle East 
 South-East Asia 
 North-East Asia 
 Southern and Central Asia 
 Americas 
 Sub-Saharan Africa 
 Multiracial  
 Other (please specify) __________________  
 Prefer not to respond  
   
4. Education: What is the highest degree or level of school you have completed? If currently 
enrolled, mark the previous grade or highest degree received. 
 No schooling completed  
 Pre-primary education 
 Primary education 
 Secondary education 
 Certificate level 
 Advanced diploma or Diploma level 
 Bachelor degree level (including honours) 
 Graduate Diploma or Graduate certificate level 
 Postgraduate degree level 
 Others (please specify) __________________ 
 Prefer not to respond  
 
5. What is your marital status? 
 Now married    Separated  
 Widowed    Never married 
 Divorced    Living with a partner in a de facto relationship 
 Prefer not to respond 
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Factors influencing patients’ adherence to antidepressant medicines in unipolar depression:  
A qualitative study 
Demographic Questionnaire, Version 1, 10th November 2014 
 
6. Which of the following are applicable to your living situation? (Check all that apply) 
 I live alone. 
 I live with roommates/housemates 
 I live with parents(s), relative(s), or guardian(s) 
 I live with a husband/wife/domestic partner/significant other 
 I live with my child/children 
 Other (please specify) __________________   
 Prefer not to respond 
 
7. Employment status: Are you currently…? 
 Employed       A homemaker  
 Self-employed      A student 
 Out of work and looking for work    Retried 
 Out of work and not currently looking for work   Unable to work 
 Other (please specify) __________________ 
 Prefer not to respond     
 
About your health status: 
 
8. Please provide some information about your current medical conditions: 
8.1 Depression: 
8.1.1 How long have you been diagnosed with depression? 
_____________________________________ 
8.1.2 How long have you taken antidepressant medicines? 
_____________________________________ 
8.1.3 Please write down the name of the antidepressant medicine/s you are currently 
taking. 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
________________________________________________________ 
8.2 Other medical conditions: 
8.2.1 Do you have any other medical conditions? 
 Yes. Please specify __________________________________________ 
 No. 
8.2.2 What medicines are you taking for these conditions? 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
____________________________________________________________ 
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APPENDIX FOUR – Study instruments for the conceptual framework 
study (Chapter Six) 
 
Table A: Initial items retrieved from previous qualitative research study and review 
literature. 
 
Dimensions Sub-dimensions Factors influencing to medication adherence 
and related references 
1. Factors relating 
to healthcare 
providers 
1.1 Healthcare 
professionals (HCPs) 
influence to 
medication 
adherence  
- HCPs role as a facilitator87  
- Qualitative study conducted by the 
researchers 
1.2 Relationships 
between HCPs and 
patients 
- Good relationship17, 35, 62, 78, 80, 81  
- Rapport established80 
- Lack of attention to the patient80 
- Apparent dismissive reaction80 
- Superficial or glib responses from doctors to 
patients80   
- Unsatisfactory interaction with HCPs78 
- Disconnected relationship78 
- Patient fear of HCPs36 
- HCPs-patient interaction66  
- Qualitative study conducted by the 
researchers 
1.3 Support from 
HCPs/ helpfulness of 
HCPs visits  
- Rating GP visits as moderately to extremely 
helpful60 
- Support from HCP37, 80 
- Qualitative study conducted by the 
researchers 
1.4 Stigma about 
depression in HCPs 
- Qualitative study conducted by the 
researchers 
1.5 Experienced 
HCPs 
- Qualitative study conducted by the 
researchers 
1.6 Collaboration 
between HCPs (GPs, 
psychiatrists, and 
pharmacists) in a 
mental health care 
team 
- Multiple prescribers36 
- Qualitative study conducted by the 
researchers 
1.7 Interactive 
communication and 
open dialogues 
between HCPs and 
patients  
- Communication60, 78, 88 
- Two-way communication/ being listened too80 
- Shared decision-making80 
- Early discussion62 
- Problems communicating with HCPs36 
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and related references 
- Qualitative study conducted by the 
researchers 
1.8 Adequate 
information about 
depressive 
treatment from HCPs 
- Adequate information38, 62, 80 
- Patients are expected to be informed about 
medicines before treatment initiation78 
- Required more information from their doctors 
before taking the first dose80 
- Sufficient information form HCPs37, 81 
- Knowledge about the causes of depression 
and mechanism of antideprssants37 (and other 
relevant issues51) 
- Qualitative study conducted by the 
researchers 
1.9 Adequate time to 
see the doctor/ 
length of GP visit  
- GP visits longer than 20 mins60 
- Sufficient time during the consultation17, 78, 80 
- No obligation to rush62 
- Qualitative study conducted by the 
researchers 
1.10 Belief about the 
efficacy of 
antidepressant 
medicine among 
HCPs 
- Qualitative study conducted by the 
researchers 
2. Factors relating 
to the healthcare 
system  
2.1 Accessibility to 
the health care 
providers/ Access to 
practice 
- Accessible36, 60 
- Qualitative study conducted by the 
researchers 
2.2 Mental health 
organisations role  
- Qualitative study conducted by the 
researchers 
2.3 Private health 
insurance 
- Qualitative study conducted by the 
researchers 
2.4 Accessibility of 
antidepressant 
medicines/ access to 
medication 
- Qualitative study conducted by the 
researchers 
2.5 The continuity of 
care in public 
system/ health 
system  
- Continuity of care60 
- Qualitative study conducted by the 
researchers 
2.6 Management 
issue 
- Long waiting time at the clinic36 
- Frequent medication refills36 
- Frequent clinic visits36 
- No supply of medications36 
- Qualitative study conducted by the 
researchers 
3.1 Patient self-
motivation 
-‘will power’62 
- Wish for complete recovery36 
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and related references 
3. Factors relating 
to patients and 
carers 
- Fear of relapse36 
- The ownership of the decision37 
- Qualitative study conducted by the 
researchers 
3.2 
Acknowledgement of 
their depression 
condition  
- Accepted their health conditions78/diagnosis62 
- Qualitative study conducted by the 
researchers 
3.3 The involvement 
of the patients in 
treatment decision-
making process  
- Qualitative study conducted by the 
researchers 
3.4 Previous 
experience of 
antidepressant 
treatment, either 
favourable or 
unfavourable   
- Previous experience of antidepressant 
treatment35, 39, 78 
- Personal or family experience of 
antidepressant medicine, frequently negative62 
- Qualitative study conducted by the 
researchers 
3.5 Family support  - Family’s attitude toward medication61 
- Family support (family/spouse/friends)36 
- Cultural beliefs36 
- Qualitative study conducted by the 
researchers 
3.6 Peer support - Trusted friends62 
- Social support36, 81, 89 
- Similar experience sharing/ support from 
people with depression79 
- Qualitative study conducted by the 
researchers 
3.7 Patient regular 
activities 
- Such as taking with a meal36 
- Qualitative study conducted by the 
researchers 
3.8 Stigma about 
depression/ self-
stigma/ 
antidepressant  
- Stigma related to perceived drug 
dependency80  
- Strong self-stigma attached80  
- ‘Felt’ Stigma79 ; refers principally to the fear of 
discrimination on the basis of perceived 
unacceptability or inferiority, as opposed to 
actual instances of discrimination. 
- Self-stigma35, 65 
- Qualitative study conducted by the 
researchers 
3.9 Mental health 
stigma from family 
members or carers 
- Qualitative study conducted by the 
researchers 
3.10 Stigma in 
society 
- Societal stigma39 
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and related references 
- This type of stigma was connected to the view 
that psychotropic medication would affect 
cognitive functions. It was based on actual 
discriminatory remarks by others and can 
therefore be interpreted as ‘enacted’ stigma.79 
- Public opinion about depression and its 
treatment reveals reluctant to consult 
practitioners about depressive symptoms, and 
evidence that counselling is favoured over 
antidepressant treatment.62  
- Stigma in society36 
- Qualitative study conducted by the 
researchers 
 3.11 Belief in 
antidepressant 
- Belief/ perception 16, 36, 62, 63, 90 
- Faith81 
- Beliefs and attitudes to depression and 
antidepressant35 
- Qualitative study conducted by the 
researchers 
- Attitudes toward antidepressant35, 78, 81 
3.12 The ability to 
self-manage on 
medication taking  
- (more) self-help practices60 
- Qualitative study conducted by the 
researchers 
3.13 Concern about 
the effect of 
stopping 
antidepressant 
therapy 
- Experiencing symptoms worsening when they 
weren’t regularly taking antidepressant39 
- Fear of withdrawal symptoms87 
- Fear of relapse87 
- Uncertainty about what would be like without 
antidepressants87  
- Qualitative study conducted by the 
researchers 
3.14 Clinical 
improvement/ 
feeling better 
- Welcoming effects of antidepressant78 
- Recovery62, 79 
- Early treatment response81 
- Feeling better55 
- Treatment outcome35 
- Qualitative study conducted by the 
researchers 
3.15 Patients who 
have trust in their 
HCPs 
- Trust in HCPs36, 78, 80 , Trust in GPs60 
- They believe that ‘doctor knows best’80 
- Qualitative study conducted by the 
researchers 
3.16 Knowledge 
about depression 
and antidepressant 
medicine 
- Knowledge 78, 80 
- Lack of knowledge about the use of 
antidepressant, the effect of antidepressant36 
- Qualitative study conducted by the 
researchers 
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and related references 
3.17 Forgetfulness  - Forgetfulness36, 39 
- Including: having a busy schedule, being away 
from home, simply forgetting to take their 
antidepressant36 
- Qualitative study conducted by the 
researchers 
3.18 Perceive drug 
dependency and 
addiction 
- Fear of drug dependency and/or addiction80 
- Fear of drug dependence36, 55 (erroneous 
belief, misconceptions about depression and/or 
antidepressant)36 
- Qualitative study conducted by the 
researchers 
3.19 Patient perceive 
and belief about 
illness (depression)  
- Perceive and belief about depression78, 80 
- Qualitative study conducted by the 
researchers 
3.20 Patient 
concerns about 
sense of self while 
using antidepressant 
medicines 
- Sense of self80, not feeling like oneself39 
- Worries about the feeling ‘fluffy’ or ‘out of 
control’ when use antidepressant80 
- Sense of self control55 
- Self-reliance39 
- Qualitative study conducted by the 
researchers 
3.21 Patient belief 
about the need of 
antidepressant   
- Belief about the need of antidepressant66, 78, 80 
- Awareness about the need to take 
antidepressant36 
- Uncertainty about the benefits of and the 
need for antidepressant87 
- Qualitative study conducted by the 
researchers 
3.22 Patient beliefs 
about the efficacy of 
antidepressant 
medicines 
- Beliefs about efficacy of antidepressant78 
- Qualitative study conducted by the 
researchers 
3.23 Attitudes 
towards 
antidepressant 
- Negative attitude such as a dislike for the pill36 
- Attitudes towards antidepressant37 
- Qualitative study conducted by the 
researchers 
3.24 Reminders -Such as using pillboxes, reminder form family 
members, keeping medications in visible 
places36 
- Qualitative study conducted by the 
researchers 
4. Demographic 
and 
socioeconomic 
factors 
4.1 Level of 
education  
- Higher level of education predicted the correct 
intake of antidepressant81 
- Education level61 
4.2 Living status/ 
marital status 
- Marital status60, 61, 92 
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and related references 
4.3 Cost of 
antidepressant 
medicines/ 
affordable 
antidepressant 
medicines 
- Cost of antidepressant36 
- Qualitative study conducted by the 
researchers 
4.4 Cost of health 
care  
- Qualitative study conducted by the 
researchers 
4.5 Benefits as main 
source of income 
- Benefits as main source of income60 
- Qualitative study conducted by the 
researchers 
4.6 Family income - Low family income35 
5. Disease and 
medicine factors 
5.1 The severity of 
depressive 
symptoms 
- Severity of depression60, 62-66 
- Qualitative study conducted by the 
researchers 
5.2 Depressive 
symptoms itself such 
as lack of motivation, 
lethargy, 
forgetfulness  
- Clinical features of depression6, 7, 9, 35 
- Qualitative study conducted by the 
researchers 
5.3 Chronic 
conditions itself that 
requires long-term 
treatment  
- Chronic condition of depression which 
requires long-term treatment60, 78 
5.4 Recurrent 
episode 
- Recurrent of depressive episode60, 61 
5.5 Comorbidity - Comorbidity35, 36, 60, 65, 80, 90-92 
- Including alcohol dependence36 and substance 
abuse90 
5.6 Length of 
depressive illness 
- Length of previous illness62 
- Longer onset of depression81 
- Treatment duration36  
5.7 Patient concerns 
about possible 
adverse drug 
reactions  
- Concern about possible adverse drug 
reactions78, 80 
- Qualitative study conducted by the 
researchers 
5.8 The effectiveness 
of antidepressant 
medicines 
- Lack of therapeutic response38 
- Lack of efficacy36, 37, 39, 55, 66 
- Qualitative study conducted by the 
researchers 
5.9 Category of 
antidepressant used 
- Category of antidepressant used60 
5.10 Other 
medicines used 
- Pill burden36 
- Qualitative study conducted by the 
researchers 
5.11 Experiencing 
ADR 
- Experiencing ADRs35-39, 55, 64, 78, 81 
- Concern about the potential ADRs39 
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- Qualitative study conducted by the 
researchers 
5.12 Medication 
duration of 
treatment  
- Medication duration of treatment61 
5.13 Medication 
onset 
- Pharmacological factors35 
 
Face and content validity of a medication adherence conceptual frameworks -- 
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Various terms have been used to describe medication taking behaviour of patients including
"compliance", "persistence", and "adherence". Recently, a European consortium working group - The
Ascertaining Barriers to Compliance project or ABC project  - established a new taxonomy for
describing different phases of medication taking behaviour. Specifically they conceptualised medication
adherence into three distinct phases: initiation, implementation, and discontinuation of therapy.
Based on this framework (initiation, implementation, and discontinuation of therapy), in-depth interviews
conducted with the consumers and a review of the literature, we have identified factors known to
influence medication taking behaviour at each of these three phases of medication taking, for
consumers with depression. 
Therefore, the aim of this study is to assess the face and content validity of factors which may facilitate
and hinder medication adherence at each of the three phases of medication taking behaviour (i.e.
initiation, implementation, and discontinuation of therapy).
There are 3 parts in this questionnaire.
1. Part 1: The influencing factors at the initiation phase of adherence
2. Part 2: The influencing factors at the implementation phase of adherence
3. Demographic data
 
You will be asked to evaluate the factors influencing (listed statements) each phase of adherence.
Specifically, you will be asked to assess relevance to practice and importance of the factor, on 5-point
scales. This questionnaire requires about 20-30 minutes to complete. 
 
If you would like to clarify any items prior to rating them, please contact Pornchanok Srimongkon via
mobile (0449 761 980) or email psri6621@uni.sydney.edu.au.
 
Thank you for participating in our survey. Your feedback is important.
 
 
 
Reference
[1] Vrijens, B., et al., A new taxonomy for describing and defining adherence to medications. Br J Clin
Pharmacol, 2012. 73(5): p. 691-705.
 
 
What is this study about?
Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
[1]
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1. Medication adherence : The process by which consumers take their medicines as prescribed.
Medication taking may be divided into three phases: initiation, implementation and discontinuation of
therapy.
     1.1 Initiation occurs when the consumer takes the first dose of a prescribed medicine .  
               i. Facilitators of initiation of therapy: factors that encourage consumers to take the first
dose of an antidepressant medicine.
               ii. Barriers to initiation of therapy: factors that discourage consumers from taking the first
dose of an antidepressant medicine.  
     1.2 Implementation is the extent to which a consumer’s actual dosing corresponds to the prescribed
dosing regimen, from initiation until the last dose is taken .
              i. Facilitators of implementation of therapy: factors that encourage consumers to keep
taking their antidepressant medicine.
               ii. Barriers to implementation of therapy: factors that discourage consumers from taking
their antidepressant medicine.
     1.3 Discontinuation occurs when the consumers stop taking their prescribed medicine, for any
reason(s) .
2. Healthcare provider refers to general practitioners (GPs), psychiatrists, pharmacists, and mental
health workers.
 
Reference
[1] Vrijens, B., et al., A new taxonomy for describing and defining adherence to medications. Br J Clin
Pharmacol, 2012. 73(5): p. 691-705.
 
Definition of terms used in this study
Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
[1]
[1]
[1]
[1]
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Figure 1: The conceptual framework for this study
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Part 1: The influencing factors at the initiation phase of adherence.
Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
Please read the following statements and indicate the extent to which you agree or
disagree with them.
The operational definitions of these terms are reported below.
- Relevance: The extent to which the statement (influencing factor) is relevant to
practice at the specified phase of medication adherence. 
- Importance: The extent to which the statement (influencing factor) is important for the
specified phase of medication adherence.
 
If you would like to add, delete or modify any item, please record your suggestions in
the comments section below the item.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
1. Following the diagnosis of a consumer with depression, GPs can influence whether
consumers commence therapy with antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
2. Following the diagnosis of a consumer with depression, psychiatrists can influence
whether consumers commence therapy with antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
3. Following the diagnosis of a consumer with depression, community pharmacists can
influence whether consumers commence therapy with antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
4. Good relationships between GPs and consumers can influence whether consumers
commence therapy with antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
5. Good relationships between psychiatrists and consumers can influence whether
consumers commence therapy with antidepressant medicines.
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Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
6. Good relationships between community pharmacists and consumers can influence
whether consumers commence therapy with antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
7. Good support from the GPs is critical to whether a consumer with depression commences
therapy with an antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
8. Good support from a psychiatrist is critical to whether a consumer with depression
commences therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
9. Good support from the community pharmacist is critical to whether a consumer with
depression commences therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
10. Any perceived stigma displayed by health care professionals toward depression can
inhibit a consumer from commencing an antidepressant medicine.
203
Part 1: The influencing factors at the initiation phase of adherence.
Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statment)
11. GPs beliefs about the efficacy of antidepressant medicines influences whether a
consumer commences therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
12. Psychiatrist beliefs about the efficacy of antidepressant medicines influences whether a
consumer commences therapy with an antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
13. Community pharmacist beliefs about the efficacy of antidepressant medicines influences
whether a consumer commences therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
14. Self-motivation of a consumer is a factor in whether they commence therapy with an
antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
15. Consumers who acknowledge their depressive condition, tend to commence therapy
when prescribed an antidepressant medicine.
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influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
16. Consumers who are involved in the treatment decision-making process are more likely to
commence therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
17. Consumers who have previous unfavourable experiences with antidepressant treatment
are less likely to commence therapy with antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
18. Consumers who have adequate information about depression and antidepressant
medicines are more likely to commence antidepressant therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
19. Stigma about depression can be a barrier to a consumer t commencing antidepressant
therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
20. Consumer beliefs about the efficacy of antidepressant medicines influences whether they
commence therapy with an antidepressant medicine.
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influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
21. Concern about possible adverse drug reactions can influence whether a consumer
commences therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
22. Consumers with higher levels of education are more willing to commence antidepressant
therapy.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
23. The accessibility of the health care providers affects when a consumer commences
therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
24. Private health insurance influences whether a consumer commences therapy with an
antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
25. Consumers who live with a partner are more likely to commence antidepressant therapy.
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Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
26. The cost of antidepressant medicines influences whether a consumer commences taking
antidepressant therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
 
Please specify any other comments (e.g. Clarity of statement)
27. The cost of health care influences when a consumer commences therapy with an
antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
28. Consumers who have family support are more likely to commence antidepressant
therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
29. Consumers who have peer support are more likely to commence antidepressant therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
30. Any perceived stigma displayed by a family member or carer toward mental health can be
a barrier to a consumer commencing antidepressant therapy.
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Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
31. Stigma in society can be a barrier to a consumer commencing antidepressant therapy.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
32. Mental health advocacy organizations such as BeyondBlue influence whether a
consumer commences therapy with an antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the initiation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
33. Consumers who have more severe depressive symptoms are more willing to commence
antidepressant medicines.
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Face and content validity of a medication adherence conceptual framework: factors
influencing consumers' adherence to antidepressant medicines in unipolar
depression
Please read the following statements and indicate the extent to which you agree or
disagree with them.
The operational definitions of these terms are reported below.
- Relevance: The extent to which the statement (influencing factor) is relevant to
practice at the specified phase of medication adherence. 
- Importance: The extent to which the statement (influencing factor) is important for the
specified phase of medication adherence.
 
If you would like to add, delete or modify any item, please record your suggestions in
the comments section below the item.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
34. Following the diagnosis of a consumer with depression, GPs can influence whether
consumers continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree 
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
35. Following the diagnosis of a consumer with depression, psychiatrists can influence
whether consumers continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
36. Following the diagnosis of a consumer with depression, community pharmacists can
influence whether consumers continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
37. Experienced GPs can influence whether consumers continue to take antidepressant
medicines.
215
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
38. Experienced psychiatrists can influence whether consumers continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation phase
of adherence.
Please specify any other comments (e.g. Clarity of statement)
39. Experienced community pharmacists can influence whether consumers continue to take
antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
40. Good relationships between GPs and consumers can influence whether consumers
continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
41. Good relationships between psychiatrists and consumers can influence whether
consumers continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
42. Good relationships between community pharmacists and consumers can influence
whether consumers continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
43. Collaboration between GPs, psychiatrists, and pharmacists in a mental healthcare team
can influence whether consumers continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree 
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
44. Interactive communication and open dialogue between health care professionals and
consumers can influence whether consumers continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
45. Lack of adequate information about depressive treatment from health care professional
can inhibit a consumer from continuing to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
46. Stigma about depression from health care professionals can inhibit a consumer from
continuing to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
47. Consumers who believe in antidepressants are more likely to continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
48. Consumers who are more able to self-manage are more likely to continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
49. Consumers who are involved in the treatment decision-making process are more likely to
continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
50. Consumers who have previous unfavourable experiences with antidepressant treatment
are more unlikely to continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
51. Consumers who are concerned about the effect of stopping antidepressant therapy are
more likely continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
52. Consumers who feel better after taking antidepressants tend to continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
53. Consumers who have trust in their health care professionals are more likely to continue to
take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
54. Consumers who have knowledge about depression and antidepressant therapy are more
likely to continue to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
55. Forgetfulness can inhibit a consumer from continuing therapy with an antidepressant
medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
56. Consumers with higher levels of education are more willing to continue to take
antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
57. Consumers who have positive experiences from antidepressant therapy are more likely to
continue to take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
58. Consumers who have few adverse drug reactions from antidepressant medicines are
more likely to continue to take them.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
59. Ineffectiveness of antidepressant treatment can inhibit a consumer from continuing
therapy with an antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
60. Consumers who have private health insurance are more likely to continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
61. The accessibility of the health care services effects whether a consumer continues to
take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
62. The accessibility of antidepressant medicines effects whether a consumer continues to
take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
63. Lack of continuity of care in the public system can inhibit a consumer from continuing
therapy with antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
64. Consumers who live with a partner are more likely to continue to take antidepressant
medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
65. Consumers who can afford antidepressants are more likely to continue to take
antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
66. Societal stigma about depression can inhibit a consumer from continuing therapy with an
antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
67. Lack of support from family can inhibit a consumer from continuing therapy with an
antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
68. Stigma about depression by family members can inhibit a consumer from continuing
therapy with an antidepressant medicine.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
69. Mental health organizations such as BeyondBlue influence whether consumers continue
to take antidepressant medicines.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
70. Consumers who have more severe depressive symptoms are more likely to continue to
take antidepressant medicines.
 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
71. Depressive symptoms can inhibit a consumer from continuing therapy with an
antidepressant medicine.
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 Strongly disagree Disagree
Neither agree nor
disagree Agree Strongly agree
The above statement
is relevant to practice.
The above statement
describes an
important influencing
factor for the
implementation
phase of adherence.
Please specify any other comments (e.g. Clarity of statement)
72. Long term treatment of depression can inhibit a consumer from continuing therapy with
an antidepressant medicine.
73. Please describe any other factors which can influence adherence to antidepressant
medicines.
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74. What is your gender?
Male 
Female
75. What is your health profession?
General practitioner
Psychiatrist
Pharmacist
Academic researcher
Other (please specify)
76. How many years have you been working as a health care professional?
Thank you very much for your time. Your response is important for us.
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